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The pro-apoptotic Bcl-2 family protein, Bax, is an essential component of neuronal
apoptotic cell death pathways. Central to the pro-apoptotic function of Bax is its
translocation from the cytosol to the outer mitochondrial membrane. Bax is thought
to engage in protein-protein interactions with regulatory factors that influence its
apoptogenic activity. However the identities of these regulatory proteins have yet to
be fully elucidated. This thesis aimed to identify Bax-binding proteins using a
proteomics-based approach in an in vitro neuronal cell model of the intrinsic
apoptotic pathway and to characterise their involvement in Bax-mediated apoptosis
using molecular techniques. An in vitro neuronal cell model was established using
human neuroblastoma SH-SY5Y cells treated with the intrinsic apoptotic pathway
inducer, staurosporine. Biochemical hallmarks of the intrinsic pathway, such as Bax
translocation and mitochondrial cytochrome c release, together with more general
indicators of apoptosis, such as analysis of cellular morphology, caspase-3 activation
and internucleosomal DNA fragmentation, were characterised. Endogenous Bax was
immunoprecipitated from SH-SY5Y whole cell lysates and bound proteins, separated
by 2D gel electrophoresis, were identified by peptide mass fingerprinting to be the
heat-shock proteins, Hsc71, GRP78 and Hsp60, and the cytoskeletal proteins, P-
actin, tubulin and vimentin. Interactions between endogenous Bax and Hsp60, P-
actin and vimentin were confirmed by co-immunoprecipitation. Affinity
chromatography with a wild type 21 amino acid C-terminal Bax peptide and a mutant
peptide containing a serine to valine substitution at position 184 (SI84V), which
mimics the membrane-targeting capacity of activated Bax, also identified Hsp60, P-
actin and the molecular chaperone nucleophosmin, with the latter binding exclusively
to the mutant peptide. These interactions were subsequently confirmed by co-
immunoprecipitation. Together, the data suggest that Bax is retained in the cytosol
of quiescent cells through association with heat shock and cytoskeletal proteins, and
that exposure of the C-terminal domain and subsequent translocation of Bax during
apoptosis may be regulated by Hsp60, p-actin and nucleophosmin. The role of
nucleophosmin in regulating the translocation of Bax was investigated further.
Interaction studies between recombinant Bax and nucleophosmin proteins were
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performed using a cell-free amplified luminescent proximity homogeneous assay and
demonstrated that nucleophosmin only bound to activated Bax following a detergent-
induced conformational alteration. Furthermore, confocal microscopy revealed that
nucleophosmin underwent translocation from the nucleolus to the cytosol during a 5h
time course of staurosporine treatment and preceded the translocation of Bax to
mitochondria. Applying RNA interference against endogenous nucleophosmin
mRNA within SH-SY5Y cells attenuated mitochondrial cytochrome c release and
procaspase-3 cleavage during staurosporine-induced apoptosis. Together these data
demonstrate that nucleophosmin is a novel regulator of Bax bioactivity and
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CHAPTER 1: General Introduction
1.1. Introduction
The multitude of cells that together form the tissue structures found within metazoan
organisms are not immortal - the death of these cells is an inevitable and natural stage
within their life cycle, and this loss, when accompanied by renewal, is an essential
homeostatic mechanism central to the survival of all multi-cellular organisms, from
worms to mammals. In a human, about a hundred thousand cells are produced every
second by mitosis, and a similar number die by a physiological suicide process known as
apoptosis (Vaux and Korsmeyer, 1999).
Apoptosis (from the Greek apo - from, ptosis - falling, literally refering to the seasonal
falling of leaves from a tree or petals from a flower) is a co-ordinated process of cell
self-destruction that is stereotyped by the fragmentation of nuclear DNA, chromatin
condensation and the emergence of a distinctive cellular morphology leading to the
eventual formation of membrane-bound apoptotic cell bodies that are finally engulfed by
neighbouring phagocytes (Kerr et al., 1972). Apoptosis is activated either by the
presence of a death stimulus or by the removal of a survival factor (Duke and Cohen,
1986), and is a normal physiological process that is fundamental to developmental tissue
remodelling and to the maintenance of tissue homeostasis throughout life (Bellamy et
al., 1995).
In 1972, researchers working at the University of Edinburgh published a seminal paper
in which the term "apoptosis" was coined and which laid the foundation for the now
widely accepted view that there are two physiologically-distinct mechanisms by which a
cell can die: 1) necrosis, a passive, unregulated process characterised by cell lysis and
the release of cellular contents into the extracellular matrix provoking an inflammatory
response, and 2) apoptosis, a highly regulated, self-programmed process leading to the
removal of damaged or ectopic cells in the absence of inflammation (Kerr et al., 1972) -
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I for a comparison of the morphological differences between these two
models of cell death. Necrotic, or lytic, cell death is usually confined to the aftermath of
acute cell injury or trauma, such as that resulting from hypoxia, heat shock, viral
invasion or exposure to various exogenous toxins, and is associated with severe
pathophysiology, principally as a consequence of subsequent inflammation and
secondary tissue damage (Leist and Nicotera, 1997). Apoptosis, in contrast, is a
programmed event dependent on continued ATP synthesis (Leist et al., 1997) by which
superfluous cells are removed during development, particularly within the immune and
nervous systems, as well as mediating the elimination of damaged or ectopic cells
throughout the course of normal tissue homeostasis within the adult organism (Steller,
1995; Adams, 2003). However, apoptosis, when inappropriately activated, is also
known to be a major contributor to cell pathology associated with numerous disease
states, including AIDS (Gougeon et al., 1993), myelodysplastic syndromes (Yoshida,
1993), myocardial and cerebral infarction (Charriaut-Marlangue et al., 1996; Olivetti et
al., 1997; Hara et al., 1997), and the neurodegenerative disorders, Alzheimer's disease
(Loo et al., 1993; Cotman and Anderson, 1995), Parkinson's disease (Jenner and
Olanow, 1998), Huntington's disease (Ona et al., 1999) and amyotrophic lateral
sclerosis (ALS) (Kostic et al., 1997). Conversely, pathophysiology associated with
dysfunctional apoptosis includes chronic inflammation and autoimmunity, due to the
impaired clearance of pro-inflammatory cells (Gilroy et al., 2004); the replication and
pathogenesis of oncogenic viruses, such as Epstein Barr virus (EBV) (Henderson et al.,
1993), human cytomegalovirus (CMV) (Goldmacher et al., 1999) and hepatitis B virus
(Bellamy et al., 1995); and tumourogenesis (Tsujimoto et al., 1985; Hollstein et al.,
1991). Thus, the extent of apoptosis within a multi-cellular organism is a finely
controlled process: too much results in excessive cell pathology whereas too little can
set the scene for cancer to take hold. Only by improving our understanding of the
molecular pathways leading to apoptosis can we stand a chance of developing
therapeutics that will allow us to manipulate the course of apoptosis to avoid either of
those two outcomes. The relevance of apoptosis to current medical research is perhaps





















Figure 1.1. Differentiating between apoptosis and necrosis. Necrotic cell death is
characterised by the swelling of the cell and organelles, the appearance of mottled
chromatin condensation and loss of membrane asymmetry. The final outcome is lysis
of the plasma and intracellular membranes with the release of cellular contents,
including proteases and lysozymes, into the extra-cellular environment triggering an
inflammatory response. Apoptosis begins with cell rounding, shrinkage of the cell
volume and compaction of the intracellular environment. The nucleus condenses and
chromatin marginalises to the nucelar envelope where it forms dense granular caps. The
fragmentation of the nucleus into membrane-bound vesicles is accompanied by blebbing
of the plasma membrane (zeiosis). The entire cell then splits into multiple membrane-
bound "apoptotic bodies" which are then rapidly engulfed by neighbouring phagocytes
without eliciting an inflammatory response.
"apoptosis" published in the past two decades - see As a result of this
intensive research, our understanding of the complexities involved in apoptotic
signalling has improved dramatically. However, despite this, a great deal of uncertainty
and controversy in the interpretation of research findings persists throughout the cell
death community.
The experiments presented within this thesis were performed within the Astellas CNS
Research in Edinburgh (ACE) laboratories (formerly known as the Fujisawa Institute for
Neuroscience in Edinburgh (FINE) until 2004). The research focus of ACE, and
therefore of this thesis, lies within neuronal cell death, in particular the contribution
made by apoptosis to the pathophysiology of cerebral ischaemic cell death and
neurodegeneration. Apoptosis can be initiated by many signals in neuronal cells.
Stimuli associated with neurodegenerative disorders include lack of trophic factor
support, release of excitotoxic amine neurotransmitters and metabolic stress (Thompson,
1995; Mattson, 2000). Central to the apoptotic pathway initiated by such stressors is
mitochondrial dysfunction (Kroemer et al., 1998) which leads to the release of
apoptogenic molecules and the execution of apoptosis. The transmission of the
apoptotic signal to the mitochondrial surface is regulated by the B-cell lymphoma
protein-2 (Bcl-2) family ofproteins, of which the pro-apoptotic protein, Bcl-2 associated
X protein (Bax), is a pivotal member. The relocalisation of Bax from the cytosol to the
mitochondrial surface is an early event within neuronal cell apoptosis (McGinnis et al.,
1999; Putcha et al., 1999), and the deletion of Bax has been shown to protect
sympathetic neurones against NGF-withdrawal-induced apoptosis (Deckwerth et al.,
1996). Identifying the regulatory factors controlling Bax activation within neuronal
cells is therefore the principle aim of this thesis, the results of which are presented
within the following chapters. However, apoptosis is a physiologically important
process in all tissues during development and throughout life and is therefore associated
with the emergence of a multitude of disease states and pathologies when deregulated.
The remainder of this introductory chapter will therefore provide an overview of the
physiological processes in which apoptosis contributes, the molecular pathways
3
Figure 1.2. World-wide research publications on apoptosis. Research papers on
apoptosis remained relatively obscure even up to the late 1980's with on average 10
papers published a year. Thereafter, the rate of publication and interest has risen
exponentially, with currently over 200 publications appearing every week that refer to
"apoptosis". Data compiled using www.pubmed.gov.
involved and an in-depth discussion on the structure and function of Bax within neuronal
cell death pathways.
1.2. Apoptosis during development
Before the concept of apoptosis had arisen, developmental biologists had for a long time
been observing the stereotyped "programmed" phases of cell death known to occur
during the development of many organisms, including insects (Lockshin and Williams,
1965), nematodes (Ellis and Horvitz, 1986) and amphibians (Tata, 1966). Indeed, this
process of naturally occurring cell death, now morphologically, biochemically and
genetically recognisable as apoptosis, is highly conserved amongst all metazoan
organisms and is essential for the developmental maturation of tissues (Vaux and
Korsmeyer, 1999).
During mammalian development, apoptosis is involved in the formation of channels and
cavities within the central nervous system, the removal of interdigital webbing, the
remodelling of bone and the involution of the mammary glands (Vaux and Korsmeyer,
1999). Furthermore, the production of excess cells and the subsequent removal of
superfluous cells by apoptosis is a feature common to the development ofmany types of
cells, tissues and organs (Oppenheim, 1991; Vaux and Korsmeyer, 1999; Opferman and
Korsmeyer, 2003), and probably exists to ensure that the optimal number of cells are
available for later demands (Oppenheim, 1991).
Studies using gene knock-out mice revealed that apoptosis plays a central role in the
developing nervous system (Motoyama et al., 1995; Kuida et al., 1996; Flakem et al.,
1998; Yoshida et al., 1998). For example, transgenic mice lacking expression of the
apoptogenic enzymes, caspase-3 and caspase-9, both key components of apoptotic
pathways, suffered excessive brain growth and neurodevelopmental abnormalities as a
result of reduced apoptosis and died perinatally (Kuida et al., 1996; Hakem et al., 1998).
Similarly, deletion of another key pro-apoptotic protein, Bax, resulted in the abolishment
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of developmental cell death occurring in sympathetic and motor neuronal cell
populations, although these mice remained viable into adulthood (Deckwerth et al.,
1996; White et al., 1998). Such a reliance by the nervous system on apoptosis is due in
part to the extensive remodelling of the central and peripheral nervous system structures
that occurs during embryonic and postnatal developmental periods (Oppenheim, 1991).
This example of so-called "morphogenetic" cell death, whereby tissue structures are
sculpted by the selective removal of excess cells, is widely observed throughout
development but is particularly pertinent to the mammalian nervous system where the
formation of various cavities and channels is essential for its function (Oppenheim,
1991).
Development of the nervous system, as with other tissues, such the immune and
haematopoietic systems, is characterised by massive cell death (ranging from 20-80%
depending on the neuronal cell population) occurring towards the latter stages of the
maturation process (Glucksmann, 1951; Oppenheim, 1991). Furthermore, this extensive
cell death appears to involve almost all neuronal types and is prevalent in both the
central and peripheral nervous systems (Oppenheim, 1991). Afflicted neurones are post¬
mitotic and display the phenotypic characteristics of their given cell type, but have failed
to establish post-synaptic connections with the appropriate afferent cells (Oppenheim,
1991; Sadoul, 1998). Elimination of these cells resembles the positive selection process
seen during the thymic maturation of T cells whereby cells die "by neglect". In the case
of neurones, this is mediated by the withdrawal of neurotrophic factors, such as nerve
growth factor (NGF), leading to the inability of these cells to counteract intrinsic
apoptotic signalling pathways (Deckwerth and Johnson, Jr., 1993; Edwards and
Tolkovsky, 1994; McKay et al., 1999).
1.3. Apoptosis in adult physiology
Once the development of cell lineages is complete, the maintenance of cell number as
well as the viability of the adult organism depends on attaining a balance between
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proliferation (mitosis) and cell death (apoptosis). Each of these two essential
physiological processes is under genetic control - cell proliferation is governed by
growth factors and proto-oncogene expression (Rozengurt, 1992) whereas cell death is
initiated by the removal of survival factors and the expression of tumour suppressor
genes (Levine, 1993).
Aside from the general maintenance of cellular homeostasis, apoptosis also performs
several well defined roles in physiological processes, particularly within the immune
system. During an immune response, there is a rapid clonal expansion of antigen-
specific lymphocytes that is sustained by the expression of pro-survival cytokines and
anti-apoptotic proteins (June et al., 1987; Boise et al., 1995). However, once the
immune threat has subsided, the large population of now redundant post-activation
lymphocytes is selectively eliminated by apoptosis through the combined effect of
reducing expression of anti-apoptotic proteins, increasing expression of pro-apoptotic
proteins and the activation of cell surface death receptors (Opferman and Korsmeyer,
2003). Similarly, the clearance of potentially harmful pro-inflammatory cells, such as
neutrophils, eosinophils and monocytes, from sites of inflammation during the latter
stages of the immune response is controlled by apoptosis (Bellamy et al., 1995) as is the
removal of autoimmune T cells that can arise as a result of somatic mutation during an
immune response (Fisher et al., 1995; Borner, 2003).
In contrast to the rapid turnover of cells in proliferative tissues, and to the extensive
remodelling during development, naturally occurring cell death within the adult nervous
system is much less apparent due to the limited capacity for self-renewal exhibited by
mature neural cells and their resultant long life span (Thompson, 1995; Mattson, 2000).
However, as will be discussed in the following section, neurones are particularly
sensitive to a variety of stress stimuli, including ischaemic, excitotoxic and oxidative
injury where apoptosis, alongside necrosis, accounts for a significant proportion of
neuronal cell loss.
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1.4. Apoptosis in pathology
As with many essential physiological processes, deregulation of apoptosis can lead to
the emergence of severe disease/pathology (Thompson, 1995). The diseases/pathologies
resulting from deregulated apoptosis are either a consequence of excessive or
inappropriate activation, such as that associated with AIDS, myocardial and cerebral
infarction, ischaemia-reperfusion damage and neurodegenerative diseases (Thompson,
1995; Olivetti et al., 1997; Mattson, 2000; Rathmell and Thompson, 2002), or when
apoptosis is non functional due to gene mutation which can lead to auto-immunity,
excess inflammation and tumour formation (Fisher et al., 1995; Zornig et al., 2001;
Green and Evan, 2002) - ee Table 1.1.
1.4.1. Apoptosis and neurological disorders
The reliance of the nervous system on apoptosis during development is equalled by its
vulnerability to disruption when neuronal apoptotic pathways become overwhelmed and
inappropriately utilised during severe insults, such as those associated with stroke and
traumatic brain and spinal cord injury (Yakovlev et al., 1997; Emery et al., 1998;
Dirnagl et al., 1999). Apoptosis has also been linked with the prolonged attrition of
neuronal cells during the course of chronic neurodegenerative diseases such as
Alzheimer's disease, Parkinson's disease, Huntington's disease and ALS (Thompson,
1995; Mattson, 2000). Apoptosis in these neurological disorders can be initiated by
numerous physiological triggers, including lack of neurotrophic factor support (McKay
et al., 1999), excitotoxicity (Choi, 1992; Ankarcrona et al., 1995; Wong et al., 1998) and
oxidative stress (Sastry and Rao, 2000).
The devastating physical and mental manifestations accompanying the progression of
neurodegenerative diseases originate from the death of specific neuronal populations
within the nervous system (Thompson, 1995). For example, death of hippocampal
neurones underlies some of the cognitive defects associated with Alzheimer's disease
7

































Table 1.1. Diseases associated with deregulated apoptosis.
(Cummings et al., 1998); the loss of dopaminergic neurones in the substantia nigra
underlies the uncoordinated movements characterising Parkinson's disease (Jenner and
Olanow, 1998); Huntington's disease is associated with the destruction of neurones in
the striatum that control body movements (Ona et al., 1999); and the loss of lower motor
neurones leads to the disabling physical prognosis faced by patients with ALS (Martin et
al., 2000). In each case, the activation of apoptotic death pathways in afflicted neurones
has been proposed to be a major contributor to cell loss and disease progression
(Thompson, 1995; Mattson, 2000).
The destructive neuronal cell damage and death resulting from stroke has also been
observed to involve a significant apoptotic component (Mattson et al., 2001).
Histochemical analysis of rodent brains removed from experimental focal ischemic
stroke models revealed a central necrotic "core", in which neurones die rapidly (within
minutes to hours) by necrosis, and a surrounding sub-optimally perfused "penumbra" in
which glial cells survive but damaged neurones die over a protracted period lasting
several days (Dirnagl et al., 1999; Mattson et al., 2001; Plesnila, 2004). Biochemical
analyses of post-mortem tissue extracted from the ischemic penumbra of stroke patients
(Guglielmo et al., 1998) and rat models of focal cerebral ischaemia (Linnik et al., 1993;
Fujimura et al., 1998) have demonstrated the occurrence of widespread apoptotic
neuronal cell death in this region. Over time, the penumbral tissue degenerates to
necrotic infarct tissue, in which all neuronal cell-types die. Hence, anti-apoptotic
pharmacological intervention within the appropriate therapeutic window (a few hours)
following stroke could potentially lead to the recovery of neuronal cell death within this
region.
As an illustration of the prevalence of apoptosis in neurological disorders, the presence
of apoptogenic active caspases has been observed in Alzheimer's disease (Gervais et al.,
1999; Chan et al., 1999; LeBlanc et al., 1999), Parkinson's disease (Hartmann et al.,
2000; Tatton, 2000), Huntington's disease (Sanchez et al., 1999), ALS (Pasinelli et al.,
1998), as well as in the neuronal cell damage associated with stroke (Namura et al.,
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1998) and spinal cord injury (Matsushita et al., 2000). Furthermore, pro-apoptotic
proteins belonging to another major group of apoptosis-regulating proteins, the Bcl-2
family of proteins, have also been implicated in contributing to the neurpathological cell
death associated with such disorders (Plesnila, 2004; Akhtar et al., 2004; Ouyang and
Giffard, 2004). Thus, alleviating apoptotic neuronal cell death by therapeutic
intervention could make a significant improvement to the prognosis faced by patients
with these disorders.
1.4.2. Apoptosis and cancer
It is a widely observed phenomenon that cells associated with many types of human
malignancies are resistant to apoptosis (Hoffman and Liebermann, 1994). Normal cells
are dependent on survival factors for continued growth and undergo apoptosis when
such factors are removed either as a result of growth factor withdrawal (Duke and
Cohen, 1986; Williams et al., 1990; Raff et al., 1993) or when a cell becomes displaced
from its physiological setting (Boudreau et al., 1995; Valentijn et al., 2004). Metastatic
tumour cells that have defective apoptosis-promoting genes are able to circumvent this
latter homeostatic restriction to relocate to distinct tissue sites and proliferate
(Thompson, 1995).
The observed immortality ofmany tumour cells is known to arise from genetic mutation
within several key apoptosis-regulating genes. The first of these to be identified was
oncogenic bcl-2 as a result of its 14; 18 translocation and over-expression in human
follicular lymphoma (Tsujimoto et al., 1984; Cleary et al., 1986). Although originally
identified as an oncogene, over-expression of the bcl-2 gene product was later found to
promote the clonal expansion of tumour cells by inhibiting apoptosis (Vaux et al., 1988;
Hockenbery et al., 1990). Aside from lymphomas, over-expression of Bcl-2 protein is
known to underlie the propagation of several other human cancers, among them prostatic
(McDonnell et al., 1992), colorectal (Hague et al., 1994) and neuroblatomas (Castle et
al., 1993). Other anti-apoptotic Bcl-2 family proteins are also potential oncogenes,
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however so far little evidence is available that directly links them to the emergence of
specific tumour types (Cory et al., 2003). In contrast, pro-apoptotic proteins within the
Bcl-2 family represent potential tumour suppressors, and loss of function of any of these
proteins could conceivably lead to tumourogenesis. For example, the loss of pro-
apoptotic Bax function is associated with some human gastrointestinal cancers
(Rampino et al., 1997) and leukemias (Meijerink et al., 1998), and mutation of the BH3-
only protein, Bim, which plays a key role in regulating lymphoid homeostasis (Bouillet
et al., 1999), represents a candidate genetic basis for the emergence of human leukemias,
although this has yet to be proven (Cory et al., 2003). However, a tumour suppressor
that is known to be a critical factor in many human cancers is the transcriptional
regulator, p53. In response to genotoxic damage, the upregulation of p53 protein leads
to the initiation of apoptosis through the transactivation of pro-apoptotic genes,
including pro-apoptotic Bcl-2 family proteins (Lowe et al., 1993; Haupt et al., 2003).
Tumour cells deficient in p53 therefore display enhanced resistance to DNA damage
induced by radiation and chemotherapeutic drug treatments (Lowe et al., 1994). Indeed,
direct gene mutation ofp53 underlies almost half of all human malignancies (Vogelstein
et al., 2000), and a proportion of the remaining tumours are associated with elevated
levels of p53-inhibiting proteins, such as MDM2 (Evan and Littlewood, 1998), or
mutations to p53 synergistic proteins, such as the pl9ARF tumour suppressor (Haber,
1997). Together, these observations demonstrate the pivotal role that apoptosis plays in
protecting metazoan organisms from the emergence and clonal expansion of malignant
cells.
1.5. Elucidating the molecular pathways of apoptosis
From pioneering genetic studies carried out in the 1980s by H. Robert Horvitz and
colleagues using the nematode Caenorhabditis elegans, it was demonstrated that the
molecular events leading to apoptosis were genetically pre-determined (Horvitz et al,
1982; Ellis & Horvitz, 1986). Of the 1090 somatic cells within the hermaphrodite worm,
131 are destined to die during development in a precisely co-ordinated manner (Ellis et
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al., 1991). Detailed microscopic observation of the morphology of the dying cells
confirmed that they were undergoing apoptosis, with their complete degradation and
engulfment by neighbouring cells taking place within one hour. This process was found
to be regulated by a number of genes known as cell death abnormal (ced) genes, the first
to be discovered being ced-3 and ced-4 which were found to be required for the
initiation of programmed cell death during this developmental period (Ellis and Horvitz,
1986). Within the mammalian system, the first gene to be identified as a key regulator
of apoptosis initiation was bcl-2 (Vaux et al., 1988). Bcl-2 was originally identified in
1984 as a gene activated as a result of a chromosomal translocation event (tl4;18) in
human follicular lymphoma (Tsujimoto et al., 1984). However, the possibility that bcl-
2, in contrast to other oncogenes involved in translocations known at that time, such as
c-abl and c-myc, could also inhibit cell death pathways rather than just promote cell
proliferation did not emerge until several years later when its over-expression was found
to prevent cells from dying when growth factor was removed (Vaux et al., 1988). This
discovery, together with the realisation that p53, one of the most frequently mutated
genes in cancer, was a key pro-apoptotic gene (Yonish-Rouach et al., 1991) and that the
apoptotic pathway initiated by p53 can be blocked by Bcl-2 (Chiou et al., 1994)
reinforced the regulatory role of Bcl-2 in apoptosis and established the profoundly
significant link between the inhibition of apoptosis and the development of cancer in
humans (Vaux, 2002). Furthermore, in 1992, definitive proof that programmed cell
death in C.elegans and apoptosis in mammals is the same evolutionary conserved
physiological process was provided by showing that the human bcl-2 gene could inhibit
developmental cell death when expressed in the worm (Vaux et al., 1992). In the same
year, another C.elegans ced gene was discovered, ced-9, that was found to inhibit the
pro-apoptotic influences of CED-3 and CED-4 (Hengartner et al., 1992) through direct
interaction with CED-4 on the mitochondrial surface (Chen et al., 2000). CED-9 was
later determined to be a homolog of the mammalian Bcl-2 protein (Hengartner and
Horvitz, 1994). As comprehension of the molecular events within mammalian apoptosis
burgeoned, other relationships linking invertebrate and vertebrate apoptotic pathways
emerged. In 1993, Yuan and colleagues published their observation that a similarity
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existed between the nematode ced-3 gene product and the mammalian interleukin-l(3
converting enzyme (ICE) (Yuan et al., 1993), at the time recently discovered to be a
unique cysteine protease involved in the maturation of interleukin-1P to its active pro¬
inflammatory, biologically-active form (Thornberry et al., 1992; Cerretti et al., 1992).
ICE, now known as caspase-1, was the first of a family of mammalian cysteinyl
proteases to be characterised that together orchestrate the dismantlement of the apoptotic
cell through the cleavage of essential cellular substrates. Furthermore, when the
mammalian caspase-activating adapter protein, apoptotic protease activating factor-1
(Apaf-1) was identified in 1997, it was found to be homologous to CED-4 (Zou et al.,
1997). To complete the unification of these two cell death pathways, the C.elegans
protein, EGL-1 (egg-/aying defective-1) was identified in 1998, again by researchers in
the Horvitz laboratory, and was found to interact with and inhibit the protective protein
CED-9 (Conradt and Horvitz, 1998) - Structural analysis of this novel
protein demonstrated that it shared sequence homology with only one region within both
CED-9 and Bcl-2 known as the BH-3 domain and represented the nematode equivalent
of a diverse group of pro-apoptotic signalling proteins active in mammalian apoptosis
known as the BH3-only proteins (Conradt and Horvitz, 1998).
Despite this apparent unification of invertebrate and vertebrate apoptotic pathways, the
mammalian apoptotic mechanism is in fact a great deal more complex as it offers an
alternative extrinsic death-receptor-initiated pathway to the more ancient and
evolutionary conserved intrinsic, or mitochondrial, pathway, as will be described in
more detail in the next section of this introduction. Furthermore, due to the propensity
for increasing complexity as one ascends the phylogenetic tree, mammalian apoptosis is
orchestrated by a multitude of regulatory proteins in contrast to the relatively simplistic
pathway operating within C.elegans.
In addition to the intrinsic and extrinsic pathways, apoptosis can also be initiated within
the mammalian system by the release of granzyme B from cytotoxic T and NK cells (Shi
et al., 1996) and an endoplasmic reticulum (ER)-directed pathway in response to
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Figure 1.3. Comparison between nematode and mammalian apoptotic cell death
pathways. Programmed cell death (apoptosis) in the nematode, C. elegans, requires
CED-4 and CED-3. CED-9 interacts directly with CED-4 and both are thought to
reside on mitochondria. In cells destined to die during development, expression of the
death-promoting protein, EGL-1 binds to CED-9 and displaces it from CED-4 which
then initiates apoptosis via CED-3. In the mammalian system, the recruitment of Apaf-
1 is inhibited by the CED-9 homolog, Bcl-2, which prevents cytochrome c from being
released from mitochondria. Bcl-2 is in turn inhibited by pro-apoptotic BH3-only
proteins that represent the mammalian homolog of EGL-1. Apaf-1 promotes the
activation of the initiator caspase, caspase-9 which in turn activates the CED-3 homolg
and executioner caspase, caspase-3. Apoptotic cell death then ensues.
perturbed intracellular Ca2+ homeostasis or the accumulation of misfolded proteins in the
cytosol and/or ER lumen (Zinszner et al., 1998; Nakagawa et al., 2000). However, there
exists a degree of overlap between all of these routes and most pathways are united in
their latter stages through the activation of caspases. These enzymes, as will be
expanded upon in the following section, account for the characteristic morphological
and biochemical hallmarks associated with apoptosis, such as nuclear fragmentation,
chromatin condensation, cell rounding, shrinkage and plasma membrane blebbing
(zeiosis) (Wyllie et al., 1980).
The stereotypical sequence of morphological changes exhibited by cells undergoing
apoptosis is directed by a tightly regulated intracellular signalling cascade involving
death receptors on the plasma membrane, signal transducing molecules, cytosolic and
membrane-bound proteins, proteolytic enzymes and transcription factors. The molecular
pathways to apoptosis can be broadly delineated into three main phases: the initiation,
execution and termination phases (Schmitz et al., 2000). In this model, apoptosis is
initiated by numerous death signals, including withdrawal of survival factors ("death by
neglect"), irradiation, hypoxia, chemotherapeutic agents and ligation of death receptors.
The death signal is then relayed throughout the cell death machinery leading to the
activation of dormant pro-apoptotic proteins and the suppression of survival factors, for
example those belonging to the Bcl-2 protein family. The execution phase is
choreographed by the caspase family of proteases that systematically cleave numerous
cellular substrates to bring about the careful dismantlement of the cellular environment
(Thornberry and Lazebnik, 1998). Finally, in the termination phase, membrane-bound
cellular material is engulfed by phagocytes (Savill et al., 1993).
1.6. Caspases
Caspase activation is a biochemical hallmark of apoptosis (Abraham and Shaham,
2004). When active, this family of proteases targets essential cellular substrates, among
them key structural proteins, such as the actin-regulatory protein, gelsolin, and the
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cytoskeletal protein, a-fodrin, which may account for some of the morphological
changes seen in apoptosis, such as zieosis and cell rounding/shrinkage (Martin et al.,
1995; Janicke et al., 1998b). Caspases are also known to have activity within the
nucleus where they activate DNases, such as DNA fragmentation factor 45kDa subunit
(DFF-45)/caspase-activated DNase (CAD), which cleave genomic DNA into ~180bp
inter-nucleosomal fragments (Tang and Kidd, 1998), one of the key determinants of
apoptotic cell death.
The caspase family are cysteine proteases that cleave their substrates after an aspartate
residue (hence their name), a target site shared by the serine protease, granzyme B, but
otherwise unique amongst mammalian enzymes (Degterev et al., 2003). The caspase
target sites within substrate polypeptides consist of a short tetrapeptide motif that all
begin with an aspartate residue (Nicholson, 1999). However, different caspase family
members exhibit a preference for specific residues within the remaining three positions,
a promiscuity that has enabled the generic classification of the caspases into three
subgroups according to their substrate specificity (Thornberry et al., 1997). This
categorisation led to the assignment of several important functionalities to caspase
groups. For example, Group III caspases, such as caspases-3 & -7, were found to share
a highly stringent target site sequence (DEXD, where X is either V, T or H) that was
also recognised by CED-3 and appeared in many proteins cleaved during apoptosis
(Nicholson, 1999). These caspases therefore represented the "effector" caspases within
the family (Thornberry et al., 1997). In contrast, caspases belonging to group II, which
included caspases-8, -9 & -10, were found to preferentially cleave a target site found on
effector caspases, which implicated them as upstream "initiator" caspases that activated
the effector caspases in response to apoptotic signalling (Thornberry et al., 1997).
Group I caspases, represented by caspases-1, 4 and 5, are also initiator caspases but
exhibit a dual role within apoptosis and inflammation where they are required for the
proteolytic maturation of pro-inflammatory cytokines, such as pro-interleukin 1(3,
interleukin-18 and pro-interferon (IFN)y inducing factor (Kuida et al., 1995; Li et al.,
1995; Thornberry et al., 1997). Classifying caspases according to structure was also
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found to result in similar grouping as those above, suggesting a close structure-function
relationship within the caspase family. For example, caspases belonging to initiator
class were found to contain extended prodomain regions that facilitated interaction with
upstream signalling pathways (Degterev et al., 2003). Furthermore, the prodomain
region of latent initiator caspases (known as procaspases) were found to contain one of
two characteristic protein-protein binding motifs - the death effector domain (DED),
found in caspases-8 and -10, and the caspase activation and recruitment domain (CARD)
present in caspase-9, as well as caspases-1, -2, -4 and -5, (Degterev et al., 2003). The
DED and CARD motifs were shown to be recognised by two different adaptor proteins,
each specifically associated with the two main pathways to apoptotic cell death in
mammalian cells - the extrinsic and intrinsic pathways, respectively. For example, the
death receptor component within the extrinsic pathway, Fas-associated death domain
(FADD), binds to the DED on procaspases-8 and -10 (Muzio et al., 1996), and the
intrinsic pathway-associated component, Apaf-1, forms a complex with procaspase-9
through its binding to CARD (Rodriguez and Lazebnik, 1999). This selective activation
of initiator caspases is a molecular hallmark that can be used to differentiate between an
extrinsic or intrinsic route to apoptosis - see Figure 1.4. However, as will be discussed
later, there is often a high degree of overlap between these two pathways that can make
such observational rules of thumb misleading.
Initiator caspases selectively activated by the extrinsic and intrinsic pathways converge
upon the effector, or "executioner", caspases, comprising caspases-3, -6 and -7. The
effector caspases, like the initiator caspases, are present in the resting cell as latent
procaspase zymogens, and require internal cleavage by initiator caspases to become
fully activated (Thornberry et al., 1997; Nicholson, 1999). However, once in their
activated form, the effector caspases proteolytically cleave numerous protein substrates,
amongst them nuclear factors (for example caspase-activated DNase (CAD) (Tang and
Kidd, 1998), cytoskeletal proteins (for example a-fodrin (Janicke et al., 1998a)) and
signalling molecules, such as protein kinases, to bring about apoptotic cell death




















Figure 1.4. Caspase activation pathways. Two ATP-dependent catalytic caspase-
generating complexes are initiated in response to either extrinsic or intrinsic stimuli.
The highly homologous caspases-8 and -10 are generated by the death-inducing
signalling complex (DISC) in response to death receptor ligation and directly activate
executioner caspases, -3, -6 and -7. In response to cellular stress, release of
apoptogenic factors from mitochondria leads to the formation of the apoptosome,
whereas ER stress activates caspase-12 (in the mouse) and perhaps the human
homolog, caspase-4. Both mitochondria and ER routes lead to the activation of
caspase-9 which then activates the executioner caspases, -3, -6 and -7.
1.7. The extrinsic and intrinsic pathways to apoptosis
As has already been mentioned, two main routes to caspase activation have been
characterised in the mammalian system: the extrinsic pathway, which relies on the
activation of cell-surface death receptors, and the more ancient and evolutionary
conserved intrinsic pathway that is activated by a variety of cellular stresses and
involves the release of apoptogenic molecules from within mitochondria (Adams, 2003).
Although both pathways are triggered by distinct stimuli and have the capacity to initiate
caspase activity independently from each other (Strasser et al., 1995), it has become
apparent that under many circumstances both pathways cooperate in order to maximise
the rate of caspase activation within any given cell undergoing apoptosis (Schmitz et al.,
2000; Degterev et al., 2003). An overview of the intrinsic and extrinsic pathways to
apoptotic cell death is provided in
1.7.1. The extrinsic (or death-receptor) pathway
The extrinsic apoptotic pathway is initiated when death ligands bind to corresponding
death receptors on the extracellular surface of the plasma membrane on the cell destined
to die (Ashkenazi and Dixit, 1998). This type of "instructive" apoptosis is particularly
important within the immune system where cytotoxic T cells expressing death ligands
on their surface engage virus-infected and/or cancerous cells and target them for
destruction by apoptosis (Boise and Thompson, 1996). The elimination of redundant
immune and inflammatory cells at the end of the immune response, as well as the
destruction of auto-reactive T- and B-cells, is also mediated by the engagement of death
receptors and the initiation of the extrinsic apoptotic pathway (Osborne, 1996),
preventing excessive cytokine release and autoimmunity that may otherwise result in
extensive tissue damage.
Of the six death receptors currently identified, Fas/CD95, TNF-R1 and TRAIL-R1 and -
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Figure 1.5. Molecular pathways leading to apoptosis in mammalian cells.
Activation of the extrinsic pathway begins with the binding of soluble or cell surface-
expressed ligands to death receptors, such as TNF-R1, FasR and TRAIL, on the plasma
membrane. This stimulates formation of the death-inducing signaling complex (DISC)
which catalyses the activation of caspase-8. Caspase-8 then directly activates the
executioner caspase, caspase-3, which leads to apoptotic cell death. Alternatively, in
response to various stress stimuli, the intrinsic pathway is initiated through the
activation and translocation of pro-apoptotic Bcl-2 family proteins, such as Bax, to the
mitochondrial surface. Genotoxic stress also activates p53 which initiates the
transcriptional upregulation of Bax, and the pro-apoptotic BH3-ony proteins Puma and
NOXA. Permeabilisation of the OMM by Bax and Bak homo-oligomers releases
cytochrome c into the cytosol which is required for the activation of capsae-9 via the
apoptosome. Caspase-9 then activates executioner caspases. Cross-talk between these
two pathways occurs as a result of caspase-8-mediated cleavage of Bid to tBid which
then promotes Bax activation, translocation and/or oligomerisation on the OMM.
proteins and contain a C-terminal intracellular tail, a membrane-spanning region and an
extracellular ligand-binding N-terminal domain (Schulze-Osthoff et al., 1998).
Respective ligands for the above receptors belong to the TNF superfamily (Schmitz et
al., 2000), and are typically found either as transmembrane proteins expressed on the
surface of specialised cells, such as Fas ligand (FasL/CD95L) on activated T cells
(Berke, 1995), or as soluble molecules (cytokines), such as TRAIL and TNFa released
from macrophages, T cells and B cells (Yoon and Gores, 2002).
The cytoplasmic tails of the death receptors, together with a specialised adapter protein
known as Fas-associated death domain (FADD) recruit initiator procaspase-8 by means
of homologous binding between death effector domains (DEDs) on FADD and within
the prodomain of procaspase-8 (Muzio et al., 1996). Together, this forms the death-
inducing signalling complex (DISC) which ramps up the autocatalytic activation of
procaspase-8 (Boatright et al., 2003). Mature caspase-8 then directly cleaves and
activates the effector caspases, -3 and -7, which leads to apoptotic cell death..
The above overview describes the pathway found in what are known as type I cells,
typified by peripheral T cells and thymocytes, in which the death receptor-mediated
activation of initiator caspases leads directly to the activation of the effector caspases-3
and -7 (Scaffidi et al., 1998). However, in type II cells, such as epithelial cells,
insufficient caspase-8 is generated from DISC to sustain this direct approach, and so an
amplification step is required (Scaffidi et al., 1998). In the type II pathway, activated
caspase-8 cleaves the pro-apoptotic Bcl-2 family protein, Bid (Luo et al., 1998; Li et al.,
1998), which initiates the release of cytochrome c from mitochondria. - see Figure 1.5.
This biochemical event constitutes a major step within the alternative intrinsic apoptotic
pathway, as will be described in the following section. Cytosolic cytochrome c then
recruits apoptosis protease activating factor-1 (Apaf-1) and procaspase-9 to form the
apoptosome which catalysis the allosteric conformational maturation of this initiator
caspase (Rodriguez and Lazebnik, 1999; Zou et al., 1999). Active caspase-9, as with
caspase-8, cleaves and activates the effector caspases-3 and -7 to bring about apoptotic
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cell death (Li et al., 1997). Thus, in type I cells apoptosis can be induced independently
of mitochondrial involvement, whereas in type II cells cytochrome c released from
mitochondria is an essential amplification loop to ensure that sufficient quantities of
active caspases are generated for apoptosis to run its course (Schmitz et al., 2000).
Indeed, in such type II cells, over-expression of the anti-apoptotic Bcl-2 family proteins,
Bcl-2 or Bc1-Xl, which function to protect the mitochondria, effectively inhibit Fas-
induced apoptosis (Adams and Cory, 1998). Therefore, the concept that the extrinsic
and intrinsic routes to apoptosis are always distinct and separate events is an over¬
simplification of the converging pathways to apoptosis.
1.7.2. The intrinsic (or mitochondrial) pathway
The intrinsic apoptotic pathway (also known as the stress-induced or mitochondrial
pathway) is initiated in response to diverse extracellular stimuli, such as ionising
radiation, hypoxia, chemotherapeutic agents or withdrawal of growth cues, such as
cytokines, NGF and serum (Adams, 2003). In response to such environmental factors,
pro-apoptotic proteins belonging to the Bcl-2 family are activated and target the
mitochondria where they liberate the release of cytochrome c and other apoptogenic
molecules across the outer mitochondrial membrane (OMM). Once in the cytosol,
cytochrome c initiates the activation of caspase enzymes, via the apoptosome, and the
execution phase of apoptosis commences.
Since this pathway is initiated in response to cellular stress, it is the principle mechanism
by which cells undergo apoptosis during or following traumatic brain injury and stroke,
as well as underlying the pathological apoptosis associated with neurodegenerative
diseases and myocardial ischaemia (Thompson, 1995; Mattson, 2000). As a result,
much effort is being employed to develop new therapeutic approaches that specifically
























Figure 1.6. Release of apoptogenic factors from the mitochondrial inter-
membrane space. The mitochondrial inner membrane space holds a host of
apoptogenic factors that are released into the cytosol following permeabilisation of the
outer mitochondrial membrane (OMM). Pro-apoptotic Bcl-2 family proteins form
multi-meric pores or stimulate opening of the mitochondrial permeability transition pore
(MPTP) to release cytochrome c. which is required to form the caspase-9 activating
apoptosome complex. The release of smac/DIABLO, which requires active caspases,
neutralises inhibitor of apoptosis proteins (IAPs), particularly XIAP, preventing them
from suppressing caspase activation. A functionally related protein, the serine protease
Omi/HtrA2, also interacts with and neutralises IAPs. The flavoprotein, apoptosis-
inducing factor (AIF), and the DNase, endonuclease G (EndoG), translocate into the
nucleus where they cleave genomic DNA independently of caspase-activated nucleases,
such as CAD/DFF40.
Initiation of the intrinsic pathway is determined by a diverse group of proteins
containing both pro- and anti-apoptotic members known as the Bcl-2 protein family, the
founding member of which has already been introduced. Bcl-2, together with other anti-
apoptotic Bcl-2 family proteins, protects the cell against apoptosis by preventing pro-
apoptotic proteins within the same family permeabilising the OMM, thus ensuring
containment of the host of apoptogenic molecules that reside within the inter-membrane
space (Yang et al., 1997; Kluck et al., 1997). The intrinsic pathway is therefore
commonly delineated into events occurring upstream of OMM permeabilisation, which
concern the Bcl-2 protein family, and those that follow the release of death-promoting
factors from mitochondria into the cytosol leading to the activation of the caspases.
However, this model is complicated by other findings which show that caspases can be
activated upstream or independently of mitochondrial events (Strasser et al., 2000;
Adams, 2003); that the release of certain apoptogenic molecules (for example,
smac/DIABLO) is caspase-dependent (Adrain et al., 2001); and that permeabilisation of
the OMM can lead to apoptotic cell death independently of caspase activity via the
mitochondrial release of such death agents as apoptosis-inducing factor (AIF) (Susin et
al., 1999) and endonuclease G (EndoG) (Li et al., 2001) that translocate directly into the
nucleus -
1.8. The role of mitochondria in the intrinsic apoptotic pathway
The role of mitochondria as the metabolic engine of the cell, generating more than 90%
of available adenosine triphosphate (ATP) by oxidative phosphorylation, and thus
essential for life, is well established (Nieminen, 2003). However, with the discovery
that Bcl-2 exerts its protective effect at the mitochondrial membrane (Hockenbery et al.,
1990) and that a mitochondria-enriched membrane fraction was required for apoptosis to
take place in Xenopus laevis oocyte extracts (Newmeyer et al., 1994), it became
apparent that mitochondria were also a central component of cell death pathways.
Moreover, the discovery that the release of the electron carrier, cytochrome c, from the
inter mitochondrial membrane space into the cytosol is required for caspase activation
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and apoptosis in response to several stress-inducing stimuli, led to the hypothesis that
the permeabilisation of the OMM is an essential checkpoint within the intrinsic
apoptotic pathway (Liu et al., 1996; Kluck et al., 1997; Li et al., 2000). However, the
loss of cytochrome c from the mitochondria has obvious implication for energy
metabolism and thus for sustaining the apoptotic process due to its reliance on ATP
production (Leist et al., 1997). During Fas-induced apoptosis in mouse hepatocytes,
mitochondrial respiration was seen to diminish over time, concomitant with cytochrome
c release (Mootha et al., 2001). It has been shown that the soluble fraction of
cytochrome c within the inter-membrane space is released early in apoptosis, before the
electrochemical gradient (Ai|/m) across the inner mitochondrial membrane (IMM)
driving ATP synthesis has been significantly disrupted (Wei et al., 2000; Shimizu and
Tsujimoto, 2000). This initial release phase is thought to be sufficient to induce
formation of the apoptosome while the remaining pool of cytochrome c that is more
tightly associated with the IMM ensures that the electron transport chain continues
operating (van Loo et al., 2002; Ott et al., 2002; Scorrano et al., 2002). Eventually, as
cytochrome c continues to be released from mitochondria and apoptosis enters its final
stages, A\j/m collapses and mitochondrial respiratory function is no longer sustainable
(Mootha et al., 2001; van Loo et al., 2002).
1.9. The Bcl-2 protein family
Proteins belonging to the Bcl-2 family are characterised structurally by their Bcl-2
homology (BH) domains and can be classified into three functionally-distinct
subfamilies according to the number ofBH domains they posses - sec Figure 1.7. Bcl-2
and its four anti-apoptotic relatives, BcI-Xl, Bcl-w, Mcl-1 and Al, contain all four BH
domains (BH 1-4) and protect the mitochondria by sequestering and inhibiting pro-
apoptotic Bcl-2 family proteins under normal conditions (Cheng et al., 2001; Cory and
Adams, 2002). The pro- apoptotic members of the Bcl-2 protein family can be further
sub-divided into two structurally and functionally distinct subgroups, both of which are
required for killing (Zong et al., 2001; Cory and Adams, 2002): 1) the multi-BH domain
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Sub-family Bcl-2 family protein Cellular localisation Noteable Functions
Anti-apoptotic
Bcl-2 (B cell lymphoma-
associated protein 2)
OMM, ER & nucelar membranes
Bcl-2, and other multi-domain anti-apoptotic proteins,
protect the cell against instrinsic stress stimuli.1
Bcl-w Loosely attached to OMM Essential for spermatogeneisis.2,3
Bcl-XL (B cell lymphoma
protein X Long isoform)
OMM & nuclear membranes A key regulator of Bax during neuronal development.4
Bcl-XES (B cell lymphoma
protein X extra short isoform)
Cytosol/OMM Inhibits Bax oligomer formation and Apaf-1 function.5
Mcl-1 (Myeloid-cell leukemia
sequence-1) Cytosol/OMM
Inhibits the pro-apoptotic activity of Bok, Bax and Bak.6
A1 OMM




Bax ( Bcl-2 associated
protein X) Cytosol
Permeabilises the OMM to release cytochrome c.8,9
Bak (Bcl-2 antagonist killer
protein)
OMM Permaebilises the OMM to release cytochrome c.10
Bok (Bcl-2-related ovarian OMM Important pro-apoptotic protein in reproductive
killer protein) tissues.11
Bcl-Xs (B cell lymphoma A pro-apoptotic cleavage product generted from Bcl-XL








Truncated by caspase-8 to form active tBid.13, 14
Promotes Bax and Bak activity.15,16
Bim (Bcl-2-interacting
mediato of cell death; Bim-
EL, Bim-L, Bim-s)
Cytosol
Promotes Bax activity.17 A major apoptogenic protein
in the immune system18 and nervous system.19
Puma (P53 upregulated
modulator of apoptosis) Nucleus/cytosol




Bad (Bcl-2 antagonist of cell
death)
Cytosol (sequestered to 14-3-3
proteins)
Inhibits Bcl-XL.23
Bik (Bcl-2-interacting killer) Cytosol
Inhibits Bcl-2 and Bcl-XL.24 Required for apoptosis in B
cells.25
Bmf (Bcl-2-modifying factor) Cytosol (sequestered tocytoskeletal proteins) May be critical to apoptosis induced by anoikis.26
BNIP3 Cytosol




apoptosis in certain neuronal cell populations.28
Noxa ("damage-causing") Cytosol Upregulated by p53.29 and inhibits Mcl-1 and A1.30
Table 1.2. The Bcl-2 protein family. References: 1, 11. Cory & Adams, 2002. 2.
Print et al., 1998. 3. Ross et al., 1998. 4. Shindler et al., 1997. 5. Schmitt et al., 2004.
6. Hsu et al., 1997. 7. Hamasaki et al., 1998. 8. Eskes et al., 1998. 9. Jurgensmeier et
al., 1998. 10, 15. Korsemeyer et al., 2000. 12. Nakagawa & Yuan, 2000. 13. Luo et al.,
1998. 14. Li et al., 1998. 16. Wei et al., 2000. 17. Marani et al., 2002. 18. Bouillet et
al., 2002. 19. Putcha et al., 2002. 20, 22. Nakagawa & Vousden, 2001. 21. Jeffers et
al., 2003. 23. Schinzel et al., 2004. 24. Letai et al., 2002. 25. Jiang & Clark, 2001. 26.
Puthalakath et al., 2001. 27. Kubasiak et al., 2002. 28. Imaizumi et al., 2004. 29. Oda
et al., 2000. 30. Yakovlev et al., 2004.
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Figure 1.7. Classification of the Bcl-2 protein family according to structure. The
Bcl-2 family proteins contain conserved Bcl-2 homology domains (BH domains) in
reference to the four BH domains (1-4) initially identified within Bcl-2 and also found
within the other multi-domain anti-apoptotic members. All Bcl-2 family proteins
contain a BH3 domain which mediates heterodimerisation between opposing members
of the family through insertion into a hydrophobic groove (or "receptor") formed by BH
domains 1-3 on multidomain proteins. The pro-apoptotic proteins are divided into two
sub-families: the multi-domain (BH1-3) proteins, Bax, Bak and Bok, and the numerous
BH3-only proteins. A carboxyl-terminal hydrophobic domain that facilitates
association with intracellular membranes (Transmembrane (TM) domain) is found in all
members except A1 and several BH3-only proteins. Known alpha helices are also
depicted. Image adapted from Cory & Adams, 2002.
Bax family, containing Bax and Bak, which are the main effectors of OMM
permeabilisation (Wei et al., 2001), as well as Bok, a poorly characterised protein
expressed in reproductive tissues (Hsu et al., 1997a), and 2) the numerous BH3-only
proteins that function as pro-death signalling factors as well as antagonists to the
protective BH1-4 proteins (Cory and Adams, 2002) - see . for a full list and
description of these proteins.
1.9.1. Cellular localisation of Bcl-2 family proteins
The principle cellular target of the Bcl-2 protein family is the mitochondria. On the
cytosolic face of the OMM reside the anti-apoptotic proteins, Bcl-2, Bcl-XL, Bcl-w and
Mcl-1 as-well as the pro-apoptotic protein, Bak (Schinzel et al., 2004a). In contrast, Bax
and the pro-apoptotic BH3-only proteins are predominantly found within the cytosol and
therefore must translocate to the OMM during apoptosis in order to make a functional
contribution (Sattler et al., 1997; Wolter et al., 1997). The presence of a C-terminal
transmembrane domain in many Bcl-2 family proteins determines their cellular
localisation to the membrane surfaces of organelles (Nguyen et al., 1993; Kaufmann et
al., 2003) and has been implicated as a membrane-targeting domain directing pro-
apoptotic proteins through the cytosol to the OMM during apoptosis (Wolter et al.,
1997; Nechushtan et al., 1999; Suzuki et al., 2000). As will be discussed in more depth
later, regulation of the exposure of this domain in the pro-apoptotic protein Bax is a key
determinant of its apoptogenic function and, as such, is currently a key focus area for
research.
In addition to mitochondria, Bcl-2 family proteins are also found on, or translocate to,
the surface of the ER membrane, where they have been proposed to initiate an ER-
directed cell death pathway in response to certain intracellular stimuli, such as the
accumulation of misfolded proteins or a perturbed Ca2+ homeostasis (Nakagawa et al.,
2000; Wei et al., 2001; Scorrano et al., 2003). In fact, the majority of endogenous Bcl-2
(about two thirds) is located on the ER membrane (Lithgow et al., 1994; Schinzel et al.,
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2004a) and the pro-apoptotic proteins, Bax and Bak, have been observed to translocate
there (Nutt et al., 2002; Scorrano et al., 2003).
1.9.2. Structure-function relationships within the Bcl-2 protein family
For nearly a decade following the discovery of Bcl-2, the underlying mechanism by
which the Bcl-2 family of proteins regulated apoptosis remained unknown (Korsmeyer,
1995). However, detailed structural analyses of Bcl-2 family proteins, together with
genetic studies in C. elegans, finally provided an insight into how these proteins were
able to regulate their own activity and thus determine the fate of the cell in response to
stress signals. The first breakthrough came with the elucidation of the structure of the
anti-apoptotic Bcl-2 family member, Bc1-Xl, using X-ray crystallography and nuclear
magnetic resonance (NMR) (Muchmore et al., 1996). This study revealed Bc1-Xl to
have a central hydrophobic core consisting of two alpha helices surrounded by five
amphipathic a helices to form a structure that bore close resemblance to certain pore-
forming bacterial toxins, namely diphtheria toxin and the colicins (Parker and Pattus,
1993). This observation gave rise to the theory that pro-apoptotic members belonging to
the Bcl-2 protein family could form membrane pores or ion channels in order to liberate
apoptogenic molecules across intracellular membranes, a mechanism that still has
support today but is currently difficult to prove in a real-time in vivo setting (Sharpe et
al., 2004). The crystal structure of Bcl-XL also illustrated how the orientation of the BH
domains formed a hydrophobic groove that was proposed to form a putative binding site
for other Bcl-2 family proteins (Muchmore et al., 1996). The following year it was
demonstrated that the amphipathic helical BH3 domain belonging to one Bcl-2 family
member could insert into the hydrophobic pocket of another (Sattler et al., 1997) - see
. This had important implications for explaining how opposing members of
the Bcl-2 protein family, for example the BH1-4 anti-apoptotic proteins and the pro-
apoptotic BH3-only proteins, could potentially interact and neutralise each other. The
theory that interaction between opposing members of the Bcl-2 protein family controlled
their activity was first put forward by researchers working in the laboratory of Stanley
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Figure 1.8. Three-dimensional structures of Bcl-xL and Bax, showing their
similarity, (a) Bcl-xL, with its four BH domains labelled, (b) Bcl-xL with the BH3
peptide of Bak (brown) bound to its surface groove, (c) Bax, showing its C-terminal tail
(yellow) tucked into the groove, but running in the opposite orientation to a BH3 ligand.
Image taken from Cory & Adams, 2002.
Korsmeyer who discovered the pro-apoptotic Bcl-2 family member, Bax, as a binding
partner of Bcl-2 (Oltvai et al., 1993). Further proof that heterodimerisation amongst
Bcl-2 family proteins was a central regulatory mechanism arose from genetic studies in
C. elegans where the BH3-only protein homolog, EGL-1, directly interacted with and
suppressed the anti-apoptotic Bcl-2 homolog, CED-9 (Conradt and Horvitz, 1998). The
mechanism by which opposing Bcl-2 family proteins heterodimerise was also proposed
to mediate homodimerisation between multi-domain pro-apoptotic Bcl-2 family
proteins, such as Bax and Bak, into large proteinaceous channels across the OMM
(Chittenden et al., 1995; Zha et al., 1996; Simonian et al., 1996). However, despite
these early reports supporting the requirement of the Bax/Bak BH3 domain for homo-
oligomerisation, subsequent studies have failed to establish their validity and so the
domains within Bax and Bak responsible for their oligomerisation on the OMM remain
unknown (Sharpe et al., 2004). Nevertheless, as will be discussed in more detail later,
the ability ofBax and Bak to from such homo-oligomers is thought to be crucial to their
pro-apoptotic activity (Gross et al., 1998; Wei et al., 2000; Antonsson et al., 2000;
Korsmeyer et al., 2000; Nechushtan et al., 2001) as it provides a possible mechanism by
which they are able to destabilise the OMM or assemble themselves into trans¬
membrane pores of sufficient size to mediate the release of death-promoting proteins
across the OMM.
1.9.3. The pro-apoptotic BH3-only proteins
Under normal conditions, the majority of pro-apoptotic BH3-only proteins lie dormant
and dispersed throughout the cytosol (Sattler et al., 1997). However, upon induction of
apoptosis, these proteins are either transcriptionally upregulated or liberated from
various post-translational checkpoints - .ee Table 1.3. It is therefore currently thought
that the BH3-only proteins represent the early responders within the Bcl-2 family to
incoming stress signals or developmental cues (Adams, 2003). Once liberated, BH3-
only proteins target either multi-domain anti-apoptotic proteins, such as Bcl-2, Bc1-xl,










Figure 1.9. Differential targeting by BH3-only proteins. During stress-induced
apoptosis, BH3-only "survival agonists" translocate to the OMM and interact with anti-
apoptotic Bcl-2 proteins in order to neutralise their activity. This targeting is mediated
either through having high affinity for multi-domain Bcl-2 family members, or by"death
agonists" utilising C-terminal I'M domains, as is the case for Bik, Hrk, Blk, and Bim.
Alternatively, the BH3-only proteins Bid/tBid, Bim-s and PUMA, are known to also
interact directly with pro-apoptotic multi-domain Bcl-2 family proteins, such as Bax, to
stimulate their activity.
Regulatory control BH3-only protein Stimulus References
Transcriptional NOXA DNA damage 1
PUMA DNA damage 2
Bims Growth factor deprivation 3
Hrk Growth factor deprivation 4
Post-translational modification:





Phosphorylation Bik ? 8
Dissocation from:
14-3-3 scaffold proteins Bad Growth factor deprivation 9
Dynein light chain 1 BimEL, BimL Ca2+ flux/taxol 10
Dynein light chain 2 Bmf UV irradiation/anoikis 11
Table 1.3. Regulation of BH3-onIy protein activation. BH3-only proteins, as
sentinels for cell stress within the Bcl-2 protein family, respond to diverse stimuli and
require either transcriptional or post-translation-modifications to become active death-
promoting proteins. References: 1. Oda et al., 2000. 2. Nakano & Vousden, 2001. 3.
Putcha et al., 2001. 4. Imaizumi et al., 1999. 5. Luo et al., 1998. 6. Li et al., 1998. 7.
Wang et al., 1999. 8. Verma et al., 2001. 9. Zha et al., 1996. 10. Puthalakath et al.,
1999. 11. Puthalakath et al., 2001.
apoptotic proteins (Yang et al., 1995; Wilson-Annan et al., 2003; Willis et al., 2005), or
promote the activation of the effector pro-apoptotic proteins of the Bcl-2 family, Bax
and Bak (Wang et al., 1996; Desagher et al., 1999; Cartron et al., 2004; Kuwana et al.,
2005) -
1.9.4. The multi-domain pro-apoptotic proteins
The multi-domain proteins, Bax and Bak, share extensive structural homology and
together represent the core components of the pro-apoptotic Bcl-2 family protein
machinery (Lindsten et al., 2000; Wei et al., 2001). This authoritative position is
demonstrated by the many observations that, in the absence of both Bax and Bak, none
of the remaining pro-apoptotic Bcl-2 family proteins are able to breach the OMM and
liberate the apoptogenic molecules within (Wei et al., 2001; Zong et al., 2001; Cheng et
al., 2001). From genetic studies, the inactivation of both genes {Bax1' Bak'1') was
observed to dramatically impair apoptosis in a wide variety of tissues in response to
classical activators of the intrinsic pathway, such as ionising radiation, DNA-damaging
drugs, the kinase inhibitor staurosporine and growth factor deprivation (Lindsten et al.,
2000; Wei et al., 2001; Cheng et al., 2001). Moreover, few Bax'1'Bak'1' mice survive to
adulthood and those that do exhibit severe developmental defects in multiple tissues as
well as impaired regulation of tissue homeostasis (Lindsten et al., 2000; Lindsten et al.,
2003) In contrast, disrupting Bak gene expression alone in mice {Bak'1') does not appear
to result in any observable phenotypic abnormalities (Lindsten et al., 2000), whereas
obvious developmental abnormalities were observed in Bax'1' mice, such as increased
populations of sympathetic and facial motor neurones indicating defective
developmental neuronal cell death (Deckwerth et al., 1996) and infertility in the males
due to impaired spermatogenesis (Knudson et al., 1995). This therefore suggests that
the intrinsic apoptotic pathway in certain tissues is Bax-dependent. However, both Bak''
and Bax'1' knock-out animals survive into adulthood (Knudson et al., 1995; Lindsten et
al., 2000) which suggests that a certain degree of functional redundancy exists between
these two proteins.
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How Bak and Bax bring about the release of apoptogenic molecules from the
mitochondrial inter-membrane space has yet to be conclusively determined (Sharpe et
al., 2004). One enduring hypothesis, based on the structural resemblance of certain Bcl-
2 family members to diphtheria toxin (Muchmore et al., 1996) is that both Bax and Bak
form pore-like channels within the OMM through which apoptogenic molecules can
pass. This model is perhaps most convincingly supported by the finding that oligomers
of Bax can form pores in liposomes that can permit the passage of cytochrome c (Saito
et al., 2000; Antonsson et al., 2000) as well as larger molecules (Kuwana et al., 2002).
Furthermore, several studies have demonstrated that both proteins insert into the OMM
and oligomerise into large complexes during apoptosis to form pore-like structures
(Nechushtan et al., 2001; Antonsson et al., 2001). However, although the existence of
these pores is well documented, their precise nature and structure remains unresolved
(Adams, 2003; Newmeyer and Ferguson-Miller, 2003). There is also evidence
consistent with an alternative model in which Bax interacts with and stimulates opening
of a large conductance channel spanning the IMM and OMM called the mitochondrial
permeability transition (MPT) pore (Tsujimoto and Shimizu, 2000; Zamzami and
Kroemer, 2001). In support of this hypothesis, Bax has been shown to be capable of
binding to the MPT pore component, voltage-dependent anion channel (VDAC) on the
OMM (Narita et al., 1998; Shimizu et al., 1999). Opening of the MTP pore leads to a
collapse in Ai|/m and the influx ofwater into the mitochondrial matrix (Green and Reed,
1998). The resultant swelling of the matrix ruptures the OMM and releases soluble
molecules within the inter-membrane space into the cytosol (Green and Reed, 1998). A
collapse in A\|/m, matrix swelling and rupture of the OMM are all features associated
with apoptosis (Petit et al., 1996), however it has been shown that none of these events
are required for Bax and/or Bak to elicit cytochrome c release and caspase activation
(Bossy-Wetzel et al., 1998; Green and Reed, 1998). This therefore suggests that an
alternative mechanism ofOMM permeabilisation is employed by these proteins.
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1.10. Bax
The multi-domain pro-apoptotic protein, Bcl-2 associated protein X (Bax), is a keystone
protein within the Bcl-2 family as it translates the intent of the pro-apoptotic BH3-only
proteins into direct action at the mitochondrial surface through permeabilisation of the
OMM (Cory and Adams, 2002).
Despite containing a C-terminal transmembrane domain, the majority of endogenous
Bax (estimates range from 60-80%) is found as a soluble monomer in the cytosol of
healthy cells (Wolter et al., 1997; Hsu and Youle, 1998; Nechushtan et al., 2001) with
the remainder found loosely attached on the surface of mitochondria and the
endoplasmic reticulum (Eskes et al., 2000; Scorrano et al., 2003). Thus, unlike Bak,
which resides on the OMM in complex with Mcl-1 and Bc1-Xl (Cuconati et al., 2003;
Willis et al., 2005), the majority of endogenous Bax has to first pass through the
cytosolic milieu before it can elicit a cytotoxic effect at the mitochondrial surface
(Wolter et al., 1997; Hsu et al., 1997b; Goping et al., 1998). This secondary, post-
transcriptional level of regulation is thought to ensure that, under normal conditions, a
protein as potentially lethal as Bax is maintained in a subcellular location distinct from
its site of action (Schinzel et al., 2004a).
How Bax becomes activated remains uncertain (Adams, 2003; Lucken-Ardjomande and
Martinou, 2005). One possibility involves the pro-apoptotic BH3-only protein Bid
(Desagher et al., 1999; Eskes et al., 2000). In response to death receptor activation, Bid
is cleaved into a 15.5kDa fragment containing its BH3 domain and C-terminal tail (tBid)
by caspase-8 (Luo et al., 1998; Li et al., 1998). tBid is then myristoylated which leads
to its translocation to the OMM (Zha et al., 2000) where it has been proposed to engage
Bax and promote its oligomerisation (Desagher et al., 1999; Eskes et al., 2000;
Korsmeyer et al., 2000; Roucou et al., 2002; Kuwana et al., 2002). However, this
interaction, if it does occur, must be only a transient one as so far co-localisation of tBid
and Bax on the mitochondrial surface has not been observed (Nechushtan et al., 2001)
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and neither has tBid been identified as a component of Bax oligomers (Wei et al., 2000;
Grinberg et al., 2002). Alternatively, tBid may intercept Bax before it has undergone
translocation to the OMM in order to initiate this event (Cartron et al., 2004).
Supporting evidence for this arose from the recent identification of a novel binding site
within the N-terminal al helix of Bax that received Bid (and the BH3-only protein
PUMA) leading to ligand-induced Bax activation and its subsequent translocation to the
OMM (Cartron et al., 2004). However, in the absence of Bid, although Fas-mediated
apoptosis in hepatocytes is impaired (Yin et al., 1999) stress-induced apoptosis that
relies on OMM permeabilisation is not (Wei et al., 2001), suggesting that other
regulatory factors/proteins play a hand in orchestrating Bax activation.
1.10.1. The role of Bax in neuronal apoptosis
Gene deletion studies have demonstrated that Bax makes an important contribution to
neuronal apoptotic pathways initiated during development and in response to
neuropathology (Deckwerth et al., 1996; White et al., 1998). As has already been
discussed, the elimination of synapse-bearing neurones by apoptosis in the developing
nervous system is a central mechanism through which neuronal cell numbers in the adult
brain are determined (Oppenheim, 1991). This process is largely orchestrated by
restricting the availability of target-derived neurotrophic support within the CNS during
this developmental phase, which leads to the initiation of the intrinsic apoptotic pathway
in neurotrophin-deprived cells (Deckwerth and Johnson, Jr., 1993; Edwards and
Tolkovsky, 1994). Consequently, Bax-knockout mice exhibit a markedly reduced
apoptotic programme within the developing nervous system, which leads to increased
neuronal cell numbers in a variety of sites, including the brainstem, cerebellum, dorsal
root ganglia, hippocampus and spinal cord (Deckwerth et al., 1996; White et al., 1998).
In contrast, the influence of Bax deletion in the development of non-neuronal tissues
appears to be less noticeable (Knudson et al., 1995). This observed dependence of
neuronal tissue on Bax function is also seen in vitro, where the withdrawal ofNGF from
cultured sympathetic neurons lacking Bax does not initiate cytochrome c release and
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apoptotic death, as is observed in wild type cultures (Deckwerth et al., 1996; Deshmukh
and Johnson, Jr., 1998).
Increased Bax activity has also been associated with certain types of neurodegeneration,
particularly seizure-induced neurodegeneration (diaschisis) (Zhang et al., 1998;
Tuunanen et al., 1999) and neurodegeneration resulting from ethanol-induced neonatal
brain injury (Young et al., 2003) and nerve injury, for example that following axotomy
of motoneurones (Gillardon et al., 1996a) or the optic nerve (Isenmann et al., 1997).
Increased expression of Bax has also been identified in several chronic
neurodegenerative diseases, including ALS and Alzheimer's disease. Increased
expression of Bax was identified in transgenic mouse models of ALS (Vukosavic et al.,
1999) as well as in the motor cortex and spinal cord motor neurons of patients who had
died from ALS (Mu et al., 1996; Ekegren et al., 1999), and the upregulation of several
pro-apoptotic proteins, including Bax, has been observed in neurons associated with
amyloid deposits in the brains of Alzheimer's patients (Tortosa et al., 1998; Mattson,
2000). In animal models of global cerebral ischeamia, increased Bax expression has
been observed in neurones within ischemia-sensitive regions of the brain, such as the
CA1 sector of the hippocampus (Krajewski et al., 1995; Hara et al., 1996), and, in a
rodent model of middle cerebral artery occlusion, elevated Bax protein expression was
identified in the penumbral region of focal infarcts (Gillardon et al., 1996b). Targeting
the apoptogenic activity of Bax by therapeutic intervention could therefore reduce the
extent of neuronal apoptotic cell death observed in all of these disorders.
1.10.2. Bax structure
Insights into how the mitochondrial targeting of Bax is regulated came from the partial
elucidation of the soluble Bax structure by NMR technology (Suzuki et al., 2000). This
study revealed that the Bax protein structure bears many similarities to other multi-
domain proteins within the Bcl-2 protein family, such BcI-Xl, the structure of which had
also been determined (Muchmore et al., 1996). However, unlike the anti-apoptotic
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Figure 1.10. Structure of Bax. A ribbon representation of the NMR structure of Bax,
viewed straight down the central hydrophobic a5 helix. The BH1-3 domains are shown
in cyan, magenta and red, respectively. The C-terminal helix (a9) is shown in green.
Image taken from Suzuki et al, 2000.
multidomain proteins, Bax does not contain a fourth BH domain (Suzuki et al., 2000).
Eight amphipathic a helices within Bax are arranged around a central hydrophobic a
helix (a5), forming a hydrophobic core to the protein - < igu.R The BH3
domain, which is required for the activity of pro-apoptotic members in the Bcl-2 family,
is in a helix 2. BH domain 1, 2 and 3 enclose a hydrophobic pocket into which the BH3
domain from a partner protein (eg, another Bax protein or Bid/tBid) has been proposed
to insert (Sattler et al., 1997). Significantly, the a9 helix, which forms part of the C-
terminal transmembrane domain, normally occupies this region, preventing accessibility
to the BH3 domains of other proteins under resting cellular conditions (Suzuki et al.,
2000). The intra-molecular folding of the transmembrane domain, which is highly
hydrophobic, increases the solubility of Bax, thus allowing it to reside as a soluble entity
within the cytosol (Suzuki et al., 2000; Schinzel et al., 2004a). This arrangement,
whereby the transmembrane domain is folded back into a hydrophobic pocket, is also
found in the anti-apoptotic Bcl-2 family protein, Bcl-w, which resides loosely attached
to the OMM under normal conditions (Hinds et al., 2003; Denisov et al., 2003; Adams,
2003). However, during apoptosis, displacement of the Bcl-w C-terminal
transmembrane domain out of the hydrophobic pocket by a BH3-only protein leads to
the insertion of Bcl-w into the OMM, in a process presumably directed by the now
exposed transmembrane domain (Wilson-Annan et al., 2003). Similarly, the C-terminal
transmembrane domain of Bax, when exposed during apoptosis, is implicated in
directing its translocation to the mitochondrial surface and mediating, either solely or in
collaboration with other domains, insertion into the OMM (Wolter et al., 1997; Goping
et al., 1998; Eskes et al., 2000; Annis et al., 2005). However, in order to accommodate
a BH3 domain within the hydrophobic pocket, structural analysis has predicted that Bax
has to undergo significant structural alterations involving not just the "unhinging" of the
C-terminal a9 helix but also other, distinct regions of the molecule, such as the N-
terminus (Goping et al., 1998; Nechushtan et al., 1999; Suzuki et al., 2000). Structural
studies by Suzuki and colleagues determined that the Bax N-terminus is flexible and
solvent-exposed; however, it is a well documented phenomenon that certain residues
with the N-terminus (Prol3-Ilel9; known as the 6A7 epitope; Hsu & Youle, 1997)
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remain hidden in cytosolic Bax and are only exposed and thus available to antibody
binding during apoptosis (Hsu and Youle, 1997; Nechushtan et al., 1999; Suzuki et al.,
2000; Cartron et al., 2002). Furthermore, removal of the first 20 residues of Bax, a
region known as the apoptosis regulation of translocation (ART) domain, results in
increased targeting of Bax to mitochondria through enforced exposure of the C-terminal
transmembrane domain (Goping et al., 1998; Ruffolo et al., 2000) - ee Figure 1 for
an overview of the key regulatory domains within Bax. These observations led to the
proposal that the N-terminus of Bax exerts an inhibitory effect on the exposure of the C-
terminal transmembrane domain through direct interaction when Bax is cytosolic
(Goping et al., 1998; Nechushtan et al., 1999; Arokium et al., 2004; Schinzel et al.,
2004b). Recent work has illuminated the role of a proline residue found within a solvent
exposed loop region directly preceding the C-terminal transmembrane domain (Pro 168)
that has been proposed to link the C-and N-termini ofBax (Schinzel et al., 2004b). This
bridging residue may therefore establish an allosteric mechanism through which
structural alterations occurring in one terminal domain can directly influence those
occurring in the other. Thus one possible model of how Bax becomes activated is that,
in response to an appropriate apoptotic stimulus, N-terminal conformational alteration,
perhaps triggered following interaction with tBid or PUMA, regulates the unhinging of
the C-terminal transmembrane domain which in turn directs the targeting of Bax to the
OMM (Sharpe et al., 2004; Schinzel et al., 2004a; Lucken-Ardjomande and Martinou,
2005).
Following on from the observation made by Muchmore and colleagues that the
arrangement of a helices 5 and 6 in Bcl-XL resembled that of certain bacterial pore-
forming toxins (Muchmore et al., 1996), structural comparisons with other Bcl-2 family
proteins also established this region as a putative pore-forming domain in the pro-
apoptotic proteins Bid and Bax (Schendel et al., 1998; Chou et al., 1999; McDonnell et
al., 1999). These findings provided one possible explanation for the ability of Bax and
other Bcl-2 family proteins to form ion-conducting pores in synthetic lipid membranes
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mechanism used by the structurally related colicin bactericidal toxins, which form pores
using a hairpin pair of a helices (Cramer et al., 1995), the polar residues of the
amphipathic a helices 5 and 6 of Bax, when inserted into the OMM, were proposed to
form the aqueous surface of the channel (Nouraini et al., 2000). Two recent studies
suggest that the pore-forming domain is a critical component of the strategy used by Bax
to permeabilise the OMM (Heimlich et al., 2004; Annis et al., 2005). Bax mutants
lacking the pore forming domain, but not those lacking the transmembrane domain or
having an impaired BH3 domain, were unable to elicit cytochrome c release from
isolated mitochondria, suggesting that neither the transmembrane nor BH3 domains are
required to permeabilise the OMM (Heimlich et al., 2004). However, although both
studies, together with another recent report (Cartron et al., 2005), agree that the pore-
forming domain is essential for Bax insertion into the OMM, Annis and colleagues
proposed that this process was the result of a concerted effort between the C-terminal a
helix 9 and the a helices 5 and 6. This study also suggested that the subsequent
oligomerisation of multiple Bax proteins is required to form pores of sufficient size to
release apoptogenic molecules across the OMM (Annis et al., 2005).
1.10.3. Regulation of Bax translocation
Both the C- and N-termini of Bax have been implicated in directing mitochondrial
targeting during apoptosis (Wolter et al., 1997; Goping et al., 1998; Cartron et al., 2003;
Schinzel et al., 2004b) and the assignment of specific roles to each of these regions
remains contentious. However, several separate studies agree that the C-terminal
transmembrane domain makes an essential contribution to this process, as the mutation
or deletion of all or part of this region prevents Bax from reaching the OMM during
apoptosis (Wolter et al., 1997; Nechushtan et al., 1999; Schinzel et al., 2004b).
Furthermore, some Bax mutants, in which specific residues within the C-terminal tail are
modified, instead exhibit constitutive mitochondrial targeting and heightened toxicity as
a consequence of prematurely exposing this region to the cytosol (Nechushtan et al.,
1999; Suzuki et al., 2000). One amino acid in particular, Serine 184 (SI84), appears to
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be critical in regulating the position of the C-terminal tail within the quiescent Bax
molecule. SI84, located within helix a9, is the only polar residue in this otherwise
hydrophobic region to face inwards towards the protein core instead of contributing to
its solvent-exposed face (Suzuki et al., 2000). The interactions between the internalised
transmembrane domain (of which helix a9 forms a part) and the BH3-binding pocket are
all hydrophobic, apart, that is, from a single hydrogen bond between SI84 and an
asparagine (A98) in helix a4 (Suzuki et al., 2000). Dissipating this bond, either by
deleting SI84 (AS 184) or replacing it with a non-polar residue, such as a valine (SI84V)
or alanine (S184A), triggers the exposure of the transmembrane domain to the cytosol -
an event normally only associated with apoptotic stimuli. Consequently, Bax-AS184,
SI84V or S184A mutants are rapidly targeted to the OMM, even in healthy cells, and
exhibit high cytotoxicity (Nechushtan et al., 1999; Suzuki et al., 2000).
A comparable outcome is seen when, instead of using full length Bax mutants as above,
these experiments are repeated using peptides corresponding to the final 21aa of Bax
(Trpl70-Glyl92) which encompasses the a9 helix (Trpl70-Prol88) (Nechushtan et al.,
1999). GFP fused to a wild-type Bax C-terminal peptide remained cytosolic when
introduced into cells, even in the presence of an apoptotic stimulus (Nechushtan et al.,
1999). However, when this experiment was repeated using a peptide containing a
AS 184, SI84V or S184A mutation, GFP was instead targeted directly to mitochondria
and remained there irrespective of whether an apoptotic stimulus was present or not
(Nechushtan et al., 1999). From this observation, SI84 appears to not only regulate the
unhinging of the C-terminal tail, but somehow also contributes to making the
transmembrane domain competent for mitochondrial targeting. When this experiment
was repeated by Schinzel and colleagues several years later, in addition to the same 21aa
Bax C-terminal peptides, they also introduced into cells peptides corresponding to the
final 22 amino acids (Thrl69-Glyl92) and 23 amino acids (Prol68-Glyl92) of the Bax
C-terminus (Schinzel et al., 2004b). In agreement with Nechushtan and colleagues, the
wild type 21aa peptide remained cytosolic in both healthy and apoptotic cells
(Nechushtan et al., 1999), as did the 22aa peptide. However, when they introduced GFP
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fused to the 23aa peptide, which includes residues within the solvent exposed loop
region directly preceding the a9 helix, they observed that it specifically co-localised
with mitochondrial markers as effectively as the mutant S184V peptide used previously
(Schinzel et al., 2004b). This important finding therefore suggests that the Bax C-
terminal transmembrane domain alone is in fact all that is required to target the whole
Bax protein to the OMM.
Thus, the activation, mitochondrial targeting and insertion of Bax into the OMM are
controlled by several distinct domains that become functionally active as a result of
extensive remodelling of the Bax protein structure. The transformation of Bax into an
actively apoptogenic protein is thought to be aided, in part, by the BH3-only protein
Bid/tBid (along with, perhaps, other BH3-only proteins, such as Bim-s and PUMA) and
suppressed by the anti-apoptotic Bcl-2 family proteins, as has already been described.
However, a large body of current and historical data suggest that the influence of each of
these regulatory Bcl-2 sub-families on Bax is largely confined to the mitochondrial
surface and only take effect once Bax has already undergone its initial activation and
translocation steps (Oltvai et al., 1993; Sedlak et al., 1995; Desagher et al., 1999; Eskes
et al., 2000; Korsmeyer et al., 2000; Roucou et al., 2002; Kuwana et al., 2002; Terrones
et al., 2004). Therefore additional proteins that may regulate earlier steps within the Bax
activation pathway, such as its conformational alteration or translocation steps -
- have been searched for and several endogenous Bax agonists and
antagonists have been recently identified (reviewed by Lucken-Ardjomande &
Martinou, 2005). However, when this thesis commenced early in 2004, few endogenous
Bax-binding proteins had been discovered. This therefore left two important questions
pertinent to the bioactivity of Bax unanswered: 1) is Bax sequestered in the cytosol of
quiescent cells through association with retention factors, and 2) does Bax rely on
chaperones during its translocation to the OMM. These are the questions that I have
addressed within this thesis, the results of which are presented in chapters 4 and 6,
respectively.
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Figure. 1.12. A suggested model for the Bax activation sequence. Under resting
conditions, Bax is predominantly cytosolic, with its C-terminal tail (TM domain) buried
in a hydrophobic pocket formed by its BH1, BH2 and BH3 domains. Following stress-
inducing signals, Bax undergoes conformational changes involving both the N- and C-
terminal regions. This may be initiated through the binding of a BH3-only protein such
as tBid or Puma, but may also involve as yet undetermined regulatory factors
(represented by X). Release of the C-terminal TM domain from the BH3-binding
pocket is thought to direct the translocation of Bax to mitochondria, a process that may
also involve unknown chaperone factors (X). Accessibility of the BH3 binding pocket
to other Bax BH3 domains has been suggested to lead to the homo-oligomerization of
Bax molecules into predicted pore-like structures on the OMM, which has also been
proposed to involve Bid/tBid. The formation of multimeric pores is one mechanism by
which Bax may permeabilise the OMM and release cytochrome c to initiate
downstream caspase activation. Image modified from Lucken-Ardjomande &
Martinou, 2005.
1.11. Therapeutic potential of Bax-regulating proteins
Many diseases are associated with dysfunctional apoptosis (Thompson, 1995), and since
the permeabilisation of the OMM is a central component in apoptotic pathways, the
identification of new agonist/antagonists to Bax has enormous implications for the
development of therapeutics targeting these diseases. The use of blood-brain barrier
permeable caspase inhibitors to attenuate apoptosis associated with neurodegeneration
has had limited success as mitochondrial dysfunction still occurs in the absence of
caspases leading to impaired ATP production and the accumulation of reactive oxygen
species (Chang et al., 2002). Inhibiting caspase activity therefore appears to merely
delay neuronal cell death rather than prevent it. As a result, efforts have instead focused
on pathways upstream of mitochondrial dysfunction, in particular identifying
pharmacologic agents capable of inhibiting the activation and translocation of Bax to the
OMM (Polster and Fiskum, 2004). Two recently identified Bax-binding proteins,
Humanin and Ku70, represent promising candidate therapeutic targets to limit Bax-
mediated mitochondrial dysfunction. Humanin, a 34kDa peptide originally identified as
a protective factor against neuronal cell death induced by amyloid-(3 protein, is a
candidate template for the development of small molecule drugs to inhibit Bax-mediated
apoptosis in neurodegenerative disorders (Guo et al., 2003). The ablation of HN
expression in glioblastoma cells by RNA interference has already been shown to
increase their sensitivity to apoptosis induced by staurosporine and serum withdrawal
(both mitochondria and thus Bax-dependent inducers of apoptosis) but not to
mitochondria-independent insults, such as that induced by TRAIL (Guo et al., 2003).
Similarly, a protective effect against Bax-dependent stimuli was attributed to a cell-
permeable five amino acid peptide derived from the Bax-binding domain of Ku70,
known as Bax-inhibiting peptide (BIP), although the efficacy of this particular inhibitor
has yet to be tested in neuronal cell lines (Sawada et al., 2003). However, the
identification of such Bax-regulatory factors also has important implications for
developing new chemotherapeutic approaches. Following UV irradiation of 293T cells,
Ku70 was shown to undergo acetylation at several C-terminal lysine residues which
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induced the dissociation of the Bax-Ku70 complex (Cohen et al., 2004). This has since
led to the development of histone deacetylase inhibitors to induce Bax-mediated
apoptosis in tumour cells, and are currently under clinical trial as potential adjuvants to
cancer therapy treatments (Subramanian et al., 2005). In light of this success, the search
for additional Bax-binding proteins is intensifying.
1.12. Summary
Apoptosis is a highly regulated physiological process that is essential for the
development and survival of all multicellular organisms. However, when the molecular
mechanisms underlying this process falter, or when apoptosis is initiated within an
inappropriate physiological setting, numerous disease states can arise, among them
cancer, auto-immunity and neurodegeneration. The mammalian nervous system is
particularly vulnerable to ischemic damage, in which apoptosis makes a significant
contribution to the resultant neuronal cell loss. Apoptosis is also an active process
contributing to the neuronal cell loss associated with neurodegenerative diseases. The
activation and translocation of the pro-apoptotic Bcl-2 family protein, Bax, to
mitochondrial membranes is a central component within stress-induced apoptotic
pathways associated with disease pathology. The regulatory factors controlling Bax
activation were, until recently, thought to be confined to other Bcl-2 family proteins.
However, the elaborate conformational alterations that Bax needs to undergo during its
activation process suggest that additional, non-related proteins, such as molecular
chaperones, play a hand in regulating the bioactivity of Bax. Such regulatory factors
therefore represent important new targets for therapeutic intervention.
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1.13. Thesis hypothesis
The overall hypothesis of this thesis is that Bax resides in the cytosol of quiescent cells
in a retentive protein complex, and that following receipt of an apoptotic stimulus, Bax
dissociates from these retentive factors and engages with novel chaperone proteins that
are required for Bax to translocate to the mitochondrial surface. This hypothesis will be
tested in a neuronal cell model of the intrinsic apoptotic pathway using a proteomics-
based approach.
1.14. Aims of the thesis
The aims of this thesis are four-fold:
1. To characterise the molecular events depicting the course of the intrinsic
apoptotic pathway in an in vitro neuronal cell model of the intrinsic apoptotic
pathway.
2. To identify Bax-binding proteins within a neuronal cell line in order to gain an
insight into how Bax might be regulated under normal cellular conditions (the
identification of Bax cytosolic retentive factors) and during apoptosis
(identification of Bax translocation factors).
3. To characterise the interaction between Bax and identified binding proteins at
the molecular level.
4. To evaluate the biological role of identified Bax-binding proteins using the
established in vitro neuronal cell model of the intrinsic apoptotic pathway.
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CHAPTER 2: General Materials & Methods
2.1. Chemicals & antibodies
All chemicals and antibodies were purchased from Sigma Aldrich Chemical Co. (Poole,
UK) unless otherwise stated.
2.2. Cell culture
All culture dishes were from Gibco (Paisley, UK). SH-SY5Y human neuroblastoma
cells were obtained from ECACC (No. 94030304) and grown in Dulbecco's modified
Eagle's medium (DMEM; Sigma-aldrich) supplemented with 10% foetal calf serum
(FCS), 2mM L-glutamine, lOOU/ml penicillin and 100pg/ml streptomycin. Cells were
cultured in 165cm3 filter-capped flasks at 37°C in a 5% CO2 atmosphere and split when
approximately 80% confluent to limit overcrowding. Passage numbers between 12 and
18 were used for all experiments. For experimental analysis, cells were seeded at a
density of 1 x 105 cell/well in 24-well culture dishes and allowed to attach for 24h prior
to treatments. Apoptosis was induced using 500nM staurosporine (STS) (McGinnis et
al., 1999). Control cells received dimethyl sulphoxide (DMSO) vehicle (1:2000).
2.3. Extraction of whole cell lysates
For the collection of whole cell lysates, DMSO-vehicle or 500nM STS (5h)-treated SH-
SY5Y cells were extracted in 150mM NaCl, lOmM HEPES-KOH (pH7.6), 1% 3-[(3-
cholamidopropyl)dimethylammonio]-l-propanesulfonic acid (CHAPS), ImM
phenylmethylsulphonylfluoride (PMSF), 10pg/mL each aprotinin, pepstatin and
leupeptin; extraction buffer). Cells were homogenised using 10 'up/down' strokes in a
tight-fitting glass Dounce homogeniser (Jencons, Leighton Buzzard, UK) and incubated
on ice for 30mins. Lysates were then centrifiiged at 13,000rpm in a micro-centrifuge to
remove intact cells and cellular debri and supernatant retained. Protein concentration
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was determined using a modified Lowry method (Bio-Rad Protein Assay Kit; Bio-Rad
Laboratories, Hemel Hempstead, UK) and lysates made up to 2mg/ml in extraction
buffer. Lysates were stored at -70 C and thawed on ice when required.
2.4, Co-immunoprecipitation
Protein A-conjugated paramagnetic dynabeads (Invitrogen, Paisley, UK) were washed
and equilibrated in extraction buffer and passed through the SH-SY5Y whole cell lysates
to clear lysate of non-specific binding. Proteins were immunoprecipitated with a pan-
reactive polyclonal Bax antibody (1:2000; Upstate Biotechnology, Lake Placid, NY,
USA), a polyclonal Bax antibody raised against residues 43-61 within human Bax
(1:500; Abeam, Cambridge, UK), a monoclonal Bax antibody recognising the
conformational-specific 6A7 epitope (residues 12-24; BD Biosciences, Cowley, UK), a
monoclonal nucleophosmin antibody raised against residues 1-68 within human
nucleophosmin (5pg; Sigma) or a monoclonal survival motor neuron (SMN) antibody
(5pg; BD Biosciences) overnight at 4°C. Immune complexes were isolated by
incubation with 20pl dynabeads for 2 hours at 4°C with gentle agitation. Beads were
collected by magnet and washed three times in extraction buffer before bound proteins
were eluted by boiling in loading buffer (25mM Tris-HCL (pH 6.8), 0.8% SDS, 1% 2-
mercaptoethanol, 4% glycerol, 0.01% bromophenol blue and 0.1M dithiothreitol
(DTT)).
2.5. ID SDS PAGE and Western blotting
Protein concentration was determined using a modified Lowry method (Bio-Rad Protein
Assay Kit; Bio-Rad Laboratories) and 20pg of protein in loading buffer pipetted into
each well of a 4-12% Tris-glycine gel (Invitrogen) and resolved by sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) for 40mins at 200mV.
Proteins were then transferred to nitrocellulose membranes (Hybond C; Amersham
Biosciences, Chalfont St Giles, Buckinghamshire, UK) for lh at 30mV. Membranes
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were incubated for lh in blocking solution (50mM Tris-HCl, 150mM NaCl, 0.05%
Tween-20) containing 5% bovine serum albumin. Membranes were then probed using
the following antibodies: pan-reactive polyclonal Bax (1:2000), monoclonal
nucleophosmin (1:1000), monoclonal P-actin (1:10,000), polyclonal Hsp60 (1:1000;
Santa Cruz Biotechnology, Santa Cruz, CA, USA), polyclonal Hsp90 (1:1000; Santa
Cruz Biotechnology), monoclonal Hsc71 (1:1000), monoclonal GRP78 (1:500),
monoclonal P-tubulin (1:500), monoclonal vimentin (1:10,000), monoclonal VDAC
(1:500; BD Biosciences), polyclonal survival motor neuron (SMN; 1:1000) and
polyclonal growth factor receptor-bound protein 2 (GRB2; 1:5000; BD Biosciences) in
blocking solution overnight at 4°C. Membranes were washed 3x5 min in Tris Buffered
Saline containing 0.05% Tween-20 (TBS-Tween) before incubation with horse radish
peroxidase (HRP)-conjugated IgG in blocking solution for lh at room temperature.
Membranes were washed 3 x 5min in TBS-Tween and then detected with enhanced
chemiluminescence (ECL plus; GE Healthcare, Chalfont St.Giles, UK).
Chemiflourescence levels were measured using a FluorChem image analyser
(Alphalnnotech, Braintree, UK). For quantification of protein expression, Nitrocellulose
membranes were re-probed with a monoclonal antibody against the housekeeping
protein P-actin, as described by Liao and colleagues (Liao et al., 2000).
Chemifluorescence was corrected for background, normalised to P-actin loading controls
and expressed as a percentage change in expression compared to controls.
2.6. Confocal microscopy
For analysis by confocal microscopy, cells were cultured in glass bottomed 24-well
culture plates (Barloworld Scientific, Aberbargoed, UK) or 35/22 mm diameter glass-
bottomed poly L-lysine coated petri dishes (Willco Wells, Roysden, Herts, UK). Cells
were washed in Hank's balanced salt solution (HBSS) and fixed in 4%
paraformaldehyde-PBS for lOmins (for BaxNT antibody) or 10% formalin/methanol for
30mins (for nucleophosmin Sigma antibody) at room temperature. Cells were then
gently rinsed three times in HBSS and permeabilised in ice-cold 100% methanol for
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lmin (for BaxNT antibody) or 2% CHAPS-PBS for 5mins at room temperature (for
nucleophosmin Sigma antibody). Cells were blocked for lh in 8% BSA before being
incubated with a pan-reactive Bax antibody (BaxNT; 1:200) or a monoclonal
nucleophosmin antibody (Sigma: 1:200) overnight at 4°C in 8% BSA solution. Cells
were washed three times in HBSS containing 0.1% Tween-20 (HBSS-T) and incubated
with lpg/ml AlexaFluor fluorescent IgG antibodies (AlexaFluor-488 and ALexaFluor-
546; Invitrogen) for 2h at room temperature in 8% BSA. Cells were rinsed three times
in HBSS containing 0.05% Tween-20 before staining with the DNA intercalating dye
TO-PRO-3 (1:1000; Invitrogen) for 5mins in HBSS followed by a final rinse in HBSS.
Analysis was performed using a Zeiss META501 laser-scanning confocal microscope
(Carl Zeiss Imaging, Welwyn Garden City, UK).
2.7. Statistical analysis
Unless otherwise stated, all data represents the mean of three independent experiments
performed on separate days. Error bars, where appropriate, represent standard error of
the mean (s.e.m). Statistical analysis was performed using SigmaStat v3.0 software
(SPSS Inc., Woking, UK). Data were analysed by one-way or two-way analysis of
variance (ANOVA) with post-hoc Dunnett's test where appropriate. Where data did not
represent parametric distribution, Kruskal-Wallis one-way ANOVA was used with post-
hoc Dunnett's test, where indicated. The significance level in all tests corresponds to a
probability (p) value of less than 0.05 compared to a control group.
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CHAPTER 3: Characterising the intrinsic apoptotic pathway
3.1. Chapter aims
In this chapter, an experimental neuronal cell model of the intrinsic apoptotic pathway
will be established and characterised.
3.2. Introduction
The ischaemic environment of neural tissue affected by stroke and the toxic
accumulation of protein aggregates in neuronal cells associated with neurodegenerative
diseases stimulates activation of the intrinsic apoptotic pathway (Thompson, 1995;
Mattson, 2000). In order to accurately study the biochemical events leading to apoptotic
cell death in such disorders ex-vivo, two fundamental experimental requirements need to
be met: 1) a relevant cell line that is genetically, physiologically and phenotypically
comparable to human neuronal cells, and 2) an apoptotic stimulus that leads to the
induction of the apoptotic pathway encountered within the in vivo setting.
The in vitro model chosen in this thesis was staurosporine (STS)-induced apoptosis in
SH-SY5Y cells. The human neuroblastoma cell line, SH-SY5Y, has been widely used
as a model in which to study neuronal cell death pathways (Boix et al., 1997; McGinnis
et al., 1999; Kitamura et al., 2003) and as an in vitro cellular model for Alzheimer's
disease (Li et al., 1996; Peraus et al., 1997) and Parkinson's disease (Sheehan et al.,
1997; Fall and Bennett, Jr., 1999). The broad spectrum protein kinase inhibitor,
staurosporine (STS) has been observed to induce apoptosis in SH-SY5Y cells that is
caspase 8-independent (Lopez and Ferrer, 2000), involves Bax translocation (Desagher
et al., 1999; McGinnis et al., 1999; Eskes et al., 2000), mitochondrial cytochrome c
release (Krohn et al., 1999; Poppe et al., 2001; Ahlemeyer et al., 2002) and that can be
inhibited by Bcl-XL over-expression (Yuste et al., 2002). Together, these observations
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suggest that STS preferentially stimulates the intrinsic pathway to apoptotic cell death in
this cell line.
3.2.1. The SH-SY5Y cell line as an in vitro model of neuronal cell apoptosis
The SH-SY5Y human neuroblastoma cell line is a thrice-cloned (SK-N-SH -> SH-SY
-> SH-SY5 SH-SY5Y) sub-line of the parental neuroepithelioma cell line, SK-N-SH,
that was originally established in 1970 from the bone marrow biopsy of a four year old
girl with metastatic neuroblastoma (Biedler et al., 1973). Neuroblastoma is an
extracranial solid tumour arising from malignant neuronal cells within the sympathetic
nervous system and is the most common cancer affecting infants (Miller et al., 1995).
The resulting neuroblasts (comprising of malignant pluripotent sympathetic cells)
invaginate and migrate along the neuroaxis during embryonic development and
consequently can develop tumours in various sites, including the adrenal medulla,
paraspinal ganglia, thorax and more distant sites such as pelvic and cervical regions
(Jennings et al., 1993). The derived SK-N-SH cell line, extracted from a bone marrow
neuroblastoma, was of sympathetic adrenergic ganglion origin, and histological analysis
confirmed the presence of three distinct cell types: 1) loosely attached, small, rounded
neuronal N-type cells possessing many neuritic processes, 2) large, flattened and
adherent epithelial/fibroblastic S-type cells, and 3) intermediate I-type cells (Ciccarone
et al., 1989).
In contrast to the parental SK-N-SH cell line, the derived SH-SY5Y cell line consists of
a comparatively homogenous population of dopaminergic neuronal N-type cells which
are morphologically and biochemically similar to sympathetic neurones (Ross et al.,
1983). When grown in culture, SH-SY5Y cells exhibit a neuroblast-like phenotype with
short neurite-like processes and angular cell bodies containing large nuclei - st
However, unless the cells are induced to terminally differentiate into a mature
neuronal phenotype (which can be achieved with addition of retinoic acid, NGF or low
doses of STS (Jensen, 1987; Jalava et al., 1992)), serial passage of the cell line will
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Figure 3.1. Phase-contrast image of undifferentiated SH-SY5Y cells. Cells typically
have a large single nucleus containing one or two visible nucleoli. Undifferentiated cells
have an average of 2-3 neuritic processes of 40-50 microns in length. Scale bar
represents 50 microns.
eventually lead to the emergence of a predominantly epithelial phenotype (Ross et al.,
1983). Therefore, SH-SY5Y cells can only be reliably used as a neuronal cell model up
to a passage number of 20 (European Collection of Cell Cultures (ECACC)
recommendations).
3.2.2. Staurosporine as an inducer of the intrinsic apoptotic pathway
Staurosporine (STS) is a bacterial alkaloid produced by Streptomyces staurospores and
is a potent and broad-spectrum inhibitor of protein kinases, such as protein kinase c
(PKC) (Jarvis et al., 1994), the cyclin-dependent kinases, CDK1 and CDK2 (Meijer,
1996), calcium/calmodulin-dependent kinase-2 (Yanagihara et al., 1991) and receptor
tyrosine kinases (Boix et al., 1997). This shutdown in the cell's phosphorylation and
signal-transducing machinery results in the induction of the intrinsic apoptotic pathway,
as demonstrated by observing the translocation of Bax and the subsequent release of
cytochrome c from mitochondria in a variety of cell lines exposed to STS (Desagher et
al., 1999; McGinnis et al., 1999; Krohn et al., 1999; Eskes et al., 2000; Poppe et al.,
2001). Together, these data support the use of STS as an appropriate apoptotic inducer
for investigating molecular events in experimental cell-based models of the intrinsic
apoptotic pathway.
The concentration of STS applied to cells has important implications for its effect,
particularly in the case of neuronal cells where STS has been observed to perform a dual
function according to the concentration delivered. At low concentrations (lOOnM and
below), STS induces neuritogenesis in a wide range of cultured neuronal cell lines, such
as PC 12 cells (Hashimoto and Hagino, 1989), dorsal root ganglia cultured from chick
embryos (Sano et al., 1994) and SH-SY5Y cells (Jalava et al., 1992; Boix et al., 1997).
In SH-SY5Y cells, administration of 25nM STS promoted morphological and
biochemical changes associated with the differentiation into mature neurones, such as
extensive neurite outgrowth, and increased expression of the mature peripheral neurone
markers, neuropeptide Y (NPY) and tyrosine hydroxylase (TH), as well as the growth-
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associated protein 43 (GAP-43) which is specifically associated with the formation of
axonal processes (Jalava et al., 1992). Although STS was shown to inhibit PKC in these
cells, other studies have shown that low dosages can activate certain growth-promoting
kinases (Pavlovic-Surjancev et al., 1993; Rasouly and Lazarovici, 1994) and stabilise
the axonal microtubule assembly protein, Tau (Rasouly et al., 1994), which may account
for the neurotrophin-like effects observed at these concentrations (Boix et al., 1997).
However, STS concentrations ranging from 50nM up to lpM can induce apoptosis in a
wide range of cells, including Jurkat T cells (Takayama et al., 1995), HL-60 cells
(Bertrand et al., 1994), HeLa cells (Tafani et al., 2001), cultured hippocampal neurons
(Krohn et al., 1999; Poppe et al., 2001) and the neuroblastoma cell lines, NB69 and SH-
SY5Y (Boix et al., 1997; McGinnis et al., 1999), indicating that there is some overlap in
the concentrations at which STS induces differentiation or cell death, and that cell-type
may also be a contributing factor to the outcome. One striking example of the latter
emerged from a study of STS-induced cell death in a variety of neuroblastoma cell lines
where exposure to increasing concentrations of STS triggered apoptotic cell death in
NB69 and SH-SY5Y lines but not in IMR-5 or IMR-32 lines (Boix et al., 1997) - ;
Figure 3.2.
A dose-response study of STS in SH-SY5Y cells demonstrated an EC50 for apoptosis
induction of approximately lOOnM (Boix et al., 1997). Although addition of the pan-
caspase inhibitor, z-VAD.fmk, was able to protect SH-SY5Y cells against STS-induced
apoptosis at STS concentrations up to 500nM, at higher concentrations cell death
escalated as a consequence of extensive oxidative damage (Yuste et al., 2002). Taken
together, these observations suggest that for induction of apoptosis in SH-SY5Y cells,
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Figure 3.2. STS-induced apoptosis in a variety of human neuroblastoma cell lines.
Only in SH-SY5Y and NB69 cell lines (*) was the characteristic pattern of inter-
nucleosomal DNA fagmentation (DNA laddering; marked by arrows) observed using
agarose gel electrophosrises following exposure to varying concentrations of STS.
Image modifed from Boix et al, 1997.
3.3. Materials & Methods
3.3.1. Cell culture
SH-SY5Y human neuroblastoma cells were maintained as described in general materials
& methods (Chapter 2). For experimental analysis, cells were seeded at a density of at 1
x 105 cells per well in 24-well tissue culture plates (Gibco) and allowed to attach for 24h
prior to treatment. Apoptosis was induced by adding 500nM STS to culture medium.
Control cells received DMSO vehicle (1:2000).
3.3.2. Assessment of Bax conformational change and translocation
Bax conformational change was assessed by immunoprecipitating endogenous Bax from
control and apoptotic whole cell lysates (500nM STS, 5h) in extraction buffer using an
antibody recognising an epitope within the N-terminus of Bax (6A7), as described in
general materials & methods (Chapter 2). Briefly, vehicle and STS-treated SH-SY5Y
whole cell lysates were immunoprecipitated with 5pg mouse monoclonal Bax 6A7
antibody and protein/antibody complexes anchored to protein-A coated dynabeads.
Bound protein was eluted by boiling in loading buffer and the presence of 6A7-reactive
Bax detected by Western blotting using a pan-reactive Bax antibody, as described in
general materials & methods (Chapter 2).
The translocation of Bax to mitochondria during apoptosis was assessed by subcellular
fractionation/Western blotting and by confocal microscopy. For analysis of Bax
translocation by subcellular fractionation, cells were collected and contaminating media
removed by two cycles of centrifugation (200g/7min) and re-suspension in HBSS. The
resultant cell pellet was re-suspended in lOmM Tris-Cl (pH 6.7), 0.25M sucrose, ImM
EGTA, lOmM KC1, 0.15mM MgCl2, O.lmM DTT, ImM PMSF, 20pM lactacystin,
2.5mM sodium pyrophosphate, ImM ((-glycerophosphate, ImM sodium orthovanadate
and 10pg/mL each aprotinin, pepstatin and leupeptin (SCF buffer) and homogenised
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using 10 'up/down' strokes in a tight-fitting glass Dounce homogeniser (Jencons).
Nuclei, insoluble material and unbroken cells were removed by centrifugation for 3 min
at 600g. An aliquot of the supernatant was removed and CHAPS added to a final
concentration of 2%. This fraction was designated the whole cell lysate. The remaining
supernatant was separated into crude cytosolic (supernatant) and mitochondrial (pellet)
fractions by centrifugation (6,000g for 15 min). The crude mitochondrial fraction was
then washed twice (6,000g for 15 min) with SCF buffer and the resultant pellet re-
suspended in SCF buffer containing 2% CHAPS. This fraction represented an enriched-
mitochondrial fraction. The crude cytosolic fraction was centrifuged at 100,000g for lh
with the resultant supernatant representing the soluble SI00 cytosolic fraction. All
fractionation procedures were performed at 4°C. Fractions were separated by ID SDS-
PAGE and analysed by Western blot for Bax, P-actin and VDAC expression, as
described in general materials & methods (Chapter 2).
For analysis of Bax translocation by confocal microscopy, SH-SY5Y cells were seeded
in glass-bottomed 24-well culture plates and allowed to attach for 24h before exposure
to 500nM STS for lh, 3h or 5h. For analysis of Bax co-localisation with mitochondria,
vehicle-treated and STS (5h;500nM)-treated cells were incubated with culture medium
containing lOOnM MitoTracker Orange CMTMRos (Invitrogen) for 15mins under
normal growth conditions prior to fixation in 4% paraformaldehyde-PBS. Cells were
then fixed, stained and analysed by confocal microscopy as described in general
materials & methods (Chapter 2).
3.3.3. Assessment of cellular morphology
The appearance of apoptotic cell morphology over a 5h timecourse of exposure to STS
was assessed qualitatively by light microscopy. Live cells in culture were viewed under
Hoffman illumination with a 40X objective (Nikon Instruments, Kigston, Surrey, UK)
and photographed with a digital camera. Progression of apoptotic cell death was
evaluated by monitoring the occurrence of morphological apoptotic hallmarks, such as
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rounding of cell bodies, shrinkage of cell volume, condensation of nuclear structures and
the eventual disintegration of nuclei into several membrane-bound fragments (Bellamy
et al., 1995).
3.3.4. Measurement of cytosolic cytochrome c
Cytosolic cytochrome c was measured using an in-house validated enzyme-linked
immunosorbent assay (ELISA). . SH-SY5Y cells were cultured in 24-well culture plates
and exposed to STS over a 5h timecourse. Cell lysis was then performed using 150mM
NaCl, lOmM HEPES-KOH (pH7.6), ImM PMSF, 10p.g/mL each aprotinin, pepstatin
and leupeptin (lysis buffer) containing either 3.125juM digitonin to extract cytosolic
fraction or 3.125pM digitonin + 1% CHAPS to extract whole cell lysate for one hour at
room temperature. Lysates were centrifuged at 10,000g for ten minutes to remove
nuclei and unbroken cells. Supernatants were serially diluted (1:3, 1:9, 1:27) in lysis
buffer and cytosolic cytochrome c content measured using a commercially available
ELISA (Caltag MedSystems, Botolph Claydon, UK) according to the manufacturer's
instructions. Briefly, 96 well plates were coated with capture antibody (purified mouse
anti-human cytochrome c monoclonal antibody; 1 pg/ml), sealed and incubated overnight
at 4°C. Plates were then washed three times with wash buffer and blocked with assay
diluent for 2h at room temperature. After a further three wash cycles with wash buffer,
lOOpl standards, samples and blanks were added to separate wells, then 50juil biotin
conjugated mouse anti-human cytochrome c antibody and plates incubated for 2h at
room temperature. Plates were washed three times with wash buffer and bound
complexes detected using goat anti-rabbit HRP antibody (lh at room temperature) and
TMB substrate solution (30min in the dark). The reaction was stopped by addition of
1M Phosphoric acid and absorbance read at 450nm within 30min. Cytosolic cytochrome
c (measured in digitonin-containing extraction buffer) was calculated as a percentage of
the total cellular content (measured in digitonin + CHAPS containing extraction buffer)
for each time point analysed.
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3.3.5. Measurement of cleaved caspase-3
SH-SY5Y cells were cultured in 24-well culture plates and exposed to STS over a 5h
timecourse. Cell lysates were extracted in lysis buffer containing 1% CHAPS as
described above. Active human caspase-3 was detected by ELISA (BD Biosciences)
according to the manufacturer's instructions. Briefly, 96-well plates were coated with
capture antibody (mouse anti-human caspase-3 monoclonal antibody; 1:240), sealed and
incubated overnight at 4°C. Plates were then washed three times with PBS containing
0.1% Tween 20 (PBS-T) and blocked with assay diluent for lh at room temperature.
After a further three wash cycles with PBS-T, standards, samples and blanks were added
to plates and incubated for 2h at room temperature. Plates were then washed five times
in PBS-T before detection antibody (rabbit anti-cleaved caspase-3 monoclonal antibody;
1:240) was added and incubated a further lh. After washing five times in PBS-T, bound
complexes were detected using goat anti-rabbit HRP antibody (lh at room temperature)
and TMB substrate solution (30min in the dark). The reaction was stopped by addition
of 2N sulphuric acid and absorbance read at 450nm within 30min. Caspase-3 activity
was calculated as a percentage of active caspase-3 in apoptotic (4pM camptothecin; 4h)
Jurkat cell lysate standards provided with the ELISA kit.
3.3.6. Detection of DNA fragmentation
SH-SY5Y cells were cultured in 24-well culture plates and exposed to STS over a 5h
timecourse Occurrence of internucleosomal DNA fragmentation was assessed
quantitatively by performing terminal deoxynuceotidyl transferase-mediated dUTP nick
end labelling (TUNEL) analysis with a commercially available ELISA (Roche
Diagnostics Ltd, Burgess Hill, UK) according to the manufacturer's instructions.
Briefly, cells were washed in HBSS and incubated with 200pl Roche kit lysis buffer for
30mins at 37°C, 5% CO2. Lysates were then transferred into micro centrifuge tubes and
centrifuged at 200g to remove cellular debris and intact cells. Supernatants were diluted
1:10 before being analysed for the presence of cytoplasmic histone-associated DNA
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fragments (mono- and oligo-nucelosomes) by ELISA according to the manufacturer's
instructions. Briefly, 20pl lysates, controls and blanks were added to wells of a
streptavidin-coated 96-well plate. 80pl immunoreagent (biotin-conjugated mouse anti-
human histone monoclonal antibody + peroxidase-conjugated mouse anti-human DNA
monoclonal antibody) was then added to each well and plates sealed and incubated on a
shaker (300rpm) for 2h at room temperature. Plates were washed three times with
incubation buffer before detection of captured complexes with ABTS solution.
Absorbance was read after sufficient colour change (10-20min) at 405nm.
3.3.7. Measurement of cell viability
SH-SY5Y cells were cultured in 24-well culture plates and exposed to STS over a 5h
timecourse. Cell viability was measured using a commercial MTS assay (Cell Titer 96*
Aqueous One Solution Assay; Promega, Southampton, UK) according to the
manufacturer's instructions. Briefly, cells were rinsed three times with warm HBSS and
replenished with fresh culture media containing a 1:5 dilution of MTS reagent. Cells
were incubated at 37°C in a 5% CO2 atmosphere until sufficient colour had developed
(typically l-4hrs). 20pl aliquots (in triplicate) were removed from each well and
transferred to a 96-well plate and absorbance read at 490nm.
49
3.4. Results
3.4.1. STS activates the intrinsic apoptotic pathway in SH-SY5Y cells
SH-SY5Y cells were exposed to 500nM STS for 5h and the induction of a Bax-directed
apoptotic pathway assessed by measuring the activation and translocation of Bax to the
mitochondrial surface. Furthermore, a 5h time course of STS treatment was performed
and the progression of apoptosis measured by analysing Bax translocation, apoptotic cell
morphology, the release of cytochrome c from mitochondria, caspase-3 activity, DNA
fragmentation and cell death.
The presence of activated Bax in STS-treated SH-SY5Y cells was assessed by
immunoprecipitating Bax from control and apoptotic SH-SY5Y lysates with a
conformation-sensitive antibody recognising the 6A7 epitope - A small
amount of 6A7-reactive Bax in vehicle-treated lysates was detected. Following 5h
exposure to STS, however, the amount of activated Bax in the cell lysate was markedly
increased.
The shift in distribution of Bax from the cytosol to the surface of mitochondria in
response to STS treatment was assessed by subcellular fractionation and Western
blotting using a pan-reactive, conformation-independent antibody -
Under control conditions, Bax was primarily cytosolic but became markedly more
abundant in the mitochondrial fraction of cells exposed to 5h STS. This translocation
event was visualised using confocal microscopy - sec Figure 3.3c. Endogenous Bax
under normal (control) conditions appeared predominantly cytosolic as indicated by
diffuse intracellular staining. Following 5h exposure to STS, however, Bax had
undergone translocation to the mitochondrial surface as evidence by its punctuate
mitochondria-like staining pattern. A time-course of Bax translocation was also
performed which demonstrated the appearance of a punctate staining pattern by lh
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Figure 3.3. STS induces Bax activation and translocation. Exposure of an N-
terminal 6A7 epitope in response to STS treatment allows Bax to be
immunoprecipitated by a 6A7-reactive antibody (a). Subcellular fractionisation and
Western blotting using a pan-reactive, conformational-independent antibody (b)
demonstrates re-distribution of Bax from the cytosol to mitochondria. P-actin and
voltage-dependant anion channel (VDAC) represent cytosolic and mitochondria-
specific proteins, respectively. Confocal microscopy (c) illustrates diffuse cytosolic
Bax (green) under normal conditions (Ctrl) and mitochondria-associated punctate
staining in apoptotic cells following 5h exposure to STS. Nuclei were
pseudostained blue using TO-PRO-3. Ctrl, control cells; STS, cells exposed to 5h
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confirmed that Bax had undergone relocalisation to mitochondria by 5h exposure to STS
Isolation and measurement of cytosolic cytochrome c content in SH-SY5Y cells was
achieved by selectively permeabilising the plasma membrane with a lysis buffer
containing 3.125pM digitonin. Previous work by Kirchoff & colleagues determined
3.125pM as the optimal concentration of digitonin detergent that would permeabilise the
plasma membrane but leave mitochondrial and other organelle membranes intact
(Kirchhoff et al., 2002). A pilot study to determine if this approach was suitable for
characterising cytochrome c release in STS-treated SH-SY5Y cells was performed by
comparing cytosolic cytochrome c levels in control and apoptotic (STS; 5h) lysates
extracted in buffers containing either 3.125pM digitonin or 3.125pM digitonin + 1%
CHAPS. The addition of CHAPS detergent ruptured all cellular membranes and
permitted the measurement of total cellular cytochrome c content, as illustrated in
. With the CHAPS-containing extraction buffer, no differentiation could be made
between cytochrome c content in untreated and apoptotic lysates as both readings
equated to the total cellular content - .With the extraction buffer
containing digitonin alone, however, the change in distribution of cytochrome c from
within mitochondria under normal conditions to its accumulation in the cytosol
following exposure to STS was readily detected - The 5h time-course
profile of cytochrome c release from mitochondria in STS-treated SH-SY5Y cells was
then measured by ELISA. An significant increase in cytosolic cytochrome c was
detectable by 0.5h exposure to STS (P= <0.05) and increased to reach a maximal
release of 70% (±9%) total cellular content by 4h -
The five hour time course profile of procaspase-3 cleavage in STS-treated SH-SY5Y
cells was also measured by ELISA. A significant increase in procaspase-3 cleavage was
detected by 1.5h exposure to STS (P = <0.05) and increased two fold within 30mins,
reaching a maximal level by 3h - see Figure 3. N.
Figure 3.6. Isolation of cytosolic cytochrome c by selectively permeabilising the
plasma membrane with 3.125pM digitonin. Selective lysis of the plasma
membrane using digitonin allows comparison between cytosolic and mitochondrial
cytochrome c pools, whereas addition of 1% CHAPS results in lysis of all cellular
membranes (a). Cytochrome c in cell lysates extracted from vehicle-treated or 5h
STS-treated cells using buffers containing 3.125pM digitonin ± 1% CHAPS was
measured by ELISA (b). Addition of CHAPS resulted in quantification of total
cellular cytochrome c whereas extraction with digitonin alone allowed measurement
of cytosolic cytochrome c. Error bars represent s.e.m of three independent
experiments.
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Figure 3.7. STS induces cytochrome c release. Cytosolic cytochrome c in SH-
SY5Y cells exposed to a 0-5h timecourse of STS treatment was measured by ELISA
according to the modified protocol described in materials & methods. Cytochrome c
was detectable in the cytosol by 0.5h and reached a maximal plateau at 3-5h post-
stimulus. Data represent mean + s.e.m of three independent experiments. Data were
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Figure 3.8. STS activates caspase-3 in SH-SY5Y cells. Casapse-3 in SH-
SY5Y cell lysates exposed to a 0-5h time course of STS treatment was
measured by ELISA. Casapse-3 activity was detectable by 1.5h and reached a
maximal level by 3h exposure to STS. Data represent mean + s.e.m of three
independent experiments. Data were analysed by one-way ANOVA with post
hoc Dunnett's test. * = p<0.05 versus Oh control.
The emergence of apoptotic cell morphology in STS-treated SH-SY5Y cells was
examined by light microscopy - - 3.9. By one hour following exposure to
STS, no observable changes to cell morphology had taken place. By three hours,
however, evidence of cell rounding and shrinkage were apparent - figure 3 - and
the appearance of morphological features associated with caspase activity, such as
membrane blebbing and dense, fragmented nuclear structures (Wyllie et al., 1980) were
detectable by 4h exposure to STS - 11 e 3,9b
The biochemical apoptotic hallmark of internucleosomal DNA fragmentation was
assessed quantitatively during STS-induced apoptosis by a TUNEL-based ELISA. A
significant increase in DNA fragmentation was detectable by 3h exposure to STS (p =
<0.05)- ,-c Figure 3.10.
A significant decrease in SH-SY5Y cell viability during STS treatment, as assessed by
MTS assay, was apparent by 3h exposure to STS (p = <0.05), falling below 50% by 4h
and reaching approximately 20-30% control levels by 5h post-treatment -
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Figure 3.10. STS leads to internucleosomal DNA fragmentation as measured
by TUNEL ELISA. DNA fragmentation in SH-SY5Y cells was detectable by 3h
during exposure to STS. Data represent mean + s.e.m of three independent
experiments. Data were analysed by one-way ANOVA with post hoc Dunnett's
test. * = p<0.05 versus Oh control.
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Figure 3.11. STS leads to cell death. A significant reduction in SH-SY5Y cell
viability, as assessed by MTS assay, was detectable by 3h during exposure to STS
and reached approximately 25% control levels by 5h. Data represent mean +
s.e.m of four independent experiments. Data were analysed by one-way ANOVA
with post hoc Dunnett's test. * = p<0.05 versus Oh control.
3.5. Discussion
Activation of the intrinsic apoptotic pathway is thought to be the principle pathway
leading to apoptotic cell death in a variety of neurodegenerative disorders (Thompson,
1995; Mattson, 2000). Hence, when modelling the physiological apoptotic cell death
associated with neurodegenerative disorders in vitro, it is important to confirm that an
appropriate signalling pathway is active within the chosen model system. The intrinsic
apoptotic pathway is characterised by a series of distinct biochemical events that can be
considered as measurable molecular hallmarks. These include the activation and
translocation of the pro-apoptotic Bcl-2 family protein, Bax, to the mitochondrial surface
(Wolter et al., 1997), the release of cytochrome c across the OMM into the cytosol (Liu
et al., 1996) and the downstream activation of caspases leading to apoptosis (Zou et al.,
1997; Li et al., 1997). However, the signal transduction pathways leading to apoptosis
differ according to the nature of the stress-inducing stimulus as well as the cell type
(Bossy-Wetzel et al., 1998; McGinnis et al., 1999). Therefore, the intrinsic pathway-
specific biochemical markers described above were used to confirm that STS treatment
of SH-SY5Y cells induces the intrinsic apoptotic pathway.
Since the main focus of this thesis is to gain a better understanding of how the activation
and translocation of Bax is regulated, it was important to confirm that STS initiated this
process in SH-SY5Y cells. Bax activation is characterised by conformational alterations
that expose previously hidden regions within both the N- and C-terminal domains
(Goping et al., 1998; Nechushtan et al., 1999; Suzuki et al., 2000). Immunoreactivity
against one of these regions, the 6A7 epitope within the Bax N-terminus, is an
established experimental marker for activated Bax in a variety of cell lines under
different apoptosis-inducing conditions (Hsu and Youle, 1997; Nechushtan et al., 1999;
Sawada et al., 2003). In this study, 6A7 immunoreactive Bax was immunoprecipitated
in SH-SY5Y lysates exposed to STS, with only a residual amount detectable in lysates
extracted from control cells. These data therefore suggest that STS induces Bax
activation within the chosen cellular model. However, exposure of the 6A7 epitope has
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been reported to occur independently of Bax translocation to mitochondria (Nechushtan
et al., 1999; Makin et al., 2001). The translocation of Bax to the OMM has previously
been observed in many cell types undergoing apoptosis (Wolter et al., 1997; Hsu et al.,
1997b; Goping et al., 1998) including neuronal cells (McGinnis et al., 1999; Makin et
al., 2001) and is a central event within the intrinsic apoptotic pathway. Therefore a
separate measurement of the translocation event was required to confirm that the
apoptosis induced by STS utilised Bax. Using subcellular fractionation, Western
blotting and confocal microscopy, endogenous Bax was observed to undergo re¬
distribution from a cytosolic to a mitochondria-associated localisation in response to
STS treatment. Moreover, this event was observed to have taken place by lh exposure
to STS, in agreement with previous findings that Bax translocation is an early event
within neuronal cell apoptosis (McGinnis et al., 1999; Putcha et al., 1999). Thus, STS
induces the conformational changes and translocation event associated with the
apoptogenic activity of Bax.
The release of cytochrome c from mitochondria into the cytosol is specifically
associated with apoptosis and is not observed during necrotic cell death (Goldstein et al.,
2000b). Furthermore, this event is considered to be a gold standard for the detection of
apoptosis operating through the intrinsic pathway (Kluck et al., 1997; Green and Reed,
1998). Cytochrome c release has been directly linked with permeabilisation of the
OMM by Bax (Jurgensmeier et al., 1998; Eskes et al., 1998; McGinnis et al., 1999), and
the rate by which cytochrome c is released into the cytosol has been shown to be directly
proportional to the amount of Bax arriving at the mitochondrial surface at any given
time (McGinnis et al., 1999). For these reasons, mitochondrial cytochrome c release
was chosen as an early and reliable indicator that a Bax-dependent apoptotic pathway
was progressing within SH-SY5Y cells in response to STS-treatment. A significant
increase in cytosolic cytochrome c was detected as early as 0.5h following onset of STS
treatment and reached a maximal level by 4h exposure to STS. Previous studies support
the view that cytochrome c is released from mitochondria in two distinct phases due to
the presence of soluble and membrane-attached fractions of cytochrome c within the
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inter-mitochondrial membrane space (Luetjens et al., 2001; Ott et al., 2002). Although
no evidence for such a bi-phasic release was found within this study, the time-course
profile of mitochondrial cytochrome c release presented here is in agreement with
previous observations made using the same STS concentration and cell line (Posmantur
et al., 1997; McGinnis etal., 1999).
Since the release of cytochrome c from mitochondria leads (via the initiator caspase-9)
to the activation of the principle effector caspase, caspase-3 (Liu et al., 1996; Bossy-
Wetzel et al., 1998; McGinnis et al., 1999), analysis of procaspase-3 cleavage in STS-
treated SH-SY5Y cells was also included to further characterise the apoptotic events
occurring downstream of Bax translocation. A significant increase in procapsase-3
cleavage was detected by 1.5h exposure to STS, placing this event downstream of
mitochondrial cytochrome c release, as has previously been reported in this model
system (McGinnis et al., 1999). However, no basal caspase 3 activity was detected as
has been previously reported for SH-SY5Y cells (Posmantur et al., 1997), perhaps due
to limitations in the sensitivity of our chosen approach. Although not representing a
significant increase, some procaspase-3 cleavage was detected at 0.5h and lh exposure
to STS. In addition to the cytosol, a proportion of procaspase-3 is also present within
the mitochondrial inter-membrane space (Mancini et al., 1998) where its cleavage and
release into the cytosol has been observed to occur concomitantly alongside cytochrome
c in response to STS treatment (Samali et al., 1999). This apoptosome-independent
route to caspase-3 activation could therefore account for the small amount of
procaspase-3 cleavage detected in this study prior to the 1.5h timepoint.
The morphological hallmarks of apoptotic cell death were first documented and reported
by Kerr and colleagues in 1972 (Kerr et al., 1972). Morphological analysis of the
structural cellular changes taking place during apoptosis has been widely used since then
as a method to characterise its progression and to distinguish this death pathway from
that leading to necrotic cell death (Walker et al., 1988; Goldstein et al., 2000a). The
first readily observable morphological changes to take place following induction of
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apoptosis are rounding of the cell body and shrinkage of cell volume (Goldstein et al.,
2000a). In this study, exposure to STS induced cell rounding and shrinkage of SH-
SY5Y cells by 3h, as observed using light microscopy. The majority of morphological
changes associated with apoptosis, such as cell rounding, shrinkage, nuclear
fragmentation and blebbing of the plasma membrane, are directed by caspase activity,
particularly as a result of caspase-mediated cleavage of essential structural components
such as cytoskeletal proteins (Janicke et al., 1998a) The emergence of distinctive
apoptotic morphology at 3h is consistent with the observed elevation in cytosolic
cytochrome c levels by 0.5h and caspase-3 activation by 1.5h exposure to STS. Loss of
plasma membrane integrity, characterised by the formation of large blebs (zeiosis), is
regarded as one of the markers of late apoptosis, occurring downstream of
phosphatidylserine (PS) exposure on the extracellular surface of the plasma membrane
(Goldstein et al., 2000a). The appearance of cell surface blebbing in STS-treated SH-
SY5Y cells was observed by four hours, by which time active caspase-3 levels in these
cells had reached their peak.
The internucleosomal fragmentation of genomic DNA was the first recognised
biochemical marker of apoptosis (Wyllie, 1980) and continues to be used as a method to
confirmation the presence of apoptosis in a cell population. In this study, the appearance
of mono- and oligo-nucleosomes within STS-treated SH-SY5Y cell lysates was
quantified using a TUNEL-based assay and was observed to correlate with maximal
caspase-3 activity. This finding is in agreement with the role played by caspase-3 in
directing DNA fragmentation via its cleavage of the nuclear factor ICAD/DFF45 into
the active DNase primarily responsible for cleaving genomic DNA during apoptosis (Liu
et al., 1997; Enari et al., 1998).
Finally, the demise in SH-SY5Y cellular viability during STS treatment was assessed by
MTS assay. This assay relies on a cell's oxidative metabolism to bioreduce a MTS
tetrazolium compound to a coloured formazan product that can then be measured
empirically. This assay is therefore an indicator of mitochondrial function rather than
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cell viability per se, but can be used, as it is here, to measure a cell's "metabolic
viability." The protracted decrease in metabolic viability observed during STS
exposure, in contrast to the more rapid escalation of apoptotic biochemical markers such
as cytochrome c release and capsase-3 activation, is in agreement with the reliance of
apoptotic pathways progression on a continued supply of ATP (Leist et al., 1997).
However, as cytochrome c continues to be released from the mitochondrial inter-
membrane space, the electron transport chain component of the oxidative
phosphorylation machinery eventually breaks down and mitochondrial ATP production
ceases to function efficiently (Mootha et al., 2001). Consequently, after 5h exposure to
STS, metabolic activity, as assessed by MTS bioreduction, had diminished to
approximately 20% normal levels.
3.6. Summary
From the analysis of such key biochemical and molecular events as Bax
activation/translocation, mitochondrial cytochrome c release, caspase-3 activation, DNA
fragmentation and the assessment of cellular morphological changes, a well
characterised model of the intrinsic apoptotic pathway in STS-treated SH-SY5Y cells
has been established. This cellular model will be used in the following chapters to 1)
identify Bax-binding proteins (Chapter 4) and 2) determine the functional contribution
of the novel Bax chaperone to the bioactivity of Bax (Chapter 6).
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CHAPTER 4: Identification of Bax-binding proteins using a
proteomics-based approach
4.1. Chapter aims
In this chapter, a proteomics-based approach will be employed to identify 1) proteins
binding the endogenous Bax whole molecule and 2) proteins binding specifically to the
Bax C-terminal transmembrane domain within the SH-SY5Y cell line.
4.2. Introduction
As already discussed in detail in the general introduction (Chapter 1), the activation and
translocation of Bax to the OMM is a pivotal event within the intrinsic apoptotic
pathway, and is implicated in the apoptotic cell death associated with several
neurodegenerative disorders. Although gel filtration experiments suggest cytosolic Bax
to be monomeric (Valentijn et al., 2003), an emerging hypothesis is that Bax may
interact with accessory proteins, both under resting conditions as well as during
apoptosis where they have been proposed to function as cytosolic retention factors and
facilitators of the Bax structure modifying and translocation events, respectively
(Lucken-Ardjomande and Martinou, 2005).
As was described in the general introduction (Chapter 1), the translocation of Bax to the
OMM is thought to rely on a discrete membrane-targeting domain within the C-terminus
(Wolter et al., 1997; Nechushtan et al., 1999; Suzuki et al., 2000; Schinzel et al.,
2004b). However, due to its hydrophobicity, this domain is normally internalised within
the Bax protein structure in a hydrophobic pocket, only becoming accessible to the
cytosolic environment during apoptosis when its membrane-targeting capability is
required (Suzuki et al., 2000). Chaperone proteins may therefore make an important
contribution to the functional maturity of Bax during apoptosis by regulating the
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exposure of the C-terminal tail and maintaining this hydrophobic region in a competent
orientation for membrane targeting.
Chaperone proteins may also function to maintain Bax as an inactive cytosolic protein in
the absence of cell stress. Such proteins would exert a critical regulatory hold over the
response of Bax to apoptotic stimuli. However, by 2004, only one such cytosolic
retention factor, humanin, had been identified in neuronal cells (Hashimoto et al., 2001;
Guo et al., 2003). Studies involving other proposed Bax retentive factors had used
different cell lines, for instance the molecular chaperone Hsp60 was identified as a Bax-
binding protein in cardiac myocytes (Kirchhoff et al., 2002), and the scaffold protein 14-
3-3g was shown to perform a similar role in epithelial cells (Nomura et al., 2003).
Although a comprehensive study of Bax-binding proteins in all tissues has yet to be
accomplished, it could be that Bax is regulated by a different subset of proteins
according to cell type. Hence, in this chapter, a proteomics-based search for Bax-
binding proteins in a neuronal cell line will be described. This chapter will also present
results obtained from a more focussed search for proteins binding specifically to the
putative Bax C-terminal membrane-targeting domain. The identification of such
regulatory proteins could have far-reaching implications in the development of new
therapeutics to limit the excessive apoptotic cell death associated with neurological
disorders in which Bax activity plays a central role.
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4.3. Materials & Methods
4.3.1 Preparation of SH-SY5Y whole cell lysates
Control (DMSO-vehicle) and apoptotic (500nM STS; 5h) SH-SY5Y whole cell lysates
were prepared as described in general materials & methods (Chapter 2).
4.3.2 Bax immunoprecipitation
Bax was immunoprecipitated overnight at 4°C from control and apoptotic SH-SY5Y
whole cell lysate (2-5mg total protein) with a pan-reactive polyclonal Bax antibody
(Upstate Biotechnology). Immunoprecipitation was performed as described in general
materials & methods (Chapter 2) except proteins were captured using protein G-agarose
beads.
4.3.3. Proteomic analysis of Bax co-immunoprecipitants
An overview of the proteomics-based approach used to identify Bax-binding proteins is
provided in . The proteomic studies described in this chapter were performed
in collaboration with the ACE proteomics group.
4.3.4. 2D-SDS PAGE
Bax co-precipitants were separated by 2-dimentional (2D) SDS-PAGE. The first
dimension separated proteins according to their isolectric point (pi) and the second
dimension according to molecular weight (Mr). First dimension separation was
performed using linear pH 3-10 IPG (immobilised pH gradient) strips (Biorad) using a
Biorad protean IEF (isoelectric focussing) cell. Samples were diluted in IEF sample
buffer (7M Urea, 2M thiourea, 4% CHAPS, 1% DTT, 0.8% ampholytes) to reach a final
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Figure 4.1. Proteomic analysis flow diagram of the proteomic analysis used in
this thesis to identify Bax-binding proteins. Proteins for analysis were extracted
form SH-SY5Y whole cell lysates and separated according molecular weight and
isoelectric point by 2D gel SDS-PAGE (a). Gels were then silver stained and imaged
(b) for spot characterisation analysis by Phoretix 2D software (c). Identified protein
spots were picked by robot (d) and digested in trypsin for analysis of peptides by
MALDI-TOF mass spectrometry (e). Peptide mass fingerprints for each protein spot
were compared to on-line proteomic databases and identities assigned to each protein
spot (f).
protein load of 300 pg (in 340pl) per strip. IPG strips were actively rehydrated for 12h
then focussed at 500V for lh, 1000V for lh and 8000V for 32,000Vh. DTT (3.5%) was
added to the cathode to maintain reducing conditions. Prior to running on the second
dimension, IPG strips were equilibrated twice for 15min in 10ml of equilibration
solution (0.1M tris HC1 (pH 6.8), 5.5M urea, 0.3% glycerol, 0.035M SDS, and 0.065M
DTT). For the second equilibration DTT was replaced by 14mM of iodoacetamide. The
second dimension separation was performed using pre-cast plastic-backed continuous
12.5% polyacrylamide gels (Amersham Biosciences) at 1 Watt per gel for 18h using the
manufacturer's proprietary buffer system. Gels were fixed for at least lh in 40%
methanol, 7% acetic acid and stained overnight using a mass spectrometry-compatible
silver stain (Biorad).
4.3.5. Imaging and analysis
Five gels from each treatment group (vehicle- and STS-treated) were imaged using a
FluorChem image analyser (Alphalnnotech) and gel images were stored as '.tif files of
2.58 MB and 16-bit resolution. Gels were analysed using Phoretix 2D software (Non¬
linear Dynamics) by first allowing the software to outline each individual protein feature
as a distinct area of stained gel. Protein features appearing across all five gels were
identified as 'seed' matches. Where the Phoretix software had failed in spot definition,
features were defined manually. The gels were then automatically matched, spot feature
to spot feature, and an experiment created within the program to group vehicle- and
staurosporine-treated gels.
4.3.6. Protein selection and identification
Selected protein features were extracted from the plastic-backed gels using a ProPic
robot (Genomics Solutions). Plugs were collected into 96-deep-well plates (Abgene,
Epsom, UK) and stored at -20°C in ethanol (20%). Protein in-gel trypsin digestion and
MALDI (matrix-assisted laser desorption/ionization) target spotting were performed
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using a Multiprobe II (PerkinElmer, Beaconsfield, UK) robotic system. Briefly, gel
plugs were washed 3 times with 50 mM ammonium bicarbonate in 50% acetonitrile
before being dehydrated with 100% acetonitrile, dried, rehydrated with unmodified
trypsin (about 200 ng; Promega) and incubated overnight at 32°C. The digested protein
mixture was spotted robotically onto a MALDI target with an equal volume of alpha-
hydroxycinnamic acid in a solution of 50% acetonitrile with 0.1% trifluoroacetic acid
(TFA).
4.3.7. Mass Spectrometry
Spectra were acquired automatically on a Voyager-DE STR mass spectrometer (Applied
Biosystems, Warrington, UK) recording masses between 800 and 3500Da. The samples
were calibrated internally using the trypsin autolysis peaks at 842.51Da and
2211.1046Da. Any spectra not automatically calibrated by this approach were re¬
calibrated manually before database interrogation. Peptide masses collected from mass
spectra were submitted to search the SwissProt database (http://us.expasv.org/) through
the Protein prospector website (http://prospector.ucsf.edu/) using Data Explorer and PS 1
software (Applied Biosystems). Protein matches were assessed on the basis of the
number of peptides matched to the target protein, the intensity of these peptides
expressed as a percentage of all submitted peptides and MOWSE score.
4.3.8. Affinity Chromatography
Affinity chromatography columns were prepared using biotinylated peptides
corresponding to the C-terminal 21 amino acids of wild type (biotin-
TVTIFVAGVLTASLTIWKKMG) and SI 84V mutant (biotin-
TVTIFVAGVLTAVLTIWKKMG) Bax (Albachem, Edinburgh, UK). Peptides were
coupled to NeutrAvidin-agarose beads (Pierce, Cramlington, Northumberland, UK)
according to the manufacturer's instructions and equilibrated in a mobile phase of
lOmM PIPES, 150mM NaCl, 1% Tween pH6.5 using a FPLC system (GE Healthcare).
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Affinity chromatography was performed using SH-SY5Y whole cell lysates (2-5mg total
protein). Specifically bound proteins were eluted using lOOmM glycine pH2 (1ml),
separated by Tris/Glycine PAGE (Invitrogen) and visualised using a mass spectrometry-
compatible silver stain. Protein bands were analysed by mass spectrometry as described
above.
4.3.9. Co-immunprecipitation and Western blotting
Co-immunoprecipitation and Western blotting were performed as described in general
materials & methods (Chapter 2). Briefly, Bax was immunoprecipitated from control
and apoptotic SH-SY5Y whole cell lysates using a non-conformation-specific Bax
antibody or a Bax antibody recognising the conformation-specific 6A7 epitope,
respectively. Immunoprecipitated proteins were separated by SDS-PAGE and analysed
by Western blot using appropriate antibodies.
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4.4. Results
4.4.1 Endogenous Bax interacts with heatshock and cytoskeletal proteins
Soluble cytosolic Bax-binding proteins originating from control and apoptotic (STS;5h)
SH-SY5Y cells were co-immunoprecipitated with Bax, analysed by 2D gel
electrophoresis and identified by mass spectrometry. Although numerous spots were
visible on the 2D gels, only six proteins were consistently present in the five replicate
gels performed using both control and apoptotic cell lysates -
Identification of these Bax-binding factors by MALDI-TOF mass spectrometry revealed
them to be: the heat shock proteins, Hsp60, Hsc71 and GRP78 and the cytoskeletal
proteins, P-actin, tubulin and vimentin. Additional analysis of these interactions was
performed using co-immunoprecipitation and Western blotting - . From
these studies, interactions between Bax and Hsp60, P-actin and vimentin were
confirmed, but not those between Bax and Hsc71, GRP78 or tubulin.
4.4.2 Hsp60, P-actin and nucleophosmin bind to the Bax C-terminal
membrane-targeting domain
Further experiments were performed to identify proteins that may be involved
specifically in regulating the translocation of Bax to the OMM. Because the
hydrophobic C-terminal region of Bax has previously been implicated as a
mitochondrial membrane targeting domain (Wolter et al., 1997; Nechushtan et al., 1999;
Suzuki et al., 2000), a synthetic peptide corresponding to the wild-type (WT) C-terminal
21 amino acids of Bax was used as bait to identify binding proteins in SH-SY5Y whole
cell lysate by affinity chromatography. From this study, the cytoskeletal protein, P-
actin, and the heat shock family proteins, Hsp60 and Hsp90, were identified as Bax C-
terminal binding proteins - • Figure 4.4. Flowever, when this experiment was


















































































Figure 4.2. 2-Dimensional (2D) gel analysis of Bax co-precipitating proteins in
control and STS-treated SH-SY5Y cells. Bax co-precipitants in vehicle-treated
(Control) and 5h STS-treated (apoptotic) SH-SY5Y whole cell lysates were
analysed by 2D gel electrophoresis and identified by mass spectrometry (a). The
master gel (top) shown for each experiment is a composite of the five individual gels
pictured below. Six proteins were consistently eluted with Bax under control and
apoptotic conditions. The accompanying table (b) details, for each protein, the
molecular mass in kDa (Mr), isoelectric point (pi), the molecular weight score
(MOWSE), the number of peptides matched from the total of peptides submitted
(hits/submitted), the overall intensity of the peptides matched as a percentage of the
total peptide intensity (intensity) and the error between the predicted and measured
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Figure 4.3. Confirming interaction between Bax and identified 2D binding
proteins by co-immunoprecipitation and Western blot. Confirmation of
interaction between Bax and Hsp60, j3 -actin and vimentin was achieved, whereas
interaction between Bax and Hsc71, GRP78, and tubulin could not be confirmed
using co-immunoprecipitation (a). Specificity of interaction between Bax and
Hsp60, P-actin and vimentin was tested by immunoprecipitating lysate with rabbit
IgG (b). Detection of proteins by Western blot (WB) in whole cell lysate (lysate)
and Bax immunoprecipitate (Bax IP) are as indicated. Images shown are









Figure 4.4. Identification of Bax C-terminus-binding proteins by affinity
chromatography. Proteins of molecular weight 48, 68 and 92kDa were eluted
with both the wild type (WT) and mutant (SI84V) Bax C-term peptides, and were
subsequently identified by mass spectrometry as Q -actin, Hsp60 and Hsp90,
respectively. However, only two proteins of molecular weight 26 and 37kDa
bound specifically to the mutant peptide. The 37kDa protein was subsequently
identified as nucleophosmin by mass spectrometry; however the identity of the
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Figure 4.5. Confirming interaction between Bax and identified Bax C-terminal-
binding proteins by co-immunoprecipitation and Western blotting. The presence
of activated Bax in STS-treated lysates was confirmed by immunoprecipitating Bax
with the conformation-specific antibody 6A7 (a). Co-immunoprecipitation studies
confirmed the interaction between 6A7-reactive Bax and Hsp60, j3 -actin and
nucleophosmin (NPM) in apoptotic cell lysate, but not that between Bax and Hsp90
(b). Detection of proteins by Western blot (WB) in whole cell lysate (lysate) and
immunoprecipitate (Bax 6A7 IP) are as indicated. Images shown are representative
of at least three independent experiments.
proteins identified using the wild type peptide, two further bands of approximately
26kDa and 42kDa were present in the final elution - . The 42kDa protein
was subsequently identified by mass spectrometry as the nucleolar phosphoprotein,
nucleophosmin, whereas no identity could be assigned to the 26kDa species.
Since all four identified proteins bound to the mutant peptide representing activated Bax,
co-immunoprecipitation studies to confirm their interaction with Bax were performed
using apoptotic (STS-treated) SH-SY5Y cell lysates. The presence of activated Bax in
this lysate was confirmed by immunoprecipitating Bax with an antibody recognising the
active conformation-exposed 6A7 epitope - see Figure 4.5a. Co-immunoprecipitation
experiments performed using this antibody confirmed the interaction between activated
Bax and Hsp60, P-actin and nucleophosmin, but not that between activated Bax and
Hsp90, under apoptotic conditions -
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4.5. Discussion
This chapter addressed two aims: 1) to identify proteins interacting with quiescent Bax
under normal conditions in neuronal cells and 2), to identify proteins binding
specifically to the putative transmembrane domain located within the Bax C-terminal
tail. Proteins belonging to the first category are candidate cytosolic retention factors,
functioning to protect the cellular environment from premature activation of Bax. The
latter proteins, however, due to their specific binding to the Bax membrane-targeting
domain, are of special interest as they are potentially important regulators of the
translocation of Bax to the mitochondrial surface. The potential contribution that each
of these proteins may bring to the regulation of Bax bioactivity will now be discussed.
In recent years, compelling evidence has accrued suggesting that Bax does not reside,
nor function, in the cytosol in isolation (reviewed by Lucken-Arjomande & Martinou,
2005). In this chapter, several novel Bax-interacting proteins, originating primarily from
the heat shock protein (Hsp) family and the cytoskeleton, were identified.
During episodes of cellular stress, Hsp proteins protect the cellular environment, in part,
by suppressing the activation and progression of the intrinsic apoptotic pathway
(Takayama et al., 2003). Certain Hsp family members are known to inhibit the activity
of pro-apoptotic Bcl-2 family proteins, including Bax (Kirchhoff et al., 2002; Mao et al.,
2004; Gotoh et al., 2004) Bak (Kirchhoff et al., 2002) and Bad (Shan et al., 2003),
sequester cytochrome c upon its release from mitochondria (Bruey et al., 2000) and
disrupt formation of the apoptosome (Beere et al., 2000; Saleh et al., 2000).
The identification of Hsp60 as a Bax-binding protein in this thesis confirmed an earlier
observation made by Kirchoff and colleagues who first demonstrated this interaction in
hypoxic cardiac myocytes in 2002 (Kirchhoff et al., 2002). Hsp60 has also been
reported to interact with Bak on the mitochondrial surface (Kirchhoff et al., 2002) and
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attenuate the apoptogenic activity of the BH3-only protein, Bad, in cardiac myocytes
exposed to doxorubicin (Shan et al., 2003). Thus, at least within cardiac cells, Hsp60
appears to inhibit apoptosis by down regulating the apoptogenic function of multiple
pro-apoptotic Bcl-2 family proteins.
Hsp60 is a molecular chaperone primarily localised to the matrix of the mitochondria
where it refolds key mitochondrial proteins (Ostermann et al., 1989). However, a small
proportion (around 15-20%) is also present in the cytosol (Itoh et al., 1995; Mills et al.,
1999). Cytosolic Hsp60 contains an N-terminal signal sequence that directs the
targeting of Hsp60 to the mitochondria in response to cellular stress (Itoh et al., 2002).
The translocation of Hsp60 to the plasma membrane has also been observed under such
conditions (Gupta and Knowlton, 2002).
The identification of Hsp60 as a Bax-binding factor in cardiac myocytes provided the
first evidence supporting a direct role for Hsp60 in regulating stress-induced apoptotic
pathways (Kirchhoff et al., 2002). From their observations, Kirchhoff and colleagues
concluded that Hsp60 retained Bax in the cytosol under normal conditions and that
dissociation between these two proteins was required for Bax to complete its
translocation to the OMM. The identification of Hsp60 as a Bax binding partner in the
SH-SY5Y neuroblastoma cell line suggests that Hsp60 may perform a similar role in
cells of neuronal origin.
However, the first reported involvement of Hsp60 in regulating apoptotic mediators
came in 1999 when two groups recognised its role in accelerating the maturation of
caspase-3 within the mitochondrial matrix (Xanthoudakis et al., 1999; Samali et al.,
1999). This led researchers to believe that Hsp60 could also function as a death-
promoting protein, perhaps under certain physiological circumstances. However, within
the mitochondria, Hsp60 functions as an important chaperone factor to numerous matrix
proteins (Ostermann et al., 1989). Since a population of procasapse-3 is also found
within the mitochondria (Mancini et al., 1998) it is probable that Hsp60 assists in the
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conformational maturation of procaspase-3 as it would with any other client protein.
Thus, the observed involvement of Hsp60 in caspase-3 maturation does not necessarily
mean that Hsp60 can also function as a pro-apoptotic protein.
Nevertheless, the affinity chromatography studies performed in this thesis identified
Hsp60 as one of five proteins binding to the Bax C-terminal transmembrane domain,
implicating Hsp60 as a potential Bax chaperone during its translocation to the OMM.
The a9 helix of Bax, which forms part of the C-terminal transmembrane domain, is
hydrophobic and is therefore internalised within the Bax molecule in a binding pocket
(Suzuki et al., 2000). However, the transmembrane domain is not exclusively
hydrophobic as it also contains several hydrophilic polar residues (Thrl72, Thrl74,
Thrl82, Serl84 and Thrl86) that, apart from Serl84, form a cytosolic face that is
thought to greatly improve the solubility of the Bax molecule within the cytosol (Suzuki
et al., 2000). Consequently, a portion of the Bax C-terminal tail is accessible to binding
prior to its activation and translocation. Thus, instead of acting as a translocation factor,
Hsp60 could instead associate with the cytosolic surfaces of the Bax C-terminus under
normal conditions as a means of maintaining Bax in an inactive conformation. This
hypothesis is in agreement with previous findings illustrating the inhibitory role of
Hsp60 on Bax bioactivity (Kirchhoff et al., 2002; Knowlton and Gupta, 2003; Shan et
al., 2003) as well as accompanying data presented in this thesis demonstrating Hsp60 as
a protein binding endogenous Bax under normal conditions.
Heat shock cognate protein 71 (Hsc71) and the ER-localised 78kDa glucose-regulated
protein, GRP78, both members of the Hsp70 protein family, were initially identified as
Bax co-precipitants in the 2D gel proteomic study but could not be confirmed as Bax-
interacting proteins by co-immunoprecipitation. This discrepancy may have arisen as a
result of using a different antibody to immunoprecipitate Bax in both experiments.
Alternatively, the transient, low binding affinity commonly observed between
chaperones and their substrates (Hendrick and Hartl, 1993) may make it difficult to
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investigate this class of protein-protein interaction using co-immunoprecipitation-based
approaches.
Nevertheless, that both proteins were identified from the 2D gel proteomic study as
proteins interacting with Bax under resting conditions is in agreement with their known
protective cellular roles as heat shock proteins. Hsp71 is a constitutively expressed
protein (Ingolia and Craig, 1982) and, as a chaperone, is involved in folding and
facilitating transportation of nascent polypeptides across intracellular membranes
(Tavaria et al., 1995). A specific anti-apoptotic role has not been attributed to Hsc71
per se, but its stress-induced variant, Hsp70, is an established cytoprotective protein that
has been implicated in inhibiting key molecular events within the intrinsic apoptotic
pathway, such as stress-induced JNK signalling (Mosser et al., 1997; Gabai et al., 1997),
cytochrome c release (Mosser et al., 2000) and apoptosome formation (Beere et al.,
2000; Saleh et al., 2000). As Hsc71 is a constitutively expressed protein, it could
instead function as a cytoprotective protein under resting cellular conditions, for instance
as a Bax retentive protein. GRP78 (also known as immunoglobulin binding protein Bip)
promotes the folding of unfolded proteins that have accumulated within the ER lumen
(Hendershot et al., 1994) and is an integral component of the unfolded protein response
(UPR) (Lee, 2001). Dysfunction of the ER stress-induced UPR is thought to be a major
contributor to neuronal cell death in Alzheimer's disease and Parkinson's disease
(Katayama et al., 1999; Imai et al., 2001; Sato et al., 2001). In one study, expression
levels of GRP78 were observed to be significantly reduced in the brains of Alzheimer's
disease patients (Katayama et al., 1999) and, in the same study, over-expressing GRP78
in a neuroblastoma cell line containing a presenilin-1 (PS1) mutation completely
restored resistance to ER stress-induced apoptosis. A direct involvement of GRP78 in
regulating ER stress-induced apoptotic pathways has been previously demonstrated. In
non-stressed cells, GRP78 binds to and maintains inactive the key ER stress transducing
protein, ATF6 (Lee, 2005) and the ER-associated caspases, caspase-7 and -12 (Rao et
al., 2002). Only upon dissociation from GRP78 are these proteins able to initiate
downstream apoptotic pathways (Lee, 2005). A hypothetical interaction between Bax
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and GRP78 is possible, as GRP78, although predominantly localised within the ER
lumen, has also been identified within the cytosol, particularly during cell stress (Rao et
al., 2002). Furthermore, an apoptogenic role for Bax at the ER is becoming increasingly
evident, where it has been proposed to initiate an apoptosome-independent route to
caspase-activation via caspase-12 (Zong et al., 2003). Further studies will be required in
order to evaluate whether a functional interaction between Bax and GRP78 has
implications in protecting neurones against ER stress-induced apoptosis.
Three proteins, p-actin, tubulin and vimentin, representatives from each of the three
main cytoskeletal structures in the cell, were also identified as proteins binding to Bax
under normal cellular conditions.
The cytoskeletal protein, tubulin, although seen in the 2D gel proteomic study, could not
be confirmed as a Bax-interacting protein by co-immunoprecipitation and Western
blotting. Tubulin is expressed at low levels in undifferentiated SH-SY5Y cells (Butler et
al., 2001) and this may have hampered our ability to detect an interaction between
tubulin and Bax using co-immunoprecipitation. However, a recent study has
demonstrated a direct interaction between recombinant Bax and extracted rat brain
tubulin (Knipling and Wolff, 2006), although it remains to be confirmed whether a
functionally relevant interaction occurs between endogenous proteins.
P-actin and vimentin, originating from the microfilament and intermediate filament
components of the cytoskeleton, respectively, were identified and confirmed from these
proteomic studies as Bax-interacting proteins. Interaction between pro-apoptotic Bcl-2
family proteins and cytoskeletal proteins is not unprecedented. The BH3-only proteins,
Bim and Bmf, are known to associate with dynein motor components of the cytoskeleton
as a means of sensing and responding to intracellular damage (Puthalakath et al., 1999;
Puthalakath et al., 2001). However, direct interactions between Bax and P-actin or
vimentin have not been identified previously.
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Vimentin is one of the most ubiquitous intermediate filament proteins in mammals
where it forms a cytoplasmic scaffold to stabilise the cellular architecture. Aside from
this structural role, vimentin has been hypothesised to conduct signal transduction
pathways as a substrate for numerous protein kinases, including the apoptosis-
suppressing kinases, Raf-1 and PKC (Eriksson et al., 2004). Phosphorylated vimentin is
also known to sequester the 14-3-3 protein (Tzivion et al., 2000), an important regulator
of apoptosis and cell-cycle progression through its ability to orchestrate the subcellular
localisation of numerous proteins (Hermeking, 2003). Of the seven human 14-3-3
isoforms, 14-3-3c has been attributed with the greatest tumour-suppressor activity, and
has been proposed to be a cytoplasmic anchor of Bax (Samuel et al., 2001). Recently it
has been demonstrated that vimentin interacts with 14-3-3/? which in turn is known to
sequester the phosphorylated form of the pro-apoptotic BH3-only protein, Bad (Schietke
et al., 2006). Thus, whether vimentin binds Bax directly, or through an intermediate
such as a 14-3-3 isoform, its influence on Bax activity is likely to be that of a cytosolic
retentive factor.
(3-actin was identified as a protein interacting with the whole Bax molecule as well as
with the Bax C-terminal transmembrane domain. The latter finding suggests that, under
cellular duress, Bax may utilise components of the cytoskeleton as a means of
translocation to the mitochondrial surface. This hypothesis is supported by a recent
study demonstrating the accumulation of P-actin at the mitochondrial surface prior to the
translocation and insertion of Bax during exposure of various cell lines to STS and UV-
irradiation (Tang et al., 2006). The authors of this report proposed that the actin
cytoskeleton might therefore facilitate the mitochondrial recruitment of Bax and other
pro-apoptotic proteins from the cytosol during apoptosis. This study, however, did not
attempt to demonstrate whether a direct interaction existed between actin and Bax in
these cells. Nevertheless, a functioning actin cytoskeleton has been shown to be
essential for the transduction of a death signal to mitochondria during TNFa treatment in
L929 cells (Li et al., 2004a). Furthermore, the actin cytoskeleton presents a natural
conduit for transporting pro-apoptotic proteins to the mitochondria, as the migration of
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mitochondria along Arp2/3-generated F-actin filaments has been observed, at least in
yeast (Boldogh et al., 2001). Moreover, the characteristic perinuclear clustering of
mitochondria observed during TNFa-induced apoptosis (De Vos et al., 1998) is, in
addition to microtubules, mediated by association with actin microfilaments (Li et al.,
2004a). Disruption to the dynamic state of actin has been linked to apoptosis initiated
by the mitochondrial release of reactive oxygen species (Posey and Bierer, 1999;
Gourlay et al., 2004) and several cytoskeletal components also contribute to the
execution phase of apoptosis where caspase-cleaved truncated actin (tActin) and
vimentin (tVimentin) fragments are both able to induce morphological changes
associated with apoptosis when ectopically expressed in culture (Mashima et al., 1999;
Byun et al., 2001). It is therefore feasible that the actin cytoskeleton, through its
association with Bax, may play an important role in facilitating the transduction of a
stress-induced apoptotic signal to the mitochondrial surface.
In addition to Hsp60 and P-actin, affinity chromatography studies using Bax C-terminal
peptides (wild-type and mutant SI84V) identified three other proteins with molecular
weights of 26kDa, 37kDa and 90kDa. The 37kDa and 90kDa proteins were
subsequently identified using mass spectrometry as nucleophosmin and Hsp90,
respectively. No identity, however, could be assigned to the low abundance 26kDa
protein, despite repeated attempts. Interestingly, the isolation of an unknown 25-26kDa
component of a Bax complex using gel exclusion chromatography was reported by
another laboratory at the fifth Interdisciplinary Euroconference on Mechanisms of Cell
Death and Disease in Portugal in 2003. However, these data have not yet been
published. Subsequent co-immunoprecipitation analyses failed to confirm the
interaction between Bax and Hsp90. Although Hsp90 is a reportedly highly abundant
protein in most cell types (Lai et al., 1984), its observed expression level in cultured SH-
SY5Y cells was low, which may have impacted on the ability to confirm the Bax-Hsp90
interaction by co-immunoprecipitation. Furthermore, Hsp90 has been shown to
associate with a large number of co-chaperones (Picard, 2002) and it is therefore
72
possible that Hsp90 may have been identified as one component of such a complex that
does not interact directly with Bax.
Significantly, the molecular chaperone nucleophosmin (NPM; also known as B23 or
numatrin) was observed to bind exclusively to the mutant peptide and therefore appears
to specifically recognise the activated Bax conformation. Nucleophosmin had recently
been proposed as a nuclear factor promoting the transcriptional activity and stability of
the tumour suppressor protein, p53, during genotoxic stress (Colombo et al., 2002).
Thus, the identification of nucleophosmin as a novel Bax-binding protein and a potential
chaperone to Bax during its translocation to the OMM provides evidence in support of
an additional regulatory mechanism for this protein within the intrinsic apoptotic
pathway.
4.6. Summary
The results presented within this chapter demonstrate that quiescent Bax, extracted from
SH-SY5Y whole cell lysates, is found in association with several regulatory factors,
including the heat shock family protein, Hsp60, and the cytoskeletal proteins, P-actin
and vimentin. Furthermore, Hsp60 and P-actin can bind specifically to the Bax C-
terminal tail, a region thought to be implicitly involved in targeting Bax to the
mitochondrial surface. These proteins may function either as putative retentive factors
or facilitators of Bax translocation, depending on whether or not the cell is undergoing
apoptosis Several additional proteins were isolated in the same study as the Bax co-
precipitants, including tubulin, Hsc71 and GRP78. Although each of these may make a
significant contribution to Bax function, subsequent analyses of their relationship with
Bax by co-immunoprecipitation and Western blotting, in this study, could not
conclusively demonstrate the existence of a direct interaction. Finally, nucleophosmin, a
molecular chaperone that has previously been linked with promoting p53 activity, was
isolated from SH-SY5Y whole cell lysates as a protein binding specifically to a mutant
(S184V) Bax C-terminal peptide. This novel interaction implicates nucleophosmin as a
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potential regulator of the mitochondrial targeting mechanism of Bax - an event that is
essential for Bax to induce cell death but which, despite extensive research, remains
poorly understood. Determining the structural and functional relationships between Bax
and nucleophosmin will therefore form the basis of the following two chapters (5 & 6),
respectively.
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CHAPTER 5: Characterising the molecular interaction between Bax
and nucleophosmin
5.1. Chapter aims
Nucleophosmin was identified as a Bax-binding protein by affinity chromatography as
described in chapter 4. In order to investigate the interaction between Bax and
nucleophosmin in more detail, the aims of this chapter are: 1) to express recombinant
full-length human Bax and nucleophosmin recombinant proteins, and 2) to develop a
cell-free amplified luminescent proximity assay in which to characterise the molecular
interaction between these recombinant proteins.
5.2. Introduction
5.2.1. Recombinant protein synthesis
The production of recombinant proteins from a wide variety of expression systems is a
frequently used approach to investigate protein structure, function and protein-protein
interactions. The quantity of protein required depends on the application: For screening
purposes, a relatively small amount (micrograms or less) of a large number of proteins is
sufficient, whereas for certain therapeutic applications (eg antibody production)
quantities approaching the metric ton scale are needed (Andersen and Krummen, 2002).
The choice of expression system depends on the amount of protein required as well as
the intended use. In the laboratory, recently developed cell-free, in vitro expression
systems using mammalian or E.coli cell extracts can provide a rapid and convenient
approach to synthesising small quantities of proteins for use in high throughput
screening assays (Swartz, 2001). Cell-free expression systems also have the added
benefit of being able to express highly toxic proteins, such as Bax. Larger protein yields
are obtainable from mammalian cell expression systems (Chinese hamster ovary (CHO)
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being the most commonly used) that have the added advantage of providing all the
necessary translational machinery to ensure correct folding and post-translational
modification of expressed nascent proteins. However, the most common expression
system used in the lab is Escherichia coli due to its relative simplicity, inexpensive and
fast high-density cultivation, its well-characterised genetics and the large number of
compatible tools available within modern biotechnology (Swartz, 2001; Sorensen and
Mortensen, 2005). Furthermore, recent advances in the genetic modification of E.coli
hosts have greatly improved their ability to express recombinant proteins that are
correctly folded and have the bioactivity associated with endogenous proteins. For
example, modifications that encourage the expression of correctly folded proteins
include E.coli mutants that co-express chaperone proteins (particularly ribosomal-
associated trigger factor, GroEL and DnaK chaperones) (Nishihara et al., 2000; Ikura et
al., 2002) or enhance disulphide bond formation (Bessette et al., 1999).
Expression of recombinant proteins is normally induced from a plasmid DNA vector
that is compatible with the transcriptional/translational machinery of the host cell.
Genetic elements typically found within most expression plasmids (as recently reviewed
by Sorensen and Mortensen, 2005) include the origin of replicon (ori), which regulates
plasmid copy number, an antibiotic resistance marker (commonly against Ampicillin,
Kanamycin or Chloramphenicol), transcriptional promoters (eg, bacteriophage T7 late or
human cytomegalovirus (CMV) immediate early promoters), translational initiation
regions (TIRs), which contain ribosome-recognition sequences specific to either
eukaryotic or prokaryotic hosts, and transcriptional and translational terminators, such as
poly-Adenosine (Poly-A) tails.
To ensure compatibility with the E.coli translational machinery, transcribed messenger
RNA (mRNA) must have a ribosome binding site (RBS) containing a Shine-Dalgarno
sequence (UAAGGAGG) 5-9 nucleotides upstream from an initiating methionine -
encoding (AUG) start codon (Ringquist et al., 1992). The RBS is recognised by the 16S
component of the ribosome which then initiates translation in prokaryotic systems.
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Eukaryotic translational machinery also uses AUG as the start codon, but the initiation
of translation in this case requires a Kozak consensus sequence (CCA/GCCAUGG) that
includes several nucleotides upstream and a single nucleotide downstream of the
proximal methionine (Kozak, 1987). Translation in eukaryotic and prokaryotic hosts is
terminated when the ribosome/tRNA complex reaches a stop codon at the end of the
mRNA transcript. UAA is preferred by E.coli, but UAG and UGA are also used (Crick,
1966; Poole et al., 1995)
High level gene expression from a plasmid vector within the host cell requires a strong
promoter. The bacteriophage T7 promoter forms the basis of the widely used pET
expression system, developed by Studier and colleagues and subsequently
commercialised by Novagen, for the high yield production of recombinant proteins in
E.coli. The T7 promoter is not recognised by E.coli RNA polymerase but is instead
recognised by the 2J9E3 phage fragment-encoded T7 RNA polymerase, which is
incorporated into the host cell genome (Studier et al., 1990; Dubendorff and Studier,
1991). Expression of T7 RNA polymerase is under the control of the lactose analogue
isopropyl-P-D-l-thiogalactopyranoside (IPTG)-inducible lac\JV5 promoter (Baneyx,
1999). Thus, expression of the recombinant protein can be induced by the addition of
IPTG (typically 50-100pM) to the E.coli culture. However, low-level basal or "leaky"
expression of T7 RNA polymerase in the absence of IPTG can lead to plasmid
expression instability, which is of particular concern if the recombinant protein is toxic
to E.coli. Leaky expression of a toxic recombinant protein can lead to the selection of
non-expressing cells over transformants within a culture prior to induction. A widely
used strategy to overcome this is to use host cells expressing basal levels of the T7 RNA
polymerase inhibitor, T7 lysozyme, from pLysS or pLysE plasmids (Studier, 1991).
Additionally, expression of the lac repressor, lacl, inhibits induction of T7 RNA
polymerase expression from the /ucUV5 promoter, and incorporation of the lacl gene,
together with a lac operator downstream from the T7 promoter on the expression
plasmid, inhibits transcription of the target gene by T7 RNA polymerase. Transcription
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Figure 5.1. Control elements within the pET expression system. Basal transcription
of T7 RNA polymerase in the uninduced state can lead to the negative selection of
transfomiants within the E.coli population. Two genetically-regulated strategies have
been developed to counteract this. Hosts carrying either pLysS or pLysE plasmids
express T7 lysozyme, which is a natural inhibitor of T7 RNA polymerase. pLysS
expresses a small amount of T7 lysozyme, whereas pLysE hosts produce more enzyme
which allows for more stringent control. Expression of the lac repressor from lacl genes
encoded in both the host genome and the pET plasmid provides additional control of
transcription by inhibiting the binding of E.coli and T7 RNA polymerases to the
/acUV5 and bacteriophage T7 promoters, respectively. Addition of IPTG to the E.coli
culture disociates lacl from the lac operator, induces transcription of T7 RNA
polymerase from the lac\JV5 promoter which then induces transcription of the target
gene from the pET plasmid. Image taken from Novagen ^Novations Newsletter
(1994). Vol. 1., No. 1.
overview of such control elements within the pET expression system is depicted in
Figure 5.1.
The versatility of recombinant protein expression is illustrated by the ability to attach
fusion partners, or "tags", to either the N- or C-termini of the nascent protein in order to
improve solubility (Davis et al., 1999), protein yield (Arechaga et al., 2003) or to ensure
compatibility with downstream affinity-based purification methods (Terpe, 2003). Two
commonly used tags to accommodate affinity-based purification of recombinant proteins
are the polyhistadine(His) tag, which is compatible with immobilized metal affinity
chromatography (IMAC), and the glutathione S-transferase (GST) tag, for purification
using glutathione-based resins (Sorensen and Mortensen, 2005).
5.2.2. Principles of the cell-free amplified luminescence proximity assay
The analysis of protein-protein interactions using recombinant proteins within a cell-free
setting provides several advantages over analyses performed in situ. Firstly,
recombinant expression systems are capable of producing quantities of a specific protein
often unattainable from natural host cells. Secondly, the truly homogeneous
environment of an in vitro system permits the researcher to determine whether or not a
direct interaction between two proteins exists. Thirdly a robust biochemical and
pharmacological analysis of the interaction between two proteins can be performed. For
example, dose-response experiments can determine interaction stoichiometry,
competition assays can provide an assessment of relative binding affinities, and the
inclusion of specific inhibitors can lead to the identification of binding interfaces
(domains or motifs) within protein structures. Overall, the use of an in vitro binding
assay provides an effective way to corroborate data obtained from experiments
performed using endogenous proteins.
For the purpose of investigating the interaction between recombinant Bax and




Figure 5.2. Principle of the AlphaScreen proximity assay. When biological
interactions between conjugated proteins bring the Donor and Acceptor beads into close
proximity (a), singlet oxygen ('02) released from laser-excited Donor beads stimulates
fluorophores on Acceptor beads to emit a highly amplified luminescent signal of 520-
620 nm. However, in the absence of a biological interaction (b), Donor and Acceptor
beads are separated by more than 200nm and consequently the emitted singlet oxygen
decays and no amplified signal is generated. Images modified from Principles of
AlphaScreen data sheet (PerkinElmer Inc.).
considered: an amplified luminescent proximity homogeneous assay (AlphaScreen;
PerkinElmer) and a biomolecular binding platform based on surface plasmon resonance
(SPR) technology (Biacore Life Sciences). Although each approach has its own specific
strengths, the AlphaScreen system was chosen due its ease-of-use, fast reading times and
high sensitivity (Glickman et al., 2002).
The principle of luminescent oxygen channelling, which forms the basis of AlphaScreen
technology, was first described in 1994 (Ullman et al., 1994) and has since been
commercialised by PerkinElmer Inc. Using this technology, the two proteins of interest
are conjugated to separate hydrogel-coated polystyrene microbeads (donor and acceptor
beads) and incubated together for up to several hours under ambient conditions. If a
biological interaction between the proteins takes place, the acceptor and donor beads are
brought together in close proximity.
Upon excitation of the donor beads with a high energy laser of wavelength 680nm,
ambient oxygen is converted to an excited singlet state (O2 'AgC^) which then
diffuses out into the surrounding aqueous environment. However, singlet oxygen has a
short lifetime in aqueous solutions (4ps) which therefore limits its diffusion from the
donor beads to a distance of approximately 200nm. Only if a biological interaction
brings the two proteins into close proximity are singlet oxygen molecules able to diffuse
across from the donor beads to the acceptor beads. On the surface of the acceptor beads,
the singlet oxygen reacts with thioxene derivatives to generate chemiluminescence at
370nm. This further stimulates fluorophores on the acceptor beads to emit a
luminescent signal at 520-620nm (Ullman et al., 1994) - sec Figure . However, if
no biological interaction exists between the proteins, then the acceptor beads will be out-
of-range of the emitted singlet oxygen molecules and thus only a background signal will
be detected - see Figure 5.2b.
The AlphaScreen technology is highly sensitive - a photosensitiser on the Donor beads
generates up to 60,000 singlet oxygen molecules per bead - which means only very
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small volumes (< 5fj.l) of reagent and protein are required to generate a detectable signal.
Consequently, multiple experiments can be performed simultaneously in 3 84-well
plates, facilitating the provision of HTS capability, if required. The hydrogel-coated
beads of uniform size minimize non-specific binding, and the high excitation
wavelength of 680nm makes it unlikely that the presence of biological or assay
substances in the reaction mix will interfere. The most likely source of error in this
system is therefore attributed to the operator. AlphaScreen technology is designed for
automated HTS, but manual operation is possible. However, due to the tiny reagent
volumes involved and the light-sensitive nature of the fluorophore-coated beads, a
meticulous and precise approach to each experiment performed using this assay is
critical if accurate and consistent data are to be obtained.
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5.3. Materials & Methods
5.3.1 Chemicals
All restriction enzymes were obtained from Promega. All plasmid DNA vectors were
supplied by Invitrogen, unless otherwise stated.
5.3.2 Subcloning of Bax and Nucleophosmin cDNAs into expression vectors
Full length open reading frame (ORJF) clones for human Bax and nucleophosmin were
obtained from Invitrogen (Ultimate™ human ORF clones; ID numbers IOH130038 and
IOH7470, respectively) and supplied in the Gateway® entry vector pENTR™221.
Plasmid DNA was transformed into competent DH10B T1-Phage resistant E. coli cells
(Invitrogen). Transformed colonies were selected, propagated and plasmid purified
(Wizard Plus SV minipreps; Promega) using standard molecular procedures (Sambrook
& Russel, 2001).
To enable in vitro expression of eukaryotic proteins, Bax and nucleophosmin full-length
ORFs were subcloned from pENTR™221 entry vectors into the Gateway® destination
expression vector, pcDNA3.2/V5-DEST. Bax and nucleophosmin ORFs were
subcloned by recombinational cloning (Hartley et al., 2000) which utilises the site-
specific recombination properties of bacteriophage lambda to transfer a gene from an
Entry clone to a Destination vector to create an Expression clone (Gateway system,
Invitrogen). Briefly, 300ng each of Entry and Destination vector plasmid DNA were
mixed with LR clonase recombination proteins (Invitrogen) and incubated overnight at
25°C. A positive control reaction for LR recombination was performed using the
pENTR-Gus (beta-Glucuronidase) Entry vector. Insertion of Bax and nucleophosmin
ORFs into pcDNA3.2/V5-DEST replaces a region previously occupied by the E.coli
cytotoxic ccdB gene and a Chloramphenicol-resistance (CmR) gene, lpl of each
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recombination reaction was used to transform competent DH5a E. coli cells and lOOpl
of transformed cells plated onto LB agar supplemented with 50pg/ml Ampicillin (to
positively select transformants containing AmpR Expression clones) or 30pg/ml
Chloramphenicol (to negatively select transformants containing CmR Destination
vectors). Selected colonies were propagated in competent DH5a E. coli cells, plasmid
purified and verified by restriction digest using the insert-specific cutting enzyme,
Bsu36I (New England Biolabs, Hitchin, Elerts, UK).
To enable in vitro expression of His-tagged proteins, Bax and nucleophosmin ORFs
were subcloned from pENTR™221 into the prokaryotic expression vector, pCR®T7/NT-
TOPO, which contains an N-terminal cleavable poly-His tag. Two sets of
oligonucleotide primers were designed to amplify the full length Bax and
nucleophosmin ORFs to facilitate expression of both tagged and native (untagged)
proteins from this vector - for primer sequences. Sequences were
amplified from pENTR221-Bax and nucleophosmin vectors using a proofreading Taq
polymerase (Expand High Fidelity Taq; Roche Applied Science) and 30 cycles of PCR
(initial melt at 94°C for 2 mins, followed by 10 cycles of 94°C for 15 sees, 45°C for 30
sees and 72°C for lmin, then 20 cycles of the same conditions where the extension step
at 72°C was increased by 5 seconds per cycle followed by a final extension at 72°C for 7
mins). The resulting Tag-amplified PCR fragments were separated by 1% agarose gel
electrophoresis and visualised by ethidium bromide staining under UV illumination.
Tag-amplified PCR fragments were TOPO-TA cloned into the prokaryotic expression
vector pCR®T7/NT-TOPO according to the manufacturer's instructions. Briefly 2pl of
the Tag-amplified PCR fragments were combined with 1 pi salt solution (200 mM NaCl,
10 mM MgCb), lpl of linearised pCR®T7/NT-TOPO vector containing covalently-
bound topisomerase I and double-distilled water up to a final volume of 6pl. The
reaction was then incubated at room temperature for 5mins. pCR*T7/NT-TOPO-Bax
and -nucleophosmin clones were transformed into competent DH5a library efficiency E.
coli cells (Invitrogen) and plated onto LB agar supplemented with 50pg/ml Ampicillin.
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Primer Sequence (5'-3')
1. Bax forward primer for tagged protein
2. Bax forward primer for native protein
3. Bax reverse primer
4. NPM forward primer for tagged protein
5. NPM forward primer for native protein











Table 5.1. Primer sequences used to TA-clone His-tagged and untagged Bax and
nucleophosmin ORFs from pENTR221 to pCRT7/NT-TOPO. Two forward primers
to each sequence were used for the sub-cloning of Bax and nucleophosmin in
conjunction with a reverse primer. Forward primers for the expression of tagged protein
(primers 1 and 4) were designed to start at the ATG initiation codon for the respective
sequences and would allow the genes to be cloned into the expression vector in frame
with the poly-histidine tag. Forward primers for expression of native protein (primers 2
and 5) were modified by the insertion of a STOP codon (TAG, highlighted in bold blue),
followed by the insertion of a ribosome binding site (RBS, AGGAGG, underlined) and
the ATG start codon (highlighted in italicised red) of the respective gene to permit
translation to re-initiate at the beginning of the cloned gene sequence. Reverse primers
were complementary to the 5' end of the ORFs and contained the stop codons
(highlighted in green) for each of the genes.
The orientation of the cloned PCR fragments in pCR®T7/NT-TOPO was determined by
direct lysis PCR. Briefly, transformed cells were disrupted by heating at 95°C for 5
mins in 20mM Tris pH8.4, 2mM EDTA, 1% Triton X100. After centrifugation at
BOOOrpm for 2 mins, the supernatant was subjected to the PCR protocol outlined above
using either the T7 promoter or T7 reverse primer in conjunction with a gene specific
reverse primer to amplify correctly orientated inserts. Plasmid DNA was then purified
and correct insert size confirmed by restriction enzyme digestion. pCR®T7/NT-Bax
clones were digested with Bsu361, Nhel and Hind III, and pCR®T7/NT-nucleophosmin
clones with Bsu361, BamHI and Hindlll using standard procedures. Clones were also
sequenced to confirm error-free recombination (DNA Sequencing Facility, Department
ofBiochemistry, University of Oxford, UK).
5.3.3 Expression of recombinant full-length Bax and Nucleophosmin proteins
In vitro expression of Eukaryotic Bax and nucleophosmin proteins were performed from
the T7 promoter of pcDNA3.2/V5-DEST expression vectors using an in vitro quick
coupled transcription and translation expression system with rabbit reticulocyte lysate
(TnT®; Promega) according to the manufacturer's instructions. Briefly, lpg purified
plasmid DNA was added to a reaction vessel containing a TnT® Quick Master mix (T7
RNA polymerase, nucleotides, salts, amino acids (except methionine), ribonuclease
inhibitors and rabbit reticulocyte lysate), to which ImM methionine and biotin-lysyl-
tRNA were added. The TnT® reaction was then incubated at 30°C for 90mins. Inclusion
of biotin-lysyl-tRNA incorporated biotinylated lysines into the translated protein for
detection using streptavidin-conjugated antibodies. A control reaction using a
luciferase-expressing plasmid was also performed. Aliquots (2pl) were subsequently
separated by SDS PAGE and visualised by SYPRO ruby staining (Invitrogen) or by
Western blotting using a polyclonal Bax antibody (Upstate Biotechnology), a
monoclonal nucleophosmin antibody or a streptavidin-HRP conjugate (Promega).
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Expression of His-tagged prokaryotic nucleophosmin protein was performed from the
T7 promoter of pCR®T7/NT-TOPO using E.coli BL21(DE3)pLysS competent cells
(Invitrogen). Plasmid DNA was transformed into competent cells and cultures grown
overnight at 37°C in Luria-Bertani (LB) broth containing 100pg/ml Ampicillin and
34pg/ml Chloramphenicol. 10ml Fresh LB broths supplemented with antibiotics were
inoculated with 500pl of overnight culture and grown to mid-log phase (until culture
density had reached an A60o of 0.5-0.8). Protein expression was then induced using
ImM Isopropylthiogalactoside (IPTG). A pilot protein expression study was performed,
where 0.2ml aliquots of culture (maintained at 37°C) were taken at 2 h intervals up 6 h
from the time of induction. Maximal expression of His-tagged nucleophosmin was
achieved 4h post induction. His-tagged nucleophosmin was extracted from BL21 cells
using a 1 in 10 dilution of Fast-break lysis buffer (Promega). Purification of His-
nucleophosmin was performed by incubating samples with MagneHis™-Nickel beads
(Promega) for 2 mins to isolate His-tagged protein. Following incubation, beads were
captured using a magnetic stand and bound protein washed 4 times in in MagneHis™
binding/wash buffer wash. Protein was eluted in 500mM imidazole and dialysed against
Tris Buffer (50mM Tris-HCl pH7.4, 150mM NaCl, ImM EDTA, 5mM DTT, 0.5%
Nonidet P40 (NP40), 0.5% Triton-X-100, 10% glycerol) using Slide-A-Lyzer cassettes
(lOKDa molecular weight cut-off; Pierce, Northumberland, UK). Aliquots of
recombinant human nucleophosmin were separated by SDS PAGE gel electrophoresis
and visualised by coomassie staining. Briefly, gels were fixed for 30min in fix solution
(40% methanol/7% acetic acid), stained overnight in Brilliant Blue G-colloidal solution
(Sigma), de-stained for lmin in de-stain solution (25% methanol/10% acetic acid) and
transferred into a 25% methanol solution for imaging. Expressed protein was also
analysed by Western blot using a monoclonal nucleophosmin antibody, as described in
general materials & methods (Chapter 2), and identified by MALDI-TOF mass
spectrometry as described in sections 4.3.5 and 4.3.6. Stock solutions of His-
nucleophosmin (2.5mg/ml) were stored at -70°C.
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His-tagged prokaryotic Bax was expressed from the T7 promoter of pCR®T7/NT-TOPO
using the Expressway™ Plus in vitro expression system (Invitrogen) according to the
manufacturer's instructions. Briefly, lpg plasmid DNA was added to a reaction vessel
containing 20pl E.coli cell extract, 20pl reaction buffer, lpl T7 enzyme mix and 75mM
methionine. Reaction vessels were shaken at 300rpm in an incubator at 37°C for 4h.
5pl RNase was then added and reaction vessels incubated for a further 15mins before
undergoing purification. Scaling up the production of His-Bax involved performing 20
replicate reactions. Purification of His-tagged proteins was performed as for His-
nucleophosmin, except MagZ Nickel-coated binding beads (Promega) were used.
Following dialysis, purified His-Bax was concentrated to approx 2mg/ml using vivaspin
concentrators (Vivascience, Hannover, Germany) and biotinylated using the ProtOn™
biotin labelling kit (Vector laboratories, Peterborough, UK) according to the
manufacturer's instructions. Aliquots of recombinant human Bax were separated by SDS
PAGE gel electrophoresis, visualised by coomassie staining and by Western blot using a
polyclonal Bax antibody (Upstate Biotechnology), and identified by MALDI-TOF mass
spectrometry. Stock solutions of His-Bax were stable if stored at 4°C for up to one
week.
5.3.4 Analysis of interaction between recombinant proteins using an in vitro
amplified luminescence proximity assay
Interaction studies between recombinant full-length human Bax and nucleophosmin and
were performed using a bead-based chemiluminescent proximity assay (AlphaScreen™
technology; Perkin Elmer) on 384-well white polystyrene proxiplates (Perkin Elmer).
This work was carried out in collaboration with Dr Jane Thompson and Mrs Eliane
Salvo-Chirmside (ACE).
Acceptor beads were conjugated with a monoclonal antibody raised against the C-
terminus of nucleophosmin (Sigma) using a standard amination procedure. 0.3mg
acceptor beads were combined with 30pg antibody in a reaction mix containing 5%
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sodium cyanoborohydride and 0.02M 2-[N-Morpholino] ethanesulphonic acid (MES;
pH6.0) and incubated for 48h at 37°C in the dark. Following incubation, a block step
was performed using 0.1M carboxymethoxylaminehemihydrochloride (CMO) for lh.
The beads were then sonicated and washed 3 times in 0.1M Tris buffer, pH8.0.
Conjugated beads were finally prepared as a 5mg/ml solution in 25mM HEPES, 0.1M
NaCl, pH 7.4 (Perkin Elmer). Confirmation of successful conjugation was assessed by
combining conjugated acceptor beads with streptavidin-conjugated donor beads
(PerkinElmer) in reactions containing serial dilutions (0.003-3nM) of biotinylated mouse
secondary antibody (Sigma).
Assay reactions comprised 5pl each of nucleophosmin monoclonal antibody-conjugated
acceptor beads and streptavidin-coated donor beads, 15pi recombinant biotinylated Bax
and nucleophosmin proteins diluted to lOOnM and 15nM, respectively, in 150mM NaCl,
lOmM HEPES-KOH pH7.4, 0.01% BSA containing 0.1% NP40, with inhibitors as
indicated, in a total assay volume of 25pl. Prior to contact with beads, recombinant
proteins were mixed together for 90mins at room temperature to encourage interaction.
For experiments containing inhibitors to either Bax or nucleophosmin, protein-inhibitor
solutions were pre-incubated separately at room temperature for 30mins prior to mixing
and incubating a further 90mins. Optimisation of reaction conditions included protein
concentrations used (0-5000nM titration of Bax protein to which was added either 5nM,
15nM, 150nM or 350nM nucleophosmin protein) and pre-assay incubation times (a
range of lmin to 240min was used).
The proximity assay was performed as follows: In a darkened room, nucleophosmin
antibody-conjugated acceptor beads were added to 384-well plates followed by
recombinant proteins and plates incubated in the dark at 37°C for 30mins. Streptavidin-
conjugated donor beads were then added and plates incubated for a further 60mins prior
to analysis using a multi-label reader (Envision Excite™; Perkin Elmer).
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Peptide inhibitors used were Bcl-2 (human, His-tagged, C-terminal truncated; Merck,
Nottingham, UK) and p53 peptide (residues 277-296; Abeam). Antibody-based
inhibitors used were raised against the Bax N-terminus (residues 1-21; Upstate
Biotechnology), a-helix 5 (residues 98-117, Ab4; Merk) and C-terminus (residues 150-
165; Abeam). Inhibitor concentrations were titrated from 0.03nM to lOOOnM when
included in the proximity assay.
Control reactions containing nucleophosmin antibody-conjugated acceptor beads and
streptavidin-conjugated donor beads with nucleophosmin or Bax alone, were run in all
experiments to assess background signal intensity.
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5.4. Results
5.4.1. Production of full-length recombinant human Bax and nucleophosmin
proteins
Confirmation that the pENTR221 Ultimate human ORF clones supplied by Invitrogen
contained the full-length Bax and nucleophosmin ORFs was assessed by restriction
digest - In order to express sufficient quantities of recombinant Bax and
nucleophosmin for use in proximity assay interaction studies, human Bax and
nucleophosmin full-length ORFs were subcloned from pENTR221 into dedicated
expression plasmid DNA vectors - for a flow-diagram of the subcloning
strategies used.
Eukaryotic expression constructs for Bax and nucleophosmin were produced by
subcloning full-length ORFs from pENTR221 into the mammalian expression vector
pcDNA3.2/V5-DEST by recombinational cloning. In order to confirm that these
expression clones contained full length ORFs, recombinant Bax and nucleophosmin
were expressed from the T7 promoter of pcDNA3.2/V5-DEST using a cell-free
expression system (TnT®) - . In the TnT® reaction, plasmid DNA was
combined with T7 RNA polymerase and rabbit reticulocyte cell lysate to initiate
eukaryotic mRNA translation (Jackson and Hunt, 1983; Craig el al., 1992). Nascent
proteins were labelled by including biotinylated lysine in the TnT® reaction mix and
visualised following SDS PAGE by Western blotting with a streptavidin-HRP-
conjugated secondary antibody. A clear signal of anticipated molecular weight was
obtained for the nucleophosmin-expressing clones, however no signal could be detected
for Bax - Figure . The inability to detect biotinylated recombinant Bax by
streptavidin-HRP could be explained by the respective number of lysine residues
contained in each protein. Lysine is one of the more frequently used amino acids and on








Figure 5.3. Validation of pENTR221 full-length Bax and nucleophosmin ORF
clones by restriction digest. Single digests with the restriction enzymes EcoRV
andNhel (pENTR221-Bax) (a) and Apal (pENTR221-nucleophosmin(NPM)) (b)
linearised the plasmid DNA clones, whereas a double digest (Dbl) generated a
830bp fragment (pENTR221-Bax) and a 1061 bp fragment (pENTR221-NPM)
containing the full length Bax and nucleophosmin ORFs, respectively. Uncut

















Figure 5.4. Sub-cloning strategy to produce recombinant Bax and
nucleophosmin proteins for use in proximity assay. Full length Bax and
nucleophosmin open reading frames (ORFs) were supplied in the pENTR221 vector.
Bax and nucleophosmin ORFs were sub-cloned into pcDNA3.2/V5-DEST by LR
recombination or into pCRT7/NT-TOPO® by TOPO®-TA cloning. Eukaryotic
proteins were expressed from the CMV promotor of pcDNA3.2/V5-DEST using a
cell-free in vitro transcription and translation (TnT®) system. Prokaryotic His-tagged
proteins were expressed from the T7 promoter of pCRT7/NT-TOPO® using the
Expressway Plus™ cell-free in vitro expression system ( Bax) or in IPTG-inducible
BL21 E. coli cells (nucleophosmin). Proteins were then purified before interaction
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Figure 5.5. Analysis of Bax and nucleophosmin protein expression from
pcDNA3.2/V5-DEST by Western blot. TnT® - expressed proteins were separated by
SDS PAGE and analysed for the presence of Bax and nucleophosmin (NPM) by
Western blot. Detection of biotinylated proteins was performed using a streptavidin-
HRP antibody (a). Western blots were also probed with antibodies raised against
human Bax (b) and nucleophosmin (c). Although only biotinylated nucleophosmin
was visible on the streptavidin blot, both proteins could be detected by their respective
human-reactive antibodies (circled). Non-specific protein bands at 32kDa and 40kDa
in the Bax and nucleophosmin blots, respectively, originate from constituents within
the TnT® reaction. Positive control reactions expressing luciferase (Luc) and negative
control reactions (-ve) containing an empty vector were also run.
respect, nucleophosmin is above average, with 33 lysines out of a total amino acid
content of 294 (11.2%). In contrast, Bax contains only 9 lysines out of 192 amino acids
(4.7%) which may limit its detection using biotinylated lysines. However, both Bax and
nucleophosmin were detected at appropriate molecular weights with human protein-
specific antibodies by Western blot, demonstrating that full-length eukaryotic Bax and
nucleophosmin proteins had indeed been expressed - see
In order to determine the yield of proteins expressed by the in vitro TnT® reactions,
proteins were separated by SDS PAGE and protein band intensity visualised by SYPRO
ruby stain - Although expression of recombinant proteins was detectable
by Western blot, protein levels were too low to be visualised by this stain. The minimal
detection threshold for SYPRO ruby stain is approximately lng (Berggren et al., 2000),
suggesting that the protein yield generated by in vitro expression of eukaryotic Bax and
nucleophosmin by a single TnT® reaction was less than this. Therefore, to increase
protein yield to a level sufficient for experimental use (ideally in the order of
milligrams), an alternative subcloning protocol was undertaken.
To maximise yield and purity of recombinant proteins, His-tag fusion proteins were
produced in E.coli cultures. To facilitate this, PCR primers were designed to isolate and
amplify Bax and nucleophosmin ORFs from pENTR221 using a high fidelity Taq
polymerase and transfer them by means of TOPO-TA cloning into the dedicated
prokaryotic expression vector, pCR®T7/NT-TOPO. The forward primers were designed
in such a way as to either permit addition of an N- terminal 6xHis-tag (by placing the
gene of interest in frame with the His-tag) or to express native proteins (by including a
STOP codon and a new ribosome binding site (RBS) to facilitate expression from the
initial ATG of the inserted gene). Taq polymerase has a terminal transferase activity
that adds a single 3' deoxyadenosine (A) overhang to each end of the generated PCR
fragments that facilitates their ligation into linearised pCR®T7/NT-TOPO plasmid DNA
containing single 3' deoxythymidine (T) overhangs. Although fast and effective, TA-
cloning is non-directional. Therefore, correct orientation of the inserted PCR fragment
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Figure 5.6. Visualisation of recombinant Bax and nucleophosmin protein
expression from pcDNA3.2/V5-DEST by SYPRO ruby stain. 2|Jl and 5pl of
each TnT® reaction were separated by SDS PAGE and protein content visualised by
SYPRO ruby stain. Despite confirmation of Bax and nucleophosmin protein
expression by Western blot (Figure 5.5), expression levels were too low to be
evident by protein stain. Visible bands are components of the rabbit reticulate lysate
used in the TnT® reaction.
into pCR®T7/NT-TOPO was confirmed by PCR using T7 forward (T7F) and reverse
(T7R) primers in combination with specific Bax or nucleophosmin reverse primers. The
rationale behind this was that if the inserted DNA fragment was successfully amplified
from pCR®T7/NT-TOPO using the T7F primer, then the insert was correctly orientated.
However, if the DNA fragment was amplified using the T7R primer, then the insert was
in the reverse orientation - . In order to confirm that these clones
contained correctly aligned full-length His-tagged ORFs, recombinant His-tagged Bax
and nucleophosmin were expressed using a prokaryotic in vitro expression system,
expressed proteins separated by SDS PAGE and detected with specific antibodies by
Western blot- ee Figure
Scaling-up the expression of His-tagged Bax and nucleophosmin was then attempted
using IPTG-inducible BL21 E.coli cultures. Although high yields (in the order of
milligrams) of recombinant nucleophosmin were produced, expression of Bax in this
system was unsuccessful as Bax over-expression was toxic to E.coli. Milligram
amounts of recombinant Bax were subsequently obtained by performing repeated in
vitro prokaryotic expression reactions. His-tagged proteins were purified using Nickel-
chelated purification columns, separated by SDS PAGE and visualised by coomassie
stain - . Recombinant proteins were confirmed as human Bax and
nucleophosmin by MALDI-TOF mass spectrometry -
5.4.2. Establishing the cell-free amplified luminescent proximity assay
A cell-free amplified luminescent proximity assay was developed to investigate the
interaction between recombinant Bax and nucleophosmin proteins at the molecular level.
Both halves of the proximity assay were established by attaching biotinylated Bax
protein to streptavidin-coated donor beads and monoclonal nucleophosmin antibody to
acceptor beads - ;ee Figure . The presence of biotinylated Bax on the donor beads
was confirmed by the inability of these beads to interact with biotin-coated acceptor
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Figure 5.7. Analysis of Bax and nucleophosmin insert orientation in
pCRT7/NT-TOPO by direct lysis PCR. In the schematic model shown in (a),
correctly orientated gene inserts are amplified by PCR using a T7 forward (T7F)
and gene-specific reverse (geneR) primer pair, but not when a T7 reverse (T7R)
primer is used. Where the gene is inserted incorrectly, the reverse is true. Direct
lysis PCR of several pCRT7/NT-TOPO-Bax (b) and -nucleophosmin (c) colonies
using either T7F/geneR or T7R/geneR primer pairs identified correctly orientated
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Figure 5.8. Confirmation of in vitro expression of His-tagged Bax and
nucleophosmin from pCR®T7/NT-TOPO by Western blot. Native and His-
tagged Bax and nucleophosmin proteins were expressed from pCR®T7/NT-TOPO
using an in vitro prokaryotic expression system. Reaction samples were separated
by SDS-PAGE and visualised by Western blot for the presence of Bax (a) and
nucleophosmin (b) using antibodies raised against respective human proteins. His-
Bax (H-Bax; 26kDa) and His-nucleophosmin (H-NPM; 42kDa) are circled on the
respective blots. Empty-vector reactions were also run as negative controls (-ve).
His-NPM His-Bax
kDa . . kDa
Figure 5.9. Expression of purified His-tagged prokaryotic nucleophosmin and
Bax. His-tagged nucleophosmin (42kDa) was expressed in BL21 pLysS cells from
pCRT7/NT-TOPO; His-tagged Bax (26kDa) was in vitro expressed using the
Expressway plus system. Purified proteins were analysed by SDS-PAGE gel
electrophoresis and coomassie stained.
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Figure 5.10. Identification of recombinant proteins by MALDI-TOF mass
spectrometry. Purified His-tagged recombinant proteins were in-gel trypsin
digested and analysed by MALDI-TOF mass spectrometry. Peptide masses from
the above mass spectra confirmed that the expressed proteins were human Bax (a)
and human nucleophosmin (b).
nucleophosmin antibody, a biotinylated secondary antibody was used to link the
acceptor beads to streptavidin-coated donor beads, thus generating a signal -
Having verified both halves of the proximity assay, experiments were performed to
determine the optimal assay conditions. Optimisation of interacting protein
concentrations was achieved by performing dose response experiments. Bax (0.05nM -
5000nM) produced a concentration-dependent increase in interaction signal when
incubated with constant concentrations of nucleophosmin (5nM, 15nM, 150nM and
350nM) - igure 5.12a. Interaction signal reached a maximum level when 5nM and
15nM nucleophosmin was added. At higher concentrations of nucleophosmin (150nM
and 350nM) maximal signal intensity decreased by approximately 30% and 40%,
respectively, compared to the highest signal observed, probably due to saturation of
antibody binding sites on the acceptor beads. Combining 15nM nucleophosmin with
increasing concentrations of Bax identified a maximal interaction signal when lOOnM
Bax was used - see Time-course studies identified a time-dependent
increase in interaction signal that reached a maximal plateau at 90min -
. Thus, in all subsequent experiments, 15nM nucleophosmin and lOOnM Bax were
incubated together for at least 90mins prior to beginning the proximity assay.
5.4.3. Nucleophosmin preferentially interacts with detergent-activated Bax
In order to determine whether the Bax-nucleophosmin interaction depends on the
activation state of Bax, the proximity assay was used to study the interaction between
Bax and nucleophosmin in the presence of the conformational change-inducing
detergent NP-40 or the non-modifying detergent CHAPS - see Figure 5.13. When
nucleophosmin was combined with Bax that had been pre-incubated with CHAPS, no
appreciable interaction signal was generated. However, when nucleophosmin was
mixed with Bax that had been pre-incubated with NP-40, a strong interaction signal was
observed - . Figure 5.13a. A widely used indicator of this apoptosis/detergent-
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Figure 5.11. Establishing a cell-free proximity assay to investigate the
interaction between recombinant Bax and nucleophosmin. An in vitro
amplified luminescent proximity assay consisting of streptavidin (SA)-conjugated
donor beads (D), monoclonal nucleophosmin antibody-conjugated acceptor beads
(A) and biotinylated (B) recombinant Bax (Bax) and nucleophosmin (NPM)
proteins was established as depicted in (a). Binding of biotinylated Bax to SA-
donor beads was confirmed by performing a competition assay with biotinylated
acceptor beads (b). Conjugation of acceptor beads with monoclonal
nucleophosmin antibodies was confirmed using a biotinylated secondary antibody
to link conjugated acceptor beads with SA-donor beads to generate an interaction




[Bax ] Log M
C.
Time (min)
Figure 5.12. Optimising proximity assay reaction conditions. Concentration
response experiments using recombinant Bax and nucleophosmin proteins were
performed to identify optimal stoichiometry for maximal interaction signal
generation (a). Reactions containing 15nM nucleophosmin gave the highest signal
which peaked when combined with lOOnMBax (b). Time-course experiments
identified an incubation time of 90mins as optimal (c). Data represent mean ± s.e.m
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Figure 5.13. Interaction between recombinant Bax and nucleophosmin
proteins in the presence of detergents. Serial dilutions of Bax and
nucleophosmin were mixed in the presence of either 0.1% CHAPS or NP-40 and
interaction measured by proximity assay. Maximal interaction between the
recombinant proteins was obtained with the Bax conformational change-inducing
detergent, NP-40, whereas in the presence of the non-modifying detergent, CHAPS,
little interaction was seen (a). Bax conformational change was assessed by
immunoprecipitating Bax from the NP40 detergent-containing reaction using the
conformation sensitive Bax 6A7 antibody (b). Data represent mean ± s.e.m of three
independent experiments.
induced structural change in Bax is to demonstrate immunoreactivity with a Bax
antibody recognising the normally concealed N-terminal 6A7 epitope (Hsu and Youle,
1997). That exposure to NP-40 had induced this conformational change in Bax was
confirmed by immunoprecipitating 6A7 reactive Bax exclusively from the detergent-
treated reaction - . Thus, NP-40 was included in the assay buffer in all
subsequent experiments.
5.4.4. Nucleophosmin interacts with the C-terminus of Bax but not with the N-
terminus or pore-forming domain
To determine whether nucleophosmin binds to additional regions within the Bax protein
structure other than the C-terminal domain, recombinant Bax was pre-incubated with
several Bax-specific antibodies recognising distinct regulatory domains before being
incubated with nucleophosmin and interaction measured by proximity assay. Antibodies
recognising epitopes within the Bax N-terminus (residues 1-21), a-helix 5 of the pore-
forming domain (Ab4; residues 98-117) and C-terminus (residues 150-165) were used as
inhibitors. Addition of the Bax C-terminal-binding antibody inhibited the interaction
between Bax and nucleophosmin with an apparent IC50 of 1.43±0.65nM whereas neither
the N-terminal nor the pore-forming-binding antibodies were able to inhibit the
interaction signal -
5.4.5. Interaction between Bax and nucleophosmin is inhibited by p53 and Bcl-
2 peptides
Putative inhibitors to Bax and nucleophosmin were added to the reaction mixtures in
order to gain further insight into the domains forming the interface between Bax and
nucleophosmin. Peptides derived from Bcl-2 (which interacts with Bax via its BH3
domain (Zha et al., 1996) and p53 (known to interact with the C-terminal domain of
nucleophosmin (Colombo et al., 2002; Lambert and Buckle, 2006)) were pre-incubated
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Figure 5.14. Competition studies with Bax-directed antibodies. Recombinant
Bax was pre-incubated with antibodies directed against the Bax N-terminus (NT),
C-terminus (CT) or a 5 helix (a5) of the pore-forming domain (Bax Ab4) prior to
measuring interaction with recombinant nucleophosmin (NPM) using the proximity
assay (a). The C-terminal antibody inhibited the Bax-nucleophosmin interaction
(IC50 = 1.43±0.65nM), whereas neither the N-terminal nor pore-forming domain-
directed antibodies were able to do so (b). A reaction containing no inhibitors was
also run (Bax/NPM). Data represent mean ± s.e.m of three independent
experiments.
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Figure 5.15. Competition studies with putative Bax/nucleophosmin inhibitors.
Recombinant Bax and nucleophosmin proteins were pre-incubated with peptides
derived from p53 and Bcl-2 prior to mixing and interaction measured using the
proximity assay (a). Addition of p53 and Bcl-2 peptides inhibited interaction
between Bax and nucleophosmin, with IC50 values of 200±70nM and 100±70nM,
respectively (b). Reactions containing Bax C-terminal antibody or without
inhibitors were included as positive and negative controls, respectively. Data
represent mean ± s.e.m of three independent experiments.
Bax-nucleophosmin interaction measured by proximity assay. Concentration response
studies revealed that both the Bcl-2 and p53 peptides inhibited the interaction between




This chapter described the design and synthesis of recombinant Bax and nucleophosmin
proteins and the analysis of their interaction at a molecular level using an in vitro
proximity assay.
Although full length human Bax and nucleophosmin ORFs were subcloned into
expression plasmids compatible with the expression of recombinant proteins in both
prokaryotic and eukaryotic host cells, recombinant proteins were, in the end, produced
using E.coli-based expression systems. A high yield (milligram quantities) of
recombinant nucleophosmin was expressed in BL21(DE3) PlysS E.coli cells from the
T7 promoter using the pET expression technology, whereas recombinant Bax was
expressed from the same plasmid using a cell-free expression system containing E.coli
extract due to the apparent cytotoxicity of Bax to E.coli host cells. Proteins were N-
terminally tagged with poly-His to ensure compatibility with down-stream affinity-based
purification steps.
Recombinant proteins expressed using eukaryotic translation machinery undergo post-
translational modifications, such as disulphide bond formation and A-linked
glycosylation of membrane-bound or secreted proteins, which ensures correct folding
and bioactivity, respectively, within the eukaryotic cell. Prokaryotically-expressed
recombinant proteins, however, do not undergo such sophisticated post-translational
steps and may therefore exhibit sub-optimal folding and bioactivity compared to
endogenous proteins (Swartz, 2001). Furthermore, differences in codon usage between
prokaryotes and eukaryotes (particularly the arginine codons AGA and AGG which are
rarely found in E.coli but are common in eukaryotes) can lead to translational defects
when attempting to express eukaryotic proteins in E.coli (Baneyx, 1999). However,
E.coli was used as the host in which the first ever recombinant DNA pharmaceutical was
produced, leading to the approval of Eli Lilly's human insulin in 1982, and was also
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used to produce Monsanto's bovine growth hormone (bGH) in 1994 (Swartz, 2001).
Both of these proteins require extensive post-translational oxidative protein folding
steps, and human insulin is a heterodimer, which together testifies to the ability of
prokaryotic hosts, such as E.coli, to produce complex recombinant eukaryotic proteins
with full bioactivity (Swartz, 2001). Nevertheless, to ensure that the prokaryotically-
expressed Bax and nucleophosmin proteins were comparable to endogenous human
proteins, recombinant proteins were subjected to analysis by SDS-PAGE, Western blot
and MALDI-TOF mass spectrometry. From these experiments, Bax and nucleophosmin
proteins of anticipated molecular weight (taking into account poly-His tags), that were
recognised by specific antibodies raised against human proteins, and that exhibited
peptide mass fingerprints matching those of human Bax and nucleophosmin, were
produced in sufficient quantity and purity for experimental analysis.
A cell-free amplified luminescent proximity assay was developed to investigate the
interaction between recombinant Bax and nucleophosmin proteins at the molecular level.
Using this assay, a direct interaction between Bax and nucleophosmin was determined,
supporting previous data obtained from the co-immunoprecipitation studies presented in
Chapter 4. Affinity chromatography studies, also performed in Chapter 4, identified
nucleophosmin as a protein binding specifically to a mutant SI84V Bax C-terminal
peptide that has been observed to mimic the conformation of this domain in activated
Bax (Nechushtan et al., 1999). Due to solubility issues, assessment of the interaction
between nucleophosmin and the Bax C-terminal peptides using the proximity assay was
not achievable. However, an interaction between recombinant full-length Bax and
nucleophosmin proteins using the proximity assay was only observed to occur in the
presence of the non-ionic detergent NP40. Exposure of Bax to non-ionic detergents
such as NP-40 has been previously demonstrated to induce structural alterations within
the Bax N- and C-termini that are representative of those occurring during apoptosis
(Hsu & Youle, 1997; 1998). One of these conformational changes, exposure of the 6A7
epitope (residues 12-24) within the Bax N-terminal domain, was confirmed by
immunoprecipitating Bax with a conformation-sensitive, 6A7-reactive Bax antibody.
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This therefore suggests that nucleophosmin preferentially binds Bax when in its
activated, 6A7-reactive, conformation. Such as interaction has been recently reported
for another Bax-binding protein, clusterin, although in contrast to the proposed role for
nucleophosmin, the Bax-clusterin interaction is thought to be inhibitory (Zhang et al.,
2005).
Furthermore, the interaction between Bax and nucleophosmin was disrupted by the
addition of an antibody directed against the Bax C-terminus, but not by antibodies
directed against ahelix 5 of the pore-forming domain or the N-terminal domain of Bax.
These data add further support to the observed binding of nucleophosmin to the Bax C-
terminal tail in the affinity chromatography studies performed in Chapter 4. In addition,
since the Bax C-terminus is thought to be solvent exposed only in the activated Bax
conformation (Nechushtan et al., 1999; Suzuki et al., 2000), this finding also provides
an explanation as to why nucleophosmin was observed to only bind to detergent-
activated Bax in the proximity assay.
The role played by the Bax C-terminal tail/ahelix 9 in the bioactivity of Bax remains
controversial due to conflicting opinions as to its role in the targeting and docking of
Bax with the OMM during apoptosis. However, there is a consensus within the
literature that the Bax C-terminus functions as a putative membrane-targeting domain to
direct the translocation of Bax to the OMM following its exposure as a result of
conformational changes occurring within both the N- and C-termini (Goping et al.,
1998; Nechushtan et al., 1999; Schinzel et al., 2004b). In this thesis, and in recently
published results originating from work within the ACE laboratory (Kerr et al., 2006),
nucleophosmin has been demonstrated to bind exclusively to a mutant SI84V Bax C-
terminal peptide using affinity chromatography (Chapter 4) and, in this chapter,
preferentially to the activated Bax conformation using a proximity assay. These data
therefore provide further evidence to support the potentially important regulatory
contribution made by nucleophosmin to the bioactivity of Bax, as will be investigated in
more detail in the following chapter.
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Putative binding partners to both Bax and nucleophosmin were included within the
proximity assay reaction mix to assess their ability to inhibit the interaction between
recombinant proteins. Peptides originating from human Bcl-2 and p53 were chosen in
order to identify additional interface domains within the Bax and nucleophosmin protein
structures, respectively. Bcl-2 is a known Bax-binding protein (Antonsson et al., 1997;
Otter et al., 1998) and was observed in this study to inhibit the interaction between Bax
and nucleophosmin with an apparent IC50 of 100±70nM. Heterodimerisation between
opposing members of the Bcl-2 protein is a central mechanism by which this protein
family regulates apoptosis, and has been demonstrated to involve the amphipathic BH3
domain (Sattler et al., 1997). Indeed, the Bax BH3 domain has been shown to be
essential for its interaction with Bcl-2 (Zha et al., 1996). However, confirmation that the
BH3 domain on Bax forms part of the interface with nucleophosmin was not achievable
since a Bax BH3 domain-reactive antibody could not be sourced to validate this result.
Consequently, it cannot be ruled out that the blocking effect observed using the Bcl-2
peptide could be due to steric hindrance with another distinct binding site on Bax.
Addition of a p53 peptide to the proximity assay reaction mix also inhibited interaction
between Bax and nucleophosmin with an apparent IC50 of 200±70nM. The interaction
between nucleophosmin and p53 has been previously shown to involve the C-terminal
heterodimerisation domain within nucleophosmin (Colombo et al., 2002; Li et al.,
2005). Recent biochemical analyses of this interaction have pin-pointed the p53-binding
motif to lie within residues 249-262 of nucleophosmin (Lambert and Buckle, 2006).
Unfortunately, the p53-binding site within nucleophosmin overlaps with the immunizing
peptide (residues 226-294) used to raise the monoclonal antibody by which
nucleophosmin is attached to the acceptor beads in the proximity assay. This therefore
casts doubt on the validity of the observed inhibitory effect attributed to the p53 peptide,
as it is possible that the p53 peptide competed with the nucleophosmin C-terminal
domain for binding to the acceptor beads instead of inhibiting the Bax-nucleophosmin
interaction. Furthermore, since nucleophosmin is attached to the acceptor beads in the
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proximity assay via its C-terminus, the resulting data suggest that it is the N-terminal
half of nucleophosmin that holds the Bax-interaction domain. The N-terminus of
nucleophosmin contains several hydrophobic regions that have together been attributed
with holding its chaperoning capability (Hingorani et al., 2000). This finding is
therefore consistent with the hypothesis, as set out in this thesis, that nucleophosmin
functions as a molecular chaperone to Bax during its translocation to the mitochondrial
surface in apoptotic cells.
For the purposes of this thesis, the proximity assay was used as a tool to characterise the
direct interaction between recombinant Bax and nucleophosmin proteins. However, this
technology can also be used as a platform to conduct HTS assays to identify small-
molecule inhibitors/enhancers of a particular protein-protein interaction. The reliability
of this 384-well assay is reflected by a signal to noise ratio of 135, an inter-plate
variance of 14.8% (across days) and a Z' value of 0.50 which puts this assay at the cusp
between marginal and excellent as a high-throughput screen (Zhang et al., 1999).
Although out-with the scope of this thesis, a manual screen of a small chemical library
(800 compounds) was performed using the proximity assay by researchers within ACE
to identify pharmacological modulators of the Bax-nucleophosmin interaction. From
these preliminary studies, 17 potential compounds were identified that modulated Bax
peptide-nucleophosmin binding either by inhibiting or enhancing the signal by 50%.
One hit compound, 2-(5-methyl-2-phenyl-l,3-thiazol-4-yl)ethanohydrazide, produced a
concentration-dependent partial inhibition of the Bax-nucleophosmin interaction with an
IC50 value of lOOnM. Furthermore, this compound was observed to confer a degree of
protection to SH-SY5Y cells against UV-irradiation when administered into culture
medium, suggesting that nucleophosmin may be involved in regulating Bax bioactivity




Recombinant full-length human Bax and nucleophosmin proteins were successfully
produced using prokaryotic-based expression systems to enable analysis of the Bax-
nucleophosmin interaction in a cell-free proximity assay. An in vitro amplified
luminescent proximity assay was established and optimised to investigate the Bax-
nucleophosmin interaction at a molecular level. Using this assay, three aspects of the
Bax-nucleophosmin interaction were determined: 1) The observed binding kinetics of
the Bax-nucleophosmin interaction are indicative of a competitive and specific
biological interaction, 2) the interaction between Bax and nucleophosmin involves the
Bax C-terminal domain and the N-terminal half of nucleophosmin, and 3)
nucleophosmin only binds to the detergent-activated Bax conformation, which suggests
that nucleophosmin interacts with Bax during apoptosis.
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CHAPTER 6: Characterising the biological role of nucleophosmin in
the intrinsic apoptotic pathway
6.1 Chapter aims
The aim of this chapter is to determine the role played by nucleophosmin, as a molecular
chaperone to Bax, within the intrinsic apoptotic pathway. To achieve this, RNA
interference will be employed to attenuate nucleophosmin protein expression and the
impact this has on the progression of the intrinsic apoptotic pathway assessed using the
neuronal cell model established in Chapter 3.
6.2 Introduction
6.2.1 Nucleophosmin
Nucleophosmin (NPM, also known as B23, numatrin and N038) is a multifunctional
phosphoprotein localised within the nucleolus of most, if not all, cells -
Nucleophosmin was first characterised as a ribosomal RNA assembly and transport
factor in the nucleolus (Olson et al., 1986), and has since been attributed with nucleic
acid binding, ribonuclease and molecular chaperone activities (Hingorani et al., 2000).
However, recent studies have identified an increasingly observed role for nucleophosmin
in the molecular pathways governing cellular proliferation, oncogenesis and apoptosis
(Colombo et al., 2002; Maiguel et al., 2004; Li et al., 2005; Ahn et al., 2005; Grisendi et
al., 2005b).
6.2.2 Nucleophosmin protein structure
Nucleophosmin belongs to the nucleoplasmin (Np) family of nuclear chaperones
(Dingwall and Laskey, 1990), the archetypal member of which was the first molecular
chaperone to be described (Laskey et al., 1978). The nucleophosmin polypeptide chain
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Nucleophosmin Nuclei
Figure 6.1. Nucleolar localisation of nucleophosmin. Nucleophosmin (green) was
identified as a protein within nucleoli (indicated by arrows) of cultured SH-SY5Y cells
using confocal microscopy. Nuclei are shown in blue (TO-PRO-3).
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exhibits a highly modular structure, containing distinct sequence motifs arranged into
several functional domains, which together account for the diverse biochemical
functions of this protein (Hingorani et al., 2000) for an overview of the
nucleophosmin protein structure. As is common to many molecular chaperones,
nucleophosmin oligomerises into hexamers and larger complexes under native
conditions within the nucleolus (Schmidt-Zachmann et al., 1987; Herrera et al., 1996)
which enhances its ability to dispel large protein aggregates. In this multimeric form,
nucleophosmin is highly stable with a cellular half life of more than 24h (Itahana et al.,
2003).
Two splice variants of nucleophosmin are expressed in mammalian tissues: B23.1 and
the C-terminal-truncated isoform, B23.2. B23.2 lacks the C-terminal nucleolar
localisation signal and is therefore distributed within the nucleoplasm in addition to the
nucleolus (Savkur and Olson, 1998). B23.1, however, is the predominantly expressed
isoform in all tissues (Wang et al., 1993).
6.2.3 Nucleophosmin "house-keeping" roles
As a multi-functional protein, nucleophosmin engages a diverse range ofproteins during
the course of its cellular activities - . Within the nucleolus, nucleophosmin
performs essential functions as a molecular chaperone (Szebeni and Olson, 1999) and in
the assembly of pre-ribosomal subunits (Savkur and Olson, 1998). As a molecular
chaperone, nucleophosmin counteracts protein aggregation within the crowded confines
of the nucleolus and aids the transport of numerous proteins across the nucleolar
membrane, including the transcription factor YY1 (Inouye and Seto, 1994), the tumour
suppressor protein, pl9ARF (Korgaonkar et al., 2005), the retinoblastoma protein (pRb)
(Takemura et al., 2002) and several viral proteins, including HIV Rev and Tat proteins
(Fankhauser et al., 1991; Li, 1997). Using immunocytochemistry, nucleophosmin has
been localised to the peripheral regions of the dense fibrillar component (DFC) and
granular component (GC) of the nucleolus (Spector et al., 1984; Biggiogera et al.,
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Caspas-3
CAD/DFF40
HIV Rev & Tat
Kaposi's sarcoma virus K cyclin
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Inhibits PKR tumour suppressor activity
Supresses RNA synthesis & cell
proliferation
MDM2 down-regulation & p53 stability
Promotes p53 transcriptional activity
pRb nucleolar translocation
Gadd45a nuclear translocation
Possible role in DNA repair response
Caspase-3 substrate target
Inhibits DNase activity
Rev & Tat nuclear translocation
NPM nuclear translocation & p53
stabilisation
Promotes viral RNA replication

















Table 6.1. Known nucleophosmin-binding proteins. References: 1. Liu et al., 1999.
2. Li et al., 1996. 3. Inouye & Seto, 1994. 4. Pang et al., 2003. 5. Itahana et al, 2003.
6. Bertwistle et al., 2004. 7. Brady et al., 2004. 8. Korgonkar et al., 2005. 9. Colombo
et al., 2005. 10. Kurki et al., 2004. 11. Colombo et al., 2002. 12. Takemura et al.,
2002. 13. Meder et al., 2005. 14. Gao et al., 2005. 15. Chou & Yung, 2001. 16. Ahn
et al., 2005. 17. Fankhauser et al., 1991. 18. Li, 1997. 19. Kurki et al., 2004. 20.
Huang et al., 2001. 21. Tsuda et al., 2006.
1990), in which the maturation of pre-ribosomal RNAs is thought to take place (Fakan
and Bernhard, 1971). Utilising its intrinsic endoribonuclease activity (Herrera et al.,
1995), nucleophosmin has been proposed to assist in the processing of ribosomal RNA
(rRNA) precursors at these sites into mature rRNA subunits prior to their export into the
nucleus (Savkur and Olson, 1998).
6.2.4 The role of nucleophosmin in development
In 2005, two landmark studies characterising the resulting phenotype of nucleophosmin
gene knockout mice demonstrated the crucial role played by nucleophosmin in
embryonic development (Colombo et al., 2005; Grisendi et al., 2005b). Homozygous
mutant offspring (Npml") suffered extensive developmental defects and death by
embryonic day (E) 12.5. Even Npml hypomorphic mutants (NpmIhy/hy), where
nucleophosmin expression was reduced to about 10-30% of normal levels, died during
embryogenesis, albeit at a later stage (El 6.5) (Grisendi et al., 2005b).
Immunohistochemical analysis of normal embryos demonstrated high and widespread
expression of nucleophosmin during this developmental period (Colombo et al., 2005).
The most visible defects arising from this genetic manipulation were in the
organogenesis of liver and forebrain (specifically the telencephalic region and eye) and
impaired development and subsequent differentiation of haematopoietic precursors
leading to a compromised foetal blood supply and severe anaemia (Grisendi et al.,
2005b). This latter finding is in agreement with another recent report demonstrating
nucleophosmin's requirement for haematopoietic stem cell expansion and
differentiation, as well as the protection of haematopoietic progenitor cells against
stress-induced DNA-damage (Li et al., 2006). Furthermore, the extensive DNA damage
and genomic instability observed in the nucleophosmin knock-out animals is in
agreement with earlier studies implicating nucleophosmin as a major DNA-damage
response protein (Wu et al., 2002; Meder et al., 2005), and the unrestricted centrosome
duplication and multiple mitotic spindle formation observed in Nprnl"" MEFs supports
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the proposed role for nucleophosmin as an essential mediator ofCDK2/cyclin E-directed
centrosome duplication during mitosis (Okuda, 2002).
6.2.5 Nucleophosmin and cancer
That nucleophosmin may play an important role in cell growth and oncogenesis was
realised by early observations that its cellular levels increased rapidly in actively
proliferating and malignant cells (Chan et al., 1989). Conversely, nucleophosmin
expression was observed to be down-regulated in cells undergoing differentiation (van
Belzen et al., 1995) or apoptosis (Patterson et al., 1995). Furthermore, the involvement
of nucleophosmin in several oncogene-forming gene translocations has made it a key
marker protein for several human haematopoietic malignancies (Grisendi et al., 2005b) -
A well characterised gene translocation involving nucleophosmin
underlies a large proportion of cases of anaplastic large cell lymphoma (ALCL), an
aggressive T-cell lymphoma most commonly seen in children (Grisendi et al., 2005a).
In this gene translocation (2;5)(p23;q35), the Npml gene (chromosomal locus 5q35)
becomes fused with the anaplastic lymphoma kinase (ALK) gene (locus 2p23) and
encodes a constitutively activated tyrosine kinase fusion gene product, NPM-ALK,
which has been proposed to function as an oncogene in part through
phosphorylation/activation of the anti-apoptotic protein kinase Akt (Rassidakis et al.,
2005). Aside form ALCL, translocation of Npml to additional fusion partners, as well
as Npml gene mutations, underlies several other human haematological malignancies,
including promyelocytic leukaemia, acute myeloid leukaemia and chronic myelogenous
leukaemia (Grisendi et al., 2006).
A role for nucleophosmin in perturbing progression of the cell cycle in response to
oncogenic cues and genotoxic stress has also been suggested through its observed
binding to several key regulatory proteins of the cell cycle. In response to genotoxic
stress and hyperproliferative signals, such as those directed by c-myc, the tumour
suppressor protein, pl9ARF, has been shown to interact functionally with nucleophosmin
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Various solid tumours: gastric,
ovarian, colon & prostate
carinomas
Acute promyelocytic leukemia
Anaplastic large cell lymphoma
Myelodysplastic syndrome &
acute myeloid leukemia
Acute myeloid leukemia with a
normal karyotype
non-small-cell lung carcinoma
Table 6.2. Genetic basis underlying the involvement of nucleophosmin in human
cancer. NPM over-expression is a marker for various tumours, including gastric, colon,
ovarian and prostate carcinomas. In addition, NPM is one of the most frequently altered
genes in haematopoietic tumours. References: 1. Grisendi et al., 2006. 2. Redner et al.,
1996. 3. Morris et al., 1994. 4. Yoneda-Kato et al., 1996. 5. Falini et al., 2005. 6.
Mendes-da-Silva et al., 2000. Table adapted from Grisendi et al., 2006.
to retard ribosome biogenesis and induce cell cycle arrest (Itahana et al., 2003;
Bertwistle et al., 2004; Brady et al., 2004; Korgaonkar et al., 2005). Reported
interaction between nucleophosmin and the tumour suppressor protein, p53, and its
inhibitor, MDM2, has also been shown to induce cell cycle arrest in response to
genotoxic stress (Colombo et al., 2002; Kurki et al., 2004). Finally, induction of cell
cycle arrest by two further cell cycle-regulatory proteins, the tumour suppressor protein,
retinoblastoma protein (pRb) and the transcription factor, Gadd45a, has also been shown
to involve nucleophosmin (Takemura et al., 2002; Gao et al., 2005). In both cases,
nucleophosmin has been observed to chaperone a nuclear translocation event late in the
cell cycle that is thought to be required for pRb and Gadd45 to induce cell cycle arrest at
the G2/M boundary.
6.2.6 Nucleophosmin and apoptosis
When this thesis was proposed, a functional involvement of nucleophosmin in positively
regulating the stability and transcriptional activity of the tumour suppressor protein, p53,
had recently been reported (Colombo et al., 2002). As a consequence of this interaction,
nucleophosmin was implicated as a facilitator of p53-depedant cell-cycle arrest and
apoptosis in response to genotoxic stress. However, this report conflicted with another
study in which the attenuation of nucleophosmin protein expression by anti-sense
treatment was observed to increase the sensitivity of cells to p53-dependent apoptosis
induced by exposure to UV irradiation (Wu et al., 2002), suggesting that nucleophosmin
normally protects cells against genotoxic stresses by suppressing p53 activity.
Furthermore, nucleophosmin had also been identified as a nuclear substrate of caspase-3
during the execution phase of apoptosis (Chou and Yung, 2001). The role of
nucleophosmin in apoptosis at the time when this thesis was proposed was therefore
somewhat ambiguous. However, its reported interaction with p53 does suggest that
nucleophosmin could be an important regulatory protein in genotoxic stress-induced
apoptosis. An identifiable role for nucleophosmin in additional apoptotic pathways or a
functional interaction with apoptogenic proteins out-with the nucleus, however, has to
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date not been demonstrated. Thus, as described within this thesis, the identification of
nucleophosmin as a novel Bax-binding protein is an exciting and novel finding, and
reveals a potential extra-nuclear function for nucleophosmin in the regulation of
apoptosis and cell proliferation.
105
6.3 Materials & Methods
6.3.1 Cell culture
SH-SY5Y cells were grown and maintained as described in general materials & methods
(Chapter 2). Seeding densities, culture vessels and protocols used were optimised for
each method as described below.
6.3.2 Co-immunoprecipitation
Co-immunoprecipitation was performed as described in general materials & methods
(Chapter 2). Briefly, SH-SY5Y whole cell lysates were immunoprecipitated with 5pg of
either a pan-reactive polyclonal Bax antibody (Upstate Biotechnology), a monoclonal
nucleophosmin antibody (Sigma) or a monoclonal SMN antibody (BD Biosciences) and
co-immunoprecipitants collected with protein A-conjugated dynabeads (Invitrogen).
Proteins were then separated by SDS-PAGE and analysed by Western blot using
antibodies against Bax, nucleophosmin and GRB2, as described in general materials &
methods (Chapter 2).
6.3.3 Confocal microscopy
Confocal microscopy was used to investigate the translocation of Bax and
nucleophosmin proteins during exposure to STS in SH-SY5Y cells as described in
general materials & methods (Chapter 2). Briefly, DMSO vehicle-treated (Control) cells
and cells exposed to 2h or 4h STS were fixed and probed with antibodies against Bax
(Upstate Biotechnology) or nucleophosmin and stained with fluorescent secondary
antibodies (AlexaFluor-488 and -546, respectively) before analysis by confocal
microscopy. Co-localisation experiments were also attempted but were unsuccessful
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due to incompatible fixing procedures for the Bax and nucleophosmin antibodies
available.
6.3.4 RNA interference
Three different methodologies were used to employ RNA interference (RNAi) against
endogenous human nucleophosmin: 1) Four hairpin siRNA (shRNA) sequences
expressed from a plasmid DNA vector back-bone (pSilencer; Ambion, Warrington, UK),
2) a single published small interfering RNA (siRNA) oligonucleotide (Colombo et ah,
2002), and 3) Dharmacon's siGenome SMARTpool™ siRNA consisting of four
individual siRNA oligonucleotides combined within a single solution (Dharmacon Inc.,
Lafayette, CO, USA).
6.3.5 Nucleophosmin shRNA expression vector design and manufacture
Complementary oligonucleotide sequences were designed for cloning into shRNA
expression vectors containing the RNA polymerase III promoters U6 (pSilencer 2.1-U6
hygro) or HI (pSilencer 3.1-H1 hygro; both from Ambion). Four target sequences
meeting the suggested criteria (21 nucleotides long, G/C content 40-55%, not containing
a run of more than 4 or 5 As or Ts (these act as termination sites for RNA polymerase
III), and spread along the length of the cDNA sequence (Reynolds et al., 2004)) were
chosen from within nucleophosmin cDNA open reading frame (ORF) using an online
siRNA target finder and design tool
(http://www.ambion.com/techlib/misc/siRNA finder.html) - for sequence
information. The specificity of each sequence for nucleophosmin mRNA was confirmed
using the on-line Basic Local Alignment Search Tool (BLAST) database
(http://www.ncbi.nlm.nih.gov/BLAST/). Oligonucleotides were synthesised
(Invitrogen) and complementary sequences annealed and cloned into each of the
pSilencer vectors - for an overview of this procedure. pSilencer plasmid
DNA was then transformed into competent DH5a cells (Invitrogen) and Ampicillin-
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L)UljU Target (antisense) A q A °
3'
Annealed hairpin siRNA insert
RNAPol 111
BamHI Target (sense) Loop Target (antisense) Termination Hindlll
I I I II II II I I I
5' GATCCCGNNNNNNNNNNNNNNNNNNNTTCAAGAGANNNNNNNNNNNNNNNNNNNTTTTTTGGAAA 3'
3' GGCNNNNNNNNNNNNNNNNNNNAAGTTCTCTNNNNNNNNNNNNNNNNNNNAAAAAACCTTTTCGA 5'
Figure 6.3. Design of shRNA expression cassette for cloning into pSilencer
expression vectors. For each 19-nucleotide target sequence, complementary 55-
60mer oligonucleotides, with 5' single-stranded restriction enzyme site overhangs,
were designed. The two complementary domains of the 19-mer hairpin target
sequences were separated by a loop sequence and the 3' end contained a poly-
thymidine tract to terminate RNA polymerase Ill-mediated transcription.
Downstream of the RNA terminator site, a short 5'-GGAA-3' sequence was
included for optimal gene silencing. The 5' ends of the two oligonucleotides were
non-complementary and included BamHI and Hindlll restriction overhangs to
facilitate efficient directional cloning into the pSilencer vectors. A guanosine
residue was included immediately downstream of the BamHI site because RNA
polymerase III transcription is more efficient when initiated at a purine.
resistant cells containing recombinant plasmid DNA were selected and plasmid DNA
prepared according to the manufacturer's instructions (Wizard Plus SV minipreps;
Promega). Cloned sequences were verified by DNA sequencing (DNA Sequencing
Facility, Department of Biochemistry, University of Oxford) and restriction digestion
using insert sequence-specific cutting enzymes.
6.3.6 Nucleophosmin siRNA design
Nucleophosmin-specific siRNA oligonucleotides were designed from published
sequences targeting nucleotides 103-125 of human nucleophosmin cDNA relative to the
first nucleotide of the start codon (Colombo et ah, 2002). The oligonucleotide
sequences were as follows: sense: 5'-UGAUGAAAAUGAGCACCAGTT-3'; antisense:
5'-CUGGUGCUCAUUUUCAUCATT-3'. An inverted sequence was used as a control
siRNA (sense: 5' -GACCACCAGUAAAAGUAGUTT-3'; antisense: 5'-
ACUACUUUUACUCGUGGUCTT-3'). All oligonucleotides were synthesised by
Invitrogen and annealed on arrival.
siRNAs targeting human nucleophosmin were also obtained from Dharmacon Inc. as
SMARTpool™ ready-to-transfect reagents containing four individual siRNAs (sequence
information unavailable). Lyophilised siRNAs were reconstituted in provided buffer to
a final concentration of 20pM and stored at -20°C.
6.3.7 Transfection of shRNA and siRNA silencing complexes
To maximise transfection efficiency of pSilencer shRNA plasmid DNA vectors into SH-
SY5Y cells, optimisation experiments were performed using a hand-held gene gun
(Helios Gene-gun; Bio-rad Laboratories) or a cationic lipid-based transfection reagent
(Lipofectamine 2000; Invitrogen) to transfect cells with plasmid DNA containing the
reporter gene Yellow Fluorescent Protein (YFP) (pZsYellowl-Nl; BD Biosciences).
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Human NPM target sequence Oligonucleotide Oligonucleotide sequence (5'-3')
Nucleotides 182-202:
AAG CAG AGG CAA TGA ATT ACG
Sense
AGC TTT TCC AAA AAA GCA GAG GCA
ATG AAT TAC GTC TCT TGA ACG TAA
TTC ATT GCC TCT GCG G
GAT CCC GCA GAG GCA ATG AAT TAC
Anti-sense GTT CAA GAG ACG TAA TTC ATT GCC
TCT GCT TTT TTG GAA A
Nucleotides 362-282:
AAG ATG CAG AGT CAG AAG ATG
Sense
AGC TTT TCC AAA AAA GAT GCA GAG
TCA GAA GAT GTC TCT TGA ACG TAA
TTC ATT GCC TCT GCG G
GAT CCC GCA GAG GCA ATG AAT TAC
Anti-sense GTT CAA GAG ACA TCT TCT GAC TCT
GCA TCT TTT TTG GAA A
Nucleotides 470-490:
AAC TTC CTG CTG ATG AAG ATG
Sense
AGC TTT TCC AAA AAA CTT CCT GCT
GAT GAA GAT GTC TCT TGA ACG TAA
TTC ATT GCC TCT GCG G
GAT CCC GCA GAG GCA ATG AAT TAC
Anti-sense GTT CAA GAG ACA TCT TCA TCA GCA
GCA AGT TTT TTG GAA A
Nucleotides 716-736:
AAG GAC CTA GTT CTG TAG AAG
Sense
AGC TTT TCC AAA AAA GGA CCT AGT
TCT GTA GAA GTC TCT TGA ACG TAA
TTC ATT GCC TCT GCG G
GAT CCC GCA GAG GCA ATG AAT TAC
Anti-sense GTT CAA GAG ACT TCT ACA GAA CTA
GGT CCT TTT TTG GAA A
Table 6.3. Details of sequences used to construct nucleophosmin shRNA
expression vectors. Target sequences within human nucleophosmin cDNA are
provided in the left hand column. For each target sequence, a sense and antisense
64-mer hairpin template was designed containing the 21-mer target sequence as its
stem (in bold) separated by a 9 nucleotide loop sequence. A 5-6 nucleotide poly(A)
tract and a 5' overhang forming the BamHI and Hindlll restriction sites were also
included.
For the gene gun-based transfection studies, SH-SY5Y cells were seeded at a density of
lxlO6 cells in 35/22 mm diameter glass-bottomed poly L-lysine coated petri dishes
(Willco Wells) and left for 24h to attach. 1pm gold particles were coated with
pZsYellowl-Nl according to the manufacturer's instructions. Briefly, 20mg gold
particles were suspended in lOOpl 0.05M spermidine and 20pg of pZsYellowl-Nl. The
gold particles were precipitated with lOOpl of 1M CaCb, washed three times in 100%
ethanol, re-suspended in 1.2ml 100% ethanol and loaded into Teflon tubing. Medium
was removed from wells just before transfection. pZsYellowl-Nl-coated gold particles
were shot into the cells with the gun pressurized at 150psi or 250psi. Each well received
lmg gold particles containing lpg pZsYellowl-Nl. A 40pm nylon mesh was placed
between the gun and culture to protect cells from the shock wave. Cells were
replenished with fresh medium after 6h and incubated for 48h before fixing and imaging
by confocal microscopy as described in general materials & methods (Chapter 2). Three
20X fields were imaged in each cover slip by confocal microscopy to provide an average
value. Transfection efficiency was calculated by counting the proportion of YFP-
labelled cells within each field area.
For the cationic lipid-based transfection studies, SH-SY5Y cells were seeded at a density
of 1 x 105 in 24-well culture plates. Ratios of plasmid DNA (pg) to transfection reagent
(pi) of 1:1, 1:2 and 1:3 were combined according to the manufacturer's instructions.
Briefly, plasmid DNA and Lipofectamine 2000 were diluted separately in Optimem
reduced serum medium and incubated at room temperature for 5mins before gently
combined. Plasmid DNA/lipid solutions were then left for 20mins at room temperature
to encourage complex formation before lOOpl was pipetted into each well. Cells were
transfected for 4h before complexes were replaced with fresh culture medium and cells
incubate a further 44h before fixing and analyses by confocal microscopy as described
above. siRNA oligonucleotides were transfected using Lipofectamine 2000 according to
the manufacturer's instructions.
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For nucleophosmin knock-down experiments, pSilencer shRNA vectors were transfected
separately or combined to form "pools" into SH-SY5Y cells using Lipofectamine 2000
transfection reagent.
6.3.8 Assessing knock-down of target protein expression
Attenuation of target protein expression was assessed by quantitative Western blot as
described in general materials & methods (Chapter 2). Optimisation of siRNA
concentration (30nM-300nM) delivered into cells and duration of silencing effect (24h-
72h) post transfection was performed. Specificity of RNAi-mediated knockdown of
target protein expression was assessed in each experiment by transfecting wells with
transfection reagent alone (vehicle) and with control shRNA vectors or siRNA duplexes
(control siRNA). The control target sequences used were either scrambled sequences
with no known homology to any mammalian mRNA sequence (shRNA experiments) or
the target sequence orientated in the opposite direction (siRNA experiments).
6.3.9 Assessment of cytochrome c release, caspase-3 activity, DNA
fragmentation and cell viability
Progression of the intrinsic apoptotic pathway in siRNA-treated, control siRNA-treated
and transfection alone-treated wells was assessed by measuring cytochrome c release,
caspase-3 activity, DNA fragmentation and cell viability as described in Chapter 3.
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6.4 Results
6.4.1. Endogenous Bax and nucleophosmin proteins interact
Interaction between endogenous Bax and nucleophosmin proteins in SH-SY5Y whole
cell lysates was confirmed using reciprocal co-immunoprecipitation -
6.4.2. Bax and nucleophosmin undergo intracellular translocation during STS-
induced apoptosis in SH-SY5Y cells
The sub-cellular localisation of endogenous Bax and nucleophosmin within SH-SY5Y
cells during exposure to STS was analysed using fluorescent antibodies and confocal
microscopy. During exposure to STS, nucleophosmin underwent a marked re¬
distribution in its subcellular localisation - . In control cells,
nucleophosmin was predominantly nucleolar. However, by 2h exposure to STS,
nucleophosmin had undergone translocation into the cytosol and remained cytosolic at
4h. In control cells, Bax staining was diffuse and cytosolic but an increasingly punctate
staining pattern indicative of mitochondrial association was evident by 2h exposure to
STS, becoming marked by 4h.
6.4.3. Attenuating expression of endogenous nucleophosmin protein in SH-
SY5Y cells using RNAi
Attempts were initially made to silence endogenous nucleophosmin expression SH-
SY5Y cells using a published siRNA sequence targeting nucleotides 103-135 that had
been successfully used to silence nucleophosmin expression by up to 60-70% in a U20S
cell line (Colombo et al., 2002). In our hands, however, transfection of this siRNA
oligonucleotide into SH-SY5Y cells was ineffective at silencing nucleophosmin protein












Figure 6.4. Confirming interaction between endogenous Bax-nucleophosmin
proteins by recipricol co-immunopreciptation and Western blot.
Nucleophosmin was confirmed as a protein co-precipitating with Bax in SH-SY5Y
whole cell lysates (a). A control co-immunoprecipitation for the unrelated protein,
growth factor-related binding protein 2 (GRB2), was included to demonstrate
specificity. Additional confirmation of the Bax-nucleophosmin interaction was
demonstrated by reciprocal immunoprecipitation with a nucleophosmin antibody
and identification of Bax in the immunoprecipitate (b). Specificity of this
interaction was demonstrated by immunoprecipitation of an unrelated protein,
survival motor neuron protein (SMN). Detection of proteins by Western blot (WB)
in whole cell lysate (lysate) and immunoprecipitate (IP) are as indicated. Data
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Figure 6.6. Failure to silence nucleophosmin protein expression in SH-SY5Y
cells using a published siRNA oligonucleotide. Nucleophosmin (NPM) protein
levels had been reportedly silenced by 60-70% using the siRNA sequence provided
in (a). This siRNA duplex was transfected into SH-SY5Y cells and nucleophosmin
protein level measured at 48h by Western blot (b). In this cell line, the siRNA
sequence was ineffective at silencing nucleophosmin protein expression. Untreated
cells (-ve); transfection reagent vehicle (veh); non-homologous siRNA (Ctrl);
nucleophosmin-targeting siRNA (NPM). Image in (a) taken from Colombo et al.,
2002. Data are representative of at least three independent experiments.
out of five experiments performed in their laboratory using this siRNA sequence
attained at least a 50% reduction in nucleophosmin protein expression. Therefore an
alternative strategy utilising short hairpin siRNAs (shRNA) was used.
6.4.4. Attenuation of nucleophosmin protein expression using shRNA
expression vectors
Four shRNA sequences were designed from the nucleophosmin cDNA ORF and ligated
into the RNA polymerase Ill-driven expression vectors pSilencer-Hl-Hygro and
pSilencer-U6-Hygro - for sequence information see the Materials & Methods section
6.3.3 and Table 6.3. Correct insertion of the shRNA expression cassettes into the
plasmid DNA vectors was confirmed by restriction digestion -
Transfection of plasmid DNA into SH-SY5Y cells was optimised using either a
ballistics approach (genegun) or a cationic lipid-based transfection reagent
(Lipofectamine 2000) Transfection efficiency was determined using plasmid DNA
expressing the YFP fluorophore and visualising successfully transfected fluorescent cells
by confocal microscopy. A maximal transfection efficiency of approximately 30% was
achieved using a plasmid DNA(pg) to Lipofectamine 2000 reagent (pi) ratio of 1:2 -
Figure 6.8.
During initial knockdown experiments, each shRNA vector was transfected separately
into SH-SY5Y cells and their effect on nucleophosmin protein expression monitored by
Western blot after 48h. From this, it became apparent that certain target sequences were
more potent silencers of nucleophosmin expression than others, with silencing effects
ranging from negligible to approximately 70% reduction in endogenous protein levels -
6.9a. The potency of individual siRNAs is known to be highly dependent on
their target sequence within the mRNA strand (Reynolds et ai, 2004). On this basis, the
use of several siRNA sequences targeting different regions within the same mRNA
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Figure 6.7. Validation of shRNA expression vectors by restriction digest. U6
and HI promoter-driven expression vectors containing ligated shRNA sequences 1-4
were digested using insert-specific restriction enzymes to generate the following
predicted DNA fragments (in bp): Sequence 1 (a) digested with BsmBI. U6 vector:
394 604 & 3855. Hlvector: 490, 604 & 3430. Sequence 2 (b) digested with Xmnl.
U6 vector: 2306 & 2589. HI vector: 1879 & 2687. Sequence 3 (c) digested with
Xmnl. U6 vector: 2307 & 2585. Hlvector: 1880 & 2687. Sequence 4 (d) digested
with EcoO 1091. U6 vector: 296, 427 & 4170. Hlvector: 523 & 4043. All ligations
were successful, apart from those indicated by X's. Undigested plasmid DNA (uc)
was run alongside each restriction digest.
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Figure 6.8. Optimising transfection of plasmid DNA into SH-SY5Y cells. YFP-
expressing plasmid DNA was transfected into cultured SH-SY5Y cells using a
genegun, pressurised to 150 or 250psi, or the cationic lipid-based transfection
reagent, Lipofectamine 2000 (LF2K), at DNA (pg) to reagent (pi) ratios of 1:1 or
1:2. The percentage transfection efficiency was determined by counting the number
of fluorescing cells within a defined field area using confocal microscopy (a).
Lipofectamine 200 reagent was more effective at transfecting plasmid DNA into SH-
SY5Y cells, with the 1:2 ratio proving a maximal transfection efficiency of









Figure 6.9. Assessment of shRNA-mediated knockdown of nucleophosmin
protein expression by Western blot. shRNA expression vectors were transfected
individually (shRNA-Hl sequences 1-4 and shRNA-U6 sequences 1 and 2) or
combined into shRNA-Hl (HI) and shRNA-U6 (U6) pools. Nucleophosmin
protein expression was assessed by Western blot at 72h post-transfection.
Individually transfected shRNAs were variable in their silencing effect (a). Pooled
HI shRNAs were the most effective at silencing nucleophosmin expression (b). A
control immunoblot for (3-actin was included in the pooled shRNA experiment to
demonstrate specificity of the silencing effect. —ve = untreated cells; veh =
transfection reagent alone; Ctrl = non-homologous siRNA control.
shRNA expression plasmids were combined together to form a pool, the silencing effect
was found to be as high as the most potent shRNA vector alone, but more consistent in
its effect - . This approach also indicated that shRNAs expressed from
the HI promoter were more effective at silencing endogenous nucleophosmin protein
expression than shRNAs expressed from the U6 promoter - Therefore,
the HI pool was used to silence nucleophosmin in all subsequent experiments using the
shRNA approach.
Although shRNA-expressing vectors were capable of effectively reducing
nucleophosmin protein expression, inconsistency of this effect proved problematic. This
was possibly due to the different amounts of active siRNA generated within the
transfected cell population between experiments. Thus, as commercially available
siRNA products with improved design and efficacy became available, siRNA-based
solutions for silencing nucleophosmin expression were evaluated again.
6.4.5. Optimisation of Dharmacon siRNA-mediated knockdown of
nucleophosmin protein expression in SH-SY5Y cells
The siGenome smartPOOL system (Dharmacon) also utilises pools of several siRNAs
each hybridising with a different region within the target mRNA strand. In order to
maximise their silencing effect, two optimisation steps were performed: 1) to determine
the optimal siRNA concentration delivered to the cell, and 2) to determine the optimal
time-point at which to measure the silencing effect on protein expression.
To determine the lowest optimal concentration of siRNA that would silence
nucleophosmin expression by at least 50% in SH-SY5Y cells compared to control-
transfected cells, siRNA concentrations were titrated from 30nM up to 300nM. When
30nM of siRNA was transfected into SH-SY5Y cells, no silencing of nucleophosmin
expression could be detected by Western blot - see urc 6 . When lOOnM siRNA
was used, nucleophosmin protein expression was reduced to 44% in comparison to
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Figure 6.10. Optimising nucleophosmin siRNA concentration. 30nM (a),
lOOnM (b), 200nM (c) and 300nM (d) siRNA was transfected into SH-SY5Y cells
and nucleophosmin (NPM) protein expression assessed by quantitative Western
blot at 72 post-transfection. lOOnM was the lowest siRNA concentration tested that
achieved a greater than 50% reduction in protein expression compared to control
siRNA-treated wells. Vehicle = transfection reagent alone. Data represent mean +
s.e.m of three independent experiments, apart from the 300nM experiment (n=l).
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Figure 6.11. Optimising nucleophosmin siRNA assay time point. lOOnM of
siRNA was transfected into SH-SY5Y cells and nucleophosmin (NPM) protein
expression assessed at 24h (a), 48h (b) and 72h (c) by quantitative Western blot.
From these studies, 72h was chosen as the optimal timepoint for assessing siRNA-
mediated silencing of nucleophosmin protein expression. Vehicle = transfection
reagent alone. Data represent mean + s.e.m of three independent experiments. Data
were analysed by one-way ANOVA with post hoc Dunnett's test. * = p<0.05 versus
control siRNA.
control siRNA-treated wells (p<0.05). Although nucleophosmin expression levels were
markedly reduced compared to vehicle-treated cells when 200nM and 300nM siRNA
was applied to cells, a significant reduction in expression compared to control siRNA-
treated cells was not observed - see . High concentrations (in
excess of lOOnM) of siRNA have been shown to increase the risk of incurring non¬
specific "off-target" silencing of protein expression that can lead to errors in the
interpretation of resulting phenotypic changes (Semizarov et al., 2003). The inclusion of
parallel experiments using non-homologous siRNA sequences (control siRNA) provides
an indication of this non-specific ablation of protein expression (Elbashir et al., 2001).
Based on these data, a siRNA concentration of lOOnM was chosen as the optimal
concentration for all further nucleophosmin siRNA knockdown experiments.
The next optimisation step was to determine the optimal post-transfection timepoint to
measure the knock-down effect. Typically, in an in vitro-based siRNA experiment, the
impact on expression of the target protein is monitored between 24h and 72h post-
transfection. This temporal window is thought to allow the introduced siRNA sufficient
time to exert a measurable impact on protein expression whilst ensuring that the
silencing effect is not diluted amongst an increasing daughter cell population as normal
cell division runs its course (Ambion siRNA seminar, Edinburgh, November 2004).
Therefore, SH-SY5Y cell lysate was collected for analysis by Western blotting at 24h,
48h and 72h following transfection of lOOnM siRNA - . These
experiments demonstrated that the longer the siRNA was allowed to mediate its effect,
the more evident its impact on protein expression became. By 72h post-transfection,
nucleophosmin protein expression in cells treated with lOOnM siRNA had been reduced
to 44% compared to control siRNA-treated wells (p<0.05). 72h post-transfection was
therefore chosen as the timepoint at which to measure the biochemical consequences of
reducing nucleophosmin protein expression within the intrinsic apoptotic pathway.
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6.4.6. Reducing nucleophosmin expression by RNAi impairs the progression of
the intrinsic apoptotic pathway but does not protect cells against STS-
induced apoptosis
Endogenous nucleophosmin protein expression in SH-SY5Y cells was attenuated to
approximately 50% using shRNA or siRNA-based RNAi approaches, compared to cells
treated with control shRNAs or siRNAs, as described above. The biological
consequences of this reduction on STS-induced apoptosis were then investigated by
measuring Bax translocation, cytosolic cytochrome c levels, cleavage of pro-caspase-3,
DNA fragmentation and cellular viability.
A comparative analysis of Bax translocation in control and nucleophosmin siRNA-
treated SH-SY5Y cells during exposure to STS was attempted using fluorescent Bax
antibodies and confocal microscopy. However, this approach was unsuccessful due to
technical difficulties, most notably the incompatible seeding densities required for
confocal analysis (optimally about 20% confluency at time of plating) and efficient
transfection of siRNA into SH-SY5Y cells, which requires at least 60% confluency. As
a result, the efficacy of the nucleophosmin siRNAs at reducing nucleophosmin protein
expression in these experiments was less than that achieved in other experiments, hence
the influence this had on Bax translocation could not be accurately determined.
However, the quantification of cytosolic cytochrome c levels and cleavage of
procaspase-3 in cells treated with nucleophosmin-targeting siRNAs was achievable.
These experiments demonstrated that reducing nucleophosmin protein levels to 51% as a
result of RNAi attenuated cytosolic cytochrome c levels to 41% and procaspase-3
cleavage to 54% (both p<0.05) in comparison to control siRNA-treated cells - see
. However, analysis of DNA fragmentation and cellular viability in nucleophosmin
siRNA-treated cells showed little or no overall corresponding protective effect when
compared to control cells - see Figure 6.13.
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Figure 6.12. Effect of RNAi-mediated knock down of nucleophosmin
expression on STS-induced apoptosis. Nucleophosmin (NPM) protein expression
in SH-SY5Y cells was silenced by approximately 50% compared to control siRNA-
treated cells as assessed by quantitative Western blot (a & b). This resulted in a
50% reduction in cytochrome c released from the mitochondria (c) and a 50%
reduction in activate caspase-3 (d) in these cells. Vehicle = transfection reagent
alone. Data represent mean + s.e.m of three independent experiments. Data were
analysed by one-way ANOVA with post hoc Dunnett's test. * = p<0.05 versus
control shRNA.
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Figure 6.13. Assessing protective effect of nucleophosmin siRNA against STS-
induced apoptosis. Nucleophosmin (NPM) protein levels were reduced by 50%
compared to control cell using siRNA as assessed by quantitative Western blot (a &
b). Internucleosomal DNA fragmentation was measured over a 5h timecourse by
TUNEL ELISA (b) and metabolic cell death measured by MTS assay (c). No
protective effect was observed in nucleophosmin siRNA-treated cells when
compared to control siRNA-treated cells. Vehicle = transfection reagent alone. Data
represent mean + s.e.m of three independent experiments. Data were analysed by
one-way and two-way ANOVA with post hoc Dunnett's test. * = p<0.05 versus
control siRNA.
6.5 Discussion
In chapter 4, an interaction between nucleophosmin and the pro-apoptotic protein Bax
was identified within the human neuroblastoma SH-SY5Y cell line. In Chapter 5, the
interaction between Bax and nucleophosmin was investigated at the molecular level
using recombinant proteins. In this chapter, the biological relevance of the Bax-
nucleophosmin interaction was investigated using RNA interference (RNAi) in
conjunction with biochemical analyses of the intrinsic apoptotic pathway using the in
vitro cell model established in Chapter 3.
As a molecular chaperone and transport factor, nucleophosmin has been proposed to
direct the intracellular trafficking of several proteins bearing a nuclear localisation
signal, such as pRb (Takemura et al., 2002) and the HIV Tat protein (Li, 1997).
Although these chaperoning activities of nucleophosmin take place within the confines
of the nucleus, nucleophosmin has also been observed to constantly shuttle between the
nucleus and the cytoplasm (Borer et al., 1989) and, from a more recent observation, to
undertake this translocation during aloe-emodin-induced apoptosis in a lung carcinoma
cell line (Lee et al., 2005). Furthermore, from studies performed within the ACE
laboratory, nucleophosmin has been demonstrated to undergo re-distribution in vivo
from the nucleus into the cytoplasm in the mouse cortex following transient focal
cerebral ischemia (Kerr et al., 2006). Significantly, this translocation event was
observed to occur prior to the translocation of Bax to the mitochondrial surface. Thus,
although Bax and nucleophosmin occupy distinct cellular compartments under normal
conditions (Bax in the cytosol and nucleophosmin in the nucleolus), the documented re¬
distribution of nucleophosmin into the cytosol during cellular stress provides an
opportunity for these two proteins to interact. In this chapter, the analysis of Bax and
nucleophosmin re-distribution during STS-induced apoptosis in SH-SY5Y cells by
confocal microscopy provides additional evidence to suggest that a functional
interaction between Bax and nucleophosmin occurs during apoptosis. From these
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studies, Bax and nucleophosmin were observed to occupy the cytosolic compartment
within a proportion of cells by 2h exposure to STS, whereupon Bax underwent
translocation to mitochondria as evidenced by the emergence of a mitochondria-
associated punctate staining pattern by 4h. However, this observation, although
consistent with the hypothesis that nucleophosmin contributes to the Bax translocation
event, does not necessarily imply that the translocation of Bax is a direct result of the
appearance of nucleophosmin in the cytosol.
Therefore, having established that Bax and nucleophosmin could interact during STS-
induced apoptosis, attention turned to determining the functional consequences of such
an interaction in the context of the intrinsic apoptotic pathway, in which Bax plays a
central and rate-determining role (Wei et al., 2001; Zong et al., 2001; Cheng et al.,
2001). Knockdown of nucleophosmin protein expression using RNAi attenuated
progression of the intrinsic apoptotic pathway in SH-SY5Y cells, as seen by a
concomitant reduction in mitochondrial cytochrome c release and cleavage of the apical
caspase zymogen, procaspase-3. Together, these data suggest that nucleophosmin is
required for Bax to exert its physiological role within the intrinsic apoptotic pathway
upstream ofmitochondrial membrane depolarisation.
Similar roles have recently been attributed to several other Bax-binding proteins, all of
which have been discovered since this thesis was begun. Such proteins include the
apoptosis-associated speck-like protein (ASC) (Ohtsuka et al., 2004), Bax-interacting
factor-1 (Bif-1) (Takahashi et al., 2005) and the BH3 only-like protein, modulator of
apoptosis-1 (MAP-1) (Baksh et al., 2005). Investigating the ability of these proteins to
promote Bax-mediate apoptosis in response to a variety of apoptotic insults indicates
that their influence is highly dependent on the type of apoptotic inducer or apoptotic
pathway stimulated. For example, knockdown of ASC was effective at limiting
apoptosis induced by p53 or etoposide (Ohtsuka et al., 2004), and knockdown of Bif-1
expression was protective against various intrinsic death stimuli (Takahashi et al., 2005).
In contrast, however, inhibiting MAP-1 conferred protection against the cell death
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receptor pathway-activating ligand, TNFa, but not to the mitochondrial pathway
inducers STS or etoposide (Baksh et al., 2005).
This disparate picture in the efficacy of Bax-binding proteins may help to explain why,
in our hands, knockdown of nucleophosmin attenuated progression of the intrinsic
apoptotic pathway in SH-SY5Y cells, whereas in response to other intrinsic pathway-
inducing stimuli, such as hypoxia or NGF deprivation, nucleophosmin knockdown has
instead been found to precipitate apoptosis (Li et al., 2004b; Ahn et al., 2005).
A similarly contradictory picture emerges when the proposed roles of nucleophosmin in
regulating the activities of other key apoptogenic factors are examined. Nucleophosmin
has recently been implicated as a key determinant in the response of the tumour
suppressor proteins, pl9ARF and p53, to genotoxic stress (Itahana et al., 2003; Kurki et
al., 2004; Bertwistle et al., 2004; Kuo et al., 2004; Korgaonkar et al., 2005) What role
nucleophosmin plays in regulating pl9ARF function appears to be highly dependent on
nucleophosmin protein expression. For instance, when nucleophosmin is aberrantly
over-expressed, as it is in many cancers, it functions as an oncogene by inhibiting
pl9ARF's stimulatory effect on p53 through sequestration of pl9ARF in the nucleolus
(Korgaonkar et al., 2005). Conversely, in non-cancerous cells, nucleophosmin exerts a
tumour-suppressive role (Lambert and Buckle, 2006; Grisendi et al., 2006), partly
through binding to and maintaining the pl9ARF protein in a stable form (Kuo et al., 2004;
Colombo et al., 2005). As for p53, numerous independent reports have demonstrated
that it directly interacts with nucleophosmin (Colombo et al., 2002; Maiguel et al., 2004;
Li et al., 2005; Lambert and Buckle, 2006). However, what appears to be less certain is
the functional consequence of this interaction, with some groups implicating
nucleophosmin as a crucial stabiliser of p53 activity during DNA damage-induced
apoptosis (Colombo et al., 2002; Kurki et al., 2004) and others insisting that its
upregulation inhibits the p53 response (Maiguel et al., 2004; Li et al., 2005). Again, the
type of apoptotic stimulus, together with its intensity and duration of effect, appears to
be highly influential in dictating whether the contribution made by nucleophosmin to
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p53 function is favourable or detrimental to cell survival. This ambiguity could not be
resolved from examining the phenotype resulting from Npml" mice, which have
recently been developed independently by two research groups (Colombo et al., 2005;
Grisendi et al., 2005b). In both studies, disruption of nucleophosmin expression led to
embryonic lethality at mid-gestation, in testament to its crucial role in haematopoiesis
and in the maintenance of genomic stability. Analysis of these embryos revealed the
presence of extensive apoptotic cell death together with stabilisation of p53. However,
although this finding may support a role for nucleophosmin in suppressing p53 activity,
it is more likely that p53 in this case is responding to the extensive DNA damage and
aberrant mitotic spindle formation arising from nucleophosmin's absence in these
embryos (Grisendi et al., 2006).
Despite reducing cytochrome c release and procspase-3 cleavage, siRNA-mediated
knockdown of nucleophosmin did not protect cells against STS-induced apoptosis, as
evidenced by the observed extent of DNA fragmentation and decrease in cellular
viability. Two possible explanations may account for these findings: 1) incomplete
silencing of nucleophosmin protein expression, and 2) activation of Bax-independent
apoptotic pathways. The RNAi methodologies employed against nucleophosmin did not
silence nucleophosmin expression, but instead reduced expression to approximately half
normal levels. Consequently, the intrinsic apoptotic pathway was still able to proceed,
albeit at a diminished rate, towards executing apoptosis. The apoptotic inducer used in
these experiments, STS, although widely used to stimulate activation of the intrinsic
apoptotic pathway in a variety of cell types (Desagher et al., 1999; McGinnis et al.,
1999; Eskes et al., 2000) (Krohn et al., 1999; Poppe et al., 2001; Ahlemeyer et al.,
2002),(Tafani et al., 2001; Yuste et al., 2002) is nevertheless a broad-spectmm kinase
inhibitor, and may therefore trigger parallel, Bax-independent, pathways leading to
apoptotic cell death. One further explanation is that other pro-apoptotic Bcl-2 family
proteins, such as Bak, can permeabilise the OMM in the absence of Bax, as has
previously been proposed (Lindsten et al., 2000; Wei et al., 2001). However, the
relative contribution made by Bax and Bak to the intrinsic pathway is thought to be
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dependent on cell type (Arnoult et al., 2004). For example, Bax has been shown to be
required for apoptosis initiated by a variety of intrinsic stress stimuli in cultured human
epithelial cancer cells (Theodorakis et al., 2002; Mikhailov et al., 2003) and it has been
demonstrated that Bax is essential for several neuronal cell populations to initiate the
intrinsic apoptotic pathway during development (Deckwerth et al., 1996; White et al.,
1998). Furthermore, the attenuation in cytosolic cytochrome c and procaspase-3
cleavage observed in this thesis as a direct consequence of ablating nucleophosmin
protein expression with siRNA is consistent with a Bax-dependent route to OMM
permeabilisation in this experimental model.
Overall, the data presented within this chapter demonstrate that a targeted reduction in
expression of the novel Bax-binding protein, nucleophosmin, although unable to rescue
neuronal cells from STS-induced apoptosis, is sufficient to attenuate key biochemical
events associated with the activation and translocation of Bax to the mitochondrial
surface.
6.6 Summary
In this chapter, the biological significance of the Bax-nucleophosmin interaction was
investigated using a neuronal cell model of the intrinsic apoptotic pathway. An
interaction between endogenous Bax and nucleophosmin was confirmed by reciprocal
co-immunoprecipitation, and evidence that nucleophosmin translocates from the
nucleolus into the cytosol during STS-induced apoptosis was provided by confocal
microscopy. The development of an RNAi-based strategy to elucidate the functional
significance of the Bax-nucleophosmin interaction within the intrinsic apoptotic pathway
was then implimented. Expression of endogenous nucleophosmin protein in SH-SY5Y
cells was reduced to approximately 50% of that found in the appropriate control-treated
cells using RNAi. How nucleophosmin-deficient cells responded to STS-induced
apoptosis was then investigated using the in vitro cell-based model of the intrinsic
apoptotic pathway established in chapter 3. As a result of reducing nucleophosmin
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protein levels by RNAi, STS-induced cytochrome c release and procaspase-3 cleavage
were attenuated, supporting the hypothesis that nucleophosmin is required for the
apoptogenic activity of Bax, possibly during the translocation process. However, due to
experimental limitations, siRNA-mediated knockdown of nucleophosmin protein
expression did not confer protection against STS-induced apoptotic cell death. Overall,
the identification of nucleophosmin as a novel Bax binding protein and potential
regulator of stress-induced neuronal apoptosis represents an important new insight into
the molecular mechanisms underlying the unwarranted apoptotic cell death associated
with neurodegenerative diseases and stroke pathology.
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CHAPTER 7: Summary & Conclusions
7.1. Summary & Conclusions
Bax, a pivotal pro-apoptotic member of the Bcl-2 protein family, is an essential
requirement for apoptosis within the developing mammalian nervous system (Deckwerth
et al., 1996; White et al., 1998) and has been implicated in contributing to the
pathological apoptotic cell death associated with neurodegenerative disorders
(Isenmann et al., 1997; Zhang et al., 1998; Tuunanen et al., 1999; Mattson, 2000). The
molecular events dictating the translocation of Bax to the mitochondrial surface remain
poorly understood, but the reliance of Bax on the enforced exposure of a hydrophobic
membrane-targeting domain (Wolter et al., 1997; Nechushtan et al., 1999; Suzuki et al.,
2000; Schinzel et al., 2004b) suggests that chaperone proteins may play a critical role in
this event.
The apoptogenic function of Bax is utilised by the intrinsic pathway to apoptosis, which,
in the central nervous system, is initiated by the withdrawal of neurotrophic factors
during development (Putcha et al., 2002) and by various cellular stress, including
hypoxia, perturbed calcium homeostasis and the accumulation of toxic protein
aggregates during the onset and progression of neurodegenerative disorders (Stefanis,
2005). In order to accurately study the apoptotic pathway associated with such
disorders, an in vitro cell-based model of the intrinsic apoptotic pathway was established
using the human neuroblastoma SH-SY5Y cell line and the intrinsic apoptotic pathway
inducer, staurosporine, as described in Chapter 3.
The proteomics-based approach described in Chapter 4 aimed to identify novel Bax-
binding proteins within whole cell lysates in which Bax protein expression levels
represented those encountered under endogenous conditions. Furthermore, the use of
detergents, with the exception of the zwitterionic detergent CHAPS, was avoided as this
is known to cause artificial interactions as a consequence of inducing Bax
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conformational changes (Hsu and Youle, 1998). Six proteins (Hsp60, Hsc71, GRP78,
vimentin, tubulin & P-actin) were consistently identified as Bax co-precipitants from 2D
gel and mass spectrometry analyses. Subsequent co-immunoprecipitation-based studies
confirmed interactions between Bax and Hsp60, vimentin and P-actin.
The identification of Bax-binding proteins originating from the Hsp family and the
cytoskeleton provides additional insight into how quiescent Bax is maintained inactive
within the cytosol prior to receiving an apoptosis-inducing stimulus. Several Hsp family
proteins are known to be important inhibitors of apoptosis, acting at various checkpoints
within the intrinsic apoptotic pathway (Garrido et al., 2001; Beere, 2004), and Hsp60
has been previously identified as a Bax-retention factor in human cardiac cells
(Kirchhoff et al., 2002). Furthermore, the novel association between Bax and the
cytoskeletal proteins, vimentin and P-actin, could also provide a mechanistic insight into
how Bax is able to sense and respond rapidly to cellular damage - perhaps utilising a
similar mechanism to the other cytoskeleton-sequestered pro-apoptotic Bcl-2 family
proteins, Bmf-1 and Bim (Puthalakath et al., 1999; Puthalakath et al., 2001).
In Chapter 4, Hsp60 and P-actin were also identified as proteins interacting with the Bax
C-terminal trans-membrane domain which is thought to regulate the targeting of Bax to
the OMM during apoptosis (Nechushtan et al., 1999; Suzuki et al., 2000). As a key
molecular chaperone involved in protein structure maturation and refolding, Hsp60
could regulate the exposure of the Bax C-terminal tail and subsequently set a threshold
for Bax activation in neuronal cells, as has been previously reported in cardiac cells
(Kirchhoff et al., 2002; Knowlton and Gupta, 2003). The identification of P-actin as a
Bax C-terminal-binding protein, however, is a novel finding and adds additional support
to the recently proposed role for the actin cytoskeleton in orchestrating the translocation
of Bax, and perhaps other Bcl-2 family proteins, to the mitochondrial surface during the
early phase of apoptosis (Tang et al., 2006).
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The key finding of this thesis, and the focus of Chapters 5 and 6, was the identification
of the molecular chaperone, nucleophosmin, as a novel binding partner to the Bax C-
terminal membrane-targeting domain within SH-SY5Y cells. Nucleophosmin was
initially identified as a protein binding specifically to a SI84V mutant Bax C-terminal
using affinity chromatography, as described in Chapter 4. This preferential binding of
nucleophosmin to the activated Bax conformation was later confirmed in Chapter 5
using recombinant proteins in a cell-free proximity assay where nucleophosmin was
observed to bind only to detergent-activated Bax. Interaction between endogenous
proteins during STS-induced apoptosis was also confirmed by reciprocal co-
immunoprecipitation in Chapter 6. Furthermore, that this interaction was a biologically
relevant interaction was demonstrated in Chapter 6 using confocal microscopy, to show
that Bax and nucleophosmin co-localised within the cytosol of SH-SY5Y cells during
STS-induced apoptosis, and RNA interference, which showed that nucleophosmin was
required for Bax to release cytochrome c across the OMM and initiate downstream
caspase activity. An overview of how the Bax-binding proteins identified in this thesis
could regualate the bioactivity of Bax in SH-SY5Y cells is provided in
During the course of this thesis, the identification of several Bax-binding proteins out-
with the Bcl-2 protein family has been reported in the literature (Gustafsson et al, 2004;
Mao et al, 2004; Gotoh et al, 2004; Zhang et al, 2005; Gardai et al, 2004; Takahashi et
al, 2005; Ohtsuka et al, 2004). The majority of these have been attributed with
inhibitory roles, mainly through sequestration of Bax as an inactive protein within the
cytosol. Furthermore, several of these regulatory proteins, such as ARC (Koseki et al.,
1998), aA-crystallin (Bloemendal, 1982), 14-3-3a (Prasad et al., 1992) and humanin
(Hashimoto et al., 2001; Tajima et al., 2002) exhibit a restricted tissue distribution,
suggesting that Bax may be regulated by different proteins according to the cell type.
Some of the Bax-binding proteins identified within this thesis, therefore, could have a
specific role in regulating Bax within neuronal cells. However, before this could be
established, the ability of such proteins to bind Bax within cell lines originating form
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Fig. 7.1. Proposed model of Bax regulation during STS-induced apoptosis in SH-
SY5Y cells. In the experimental cell model used in thesis, several heat shock and
cytoskeletal proteins were identified from 2D gel electrophoresis as potential cytosolic
Bax retentive factors in unstressed (control) cells. However, three of these proteins,
Tubulin, Hsp90 and the ER chaperone, GRP78, cold not be confirmed as Bax-binding
proteins. Affinity chromatography experiments identified several proteins specifically
binding to the putative Bax C-terminal membrane-targeting domain, among them the
molecular chaperone, nucleophosmin, and the cytoskeletal protein, P-actin. A direct
interaction between nucleophosmin and the activated Bax conformation was confirmed
using recombinant proteins in a proximity assay. Recently published data has identified
a potential role for the actin cytoskeleton in the Bax translocation event (Tang et al.,
2006). Data from this thesis supports the hypothesis that nucleophosmin is a novel
regulator of the apoptogenic function of Bax, and is required for Bax to elicit the
mitochondrial release of apoptogenic factors in SH-SY5Y cells exposed to STS.
Significantly, as discussed in Chapter 6, three recently identified binding proteins, Bif-1,
ASC and the BH3-like protein, MAP-1, have been suggested, as nucleophosmin has in
this thesis, to promote the apoptogenic activity of Bax (Ohtsuka et al., 2004; Takahashi
et al., 2005; Baksh et al., 2005). Until the identification of such proteins, Bax was
thought to rely solely on the functional interaction with other pro-apoptotic Bcl-2 family
proteins, such asBid/tBid, Bim and PUMA (Wang et al., 1996; Desagher et al., 1999;
Eskes et al., 2000; Marani et al., 2002; Cartron et al., 2004). The identification of Bif-1,
ASC, MAP-1 and, from this thesis, nucleophosmin, supports an emerging hypothesis
that Bax relies on a functional collaboration with several different proteins, the
involvement of each perhaps depending on cell type and apoptotic stimulus, in order to
fulfil its apoptogenic role at the mitochondrial surface (Lucken-Ardjomande and
Martinou, 2005).
The in vitro-derived data presented within this thesis has recently been corroborated in
vivo using a mouse model of ischemic stroke (Kerr et al., 2006). Histological
assessment of mouse brains taken from animals subjected to 30mins transient occlusion
of the middle cerebral artery (MCA) revealed the presence of activated Bax 3h following
onset of the ischemic insult. Analysis of the subcellular distribution of both Bax and
nucleophosmin within the cortex at this time point was then performed by isolating
nuclear, mitochondrial and cytosolic fractions and measuring relative proteins levels in
each by quantitative Western blot. Using this approach, while Bax localisation remained
relatively unaltered between sham operated and the ischemic cortex, nucleophosmin was
observed to have undergone translocation from the nuclear compartment into the
mitochondrial and cytosolic fractions by 3h post-insult. This data is in agreement with
the in vitro confocal microscopy-based analysis presented within Chapter 6 of this thesis
and therefore represents a promising confirmation that the Bax-nucleophosmin
interaction is of physiological importance in vivo and that it may therefore represent an
important target for therapeutic intervention in diseases associated with deregulated
apoptosis.
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Overall, the key findings presented within this thesis suggest that: 1) Bax is sequestered
within the cytosol of neuronal cells in an inactive state by association with the anti-
apoptotic protein, Hsp60, and the cytoskeletal proteins, vimentin and [3-actin, 2) Hsp60
and (3-actin specifically interact with the Bax C-terminus and may function to either
regulate its exposure or assist in the translocation of Bax to the OMM, 3) The molecular
chaperone, nucleophosmin, engages in a novel interaction with the C-terminal domain of
activated Bax, 4) Nucleophosmin is required for the apoptogenic activity of Bax
upstream of mitochondrial membrane permeabilisation during STS-induced apoptosis in
SH-SY5Y cells and, as such, represents a novel target for therapeutic intervention of
intrinsic apoptotic neuronal cell death.
7.2. Future studies
During the course of this thesis, several further studies were considered but were not
performed due to constraints placed on these studies by time and available resources.
However, they are presented here as potential future studies that could be performed as
part of a research project to add further insight into the role of Bax binding proteins, and
particularly nucleophosmin, in regulating the apoptogenic activity of Bax.
1) Establishing the functional contribution made by Hsp60, vimentin and B-actin to
the bioactivity ofBax within SH-SY5Y cells.
2) Investigating the interaction between Bax and nucleophosmin, and the functional
consequences of this interaction, using a variety of cell lines and apoptotic
inducers.
3) Using subcellular fractionation techniques to determine the relative cellular
translocation timecourses of Bax and nucleophosmin during STS-induced
apoptosis
4) Using RNAi methodologies targetting Bax to determine the significance of Bax
in STS-induced apoptosis in SH-SY5Y cells.
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